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ABSTRACT 
The main objective of this thesis was to contribute to immunomodulatory interventions 
that are important for the clinical outcome in patients undergoing haematopoietic stem 
cell transplantation (HSCT) and in patients with antibody deficiency or increased 
susceptibility to infections. 
 
Graft-versus-host disease (GVHD), infections, and relapse of the underlying disease are 
the main complications after allogeneic haematopoietic stem cell transplantation. In 
study I, we retrospectively examined 179 patients who had undergone HSCT, with the 
aim of evaluating the effects and kinetics of IgG levels after HSCT. We concluded that 
IgG levels increased after transplantation throughout the five-year study period. 
Patients with low IgG levels (< 4 g/L) on two occasions during the first year after 
HSCT showed a reduced survival rate and an increased incidence of transplant-related 
mortality compared with patients with normal levels. Persistently low levels of IgG 
were found to be a risk factor for death after HSCT. 
 
In vivo T-cell depletion with anti-thymocyte globulin is a commonly used strategy for 
the prevention of GVHD and to avoid rejection after transplantation. In study II, we 
retrospectively compared 36 patients given Campath as part of the conditioning with a 
matched cohort of 72 patients receiving thymoglobulin (TMG). The objective was to 
compare the two different drugs with regard to clinical outcome after HSCT. No 
differences in transplant related mortality, overall survival, or relapse-free survival 
were found between the two groups. Furthermore, Campath was associated with less 
overall acute GVHD but more chronic GVHD. Finally, we noted a trend towards more 
fungal infections in the patients treated with Campath. In conclusion, TMG and 
Campath as part of the conditioning appear to result in a similar clinical outcome. 
 
Low serum levels of vitamin D are associated with an increased risk of respiratory tract 
infections (RTIs). To date, clinical trials with vitamin D against various infections have 
not been conclusive. Thus, our objective was to investigate whether supplementation 
with vitamin D could reduce infectious symptoms and antibiotic consumption in 
patients with antibody deficiency or increased susceptibility to RTI. 140 patients with 
 > 42 days of symptoms from the respiratory tract over a 12-month period prior to 
inclusion were included in study III. They were randomized to receive vitamin D 
(4,000 IU) or placebo daily for 1 year. The primary endpoint was an infectious score 
based on five parameters: symptoms from the respiratory tract, ears and sinuses, 
malaise, and antibiotic consumption. Secondary endpoints were serum levels of 
25(OH)D, microbiological findings, and levels of anti-microbial peptides (AMPs) in 
nasal fluids. The key message from this study was that vitamin D supplementation 
reduced symptoms and antibiotic consumption in patients with an increased frequency 
of respiratory tract infections. 
 
The role of vitamin D in HSCT is not fully understood. To address this issue, we 
designed a study which included 123 children who were followed retrospectively for up 
to 8 years after HSCT. The aim of study IV was to determine whether vitamin D levels 
at baseline were associated with short- and long-term outcome parameters. Vitamin D 
  
deficiency was defined as a pre-transplant level of 25(OH)D  below 50 nmol/L. We 
found that the frequency of acute GVHD was higher and that of chronic GVHD lower 
in patients with sufficient vitamin D levels (> 50 nmol/L) compared with those with 
vitamin D deficiency. In patients transplanted due to malignancies, overall survival was 
higher in the group with sufficient vitamin D levels. We also found that relapse was 
more common in the insufficient-level group. Since vitamin D deficiency was 
associated with an increased risk of death, relapse, and chronic GVHD, we concluded 
that baseline vitamin D status appears to influence the clinical course in children 
undergoing HSCT. However, randomized and placebo-controlled trials will fully 
clarify this issue. 
 
The main conclusions are that (1) low IgG levels are a risk factor for death after HSCT, 
(2) TMG and Campath as part of the conditioning before HSCT result in similar 
outcome, (3) supplementation with vitamin D may reduce disease burden in patients 
with frequent RTIs, and (4) vitamin D appears to affect the clinical outcome in children 
undergoing HSCT. 
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1 INTRODUCTION 
 
1.1 THE IMMUNE SYSTEM 
The immune system consists of a variety of cells and molecules that mediate defence 
against all sorts of pathogens and growth of virus-induced tumour cells. One can think 
of the immune system as “two lines of defence”. These two parts are called innate and 
adaptive immunity. While the innate immunity acts immediately, it takes a longer time 
for the adaptive immune response to fully mature. The adaptive immunity is 
characterized by clonal specificity and memory. 
 
1.2 INNATE IMMUNITY  
This is the first line of defence that is activated after an infection. When there is 
intrusion by a pathogen, the innate response is very quick, and it was originally thought 
to react in a similar way irrespective of how many times we become infected. In recent 
years, it has been shown that the innate system has an ability to remember previously 
encountered antigens (1). The innate immune system is a universal and ancient form of 
host defence against infection, and it relies on a limited number of germline-encoded 
receptors. These pattern-recognition receptors (PRRs) are made to recognize conserved 
products from different microorganisms and endogenous molecules such as uric acid 
and hyaluronic acid. The innate immune system is able to distinguish “infectious” non-
self from non-infectious “self” (2). Toll-like receptors (TLRs) are a family of PRRs that 
are expressed by several different cell types such as dendritic cells (DCs) and 
macrophages. Activation of a TLR by recognition of a pathogen leads to activation of 
genes encoding inflammatory molecules, cytokines, and anti-microbial peptides 
(AMPs). The innate immune system also includes intracellular mechanisms as helicases 
(enzymes that recognize nucleic acids from for example viruses), and the protective 
barrier composed of the mucosa, cilia in the respiratory tract, and skin.  
 
If a barrier is destroyed, an inflammatory response is initiated. The definition of 
inflammation is based on classical clinical signs such as elevated temperature, redness, 
pain, swelling, and loss of function. These symptoms arise due to the effect of 
inflammatory mediators, including cytokines and complement fragments, that cause 
dilatation of the vessels and increased permeability. The cytokines change the 
properties of the vessels in such a way that the circulating leukocytes can easily adhere 
to the walls of the vessels and later on—attracted by inflammatory mediators—migrate 
to the injured site. 
 
Fever is a complex systemic response to infection and injury (3), and is mediated by IL-
1, IL-6, and prostaglandins (PGE2) for example. Increasing body temperature confers 
protection by improving pathogen clearance in vivo (4-6). A body temperature above 
39°C activates cellular signalling and mobilization of cells to sites of inflammation. 
 
1.2.1 Antimicrobial peptides (AMPs) 
AMPs are considered to be effector molecules of the innate immune system, acting as a 
first line of protection against invading pathogens (7-9). They protect the mucosal and 
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dry epithelial surfaces of all multicellular organisms (10). The fundamental structural 
principle underlying all classes of AMPs is the ability of the molecule to adopt an 
amphipathic character, i.e. to have clusters of hydrophobic and cationic amino acids 
spatially organized in discrete sectors of the molecule. In humans, two major classes of 
AMPs have been described: defensins and cathelicidins (10). Alpha-defensin -1, -2, and 
-3 (also known as HNP1-3) are AMPs found in human neutrophils (11). The targets for 
most AMPs are the membranes of invading microbes. Bacterial membranes are 
organized in such a way that the outermost leaflet of the bilayer, the surface exposed to 
the outer world, is covered by lipids with negatively charged phospholipid head groups. 
In contrast, membranes of eukaryotic cells are mostly composed of lipids with no net 
charge (neutral). This model proposes interaction of the peptide with the pathogen 
membrane, followed by displacement of lipids and in some cases entry of the peptide 
into the invading pathogen. It has also been demonstrated that some AMPs can promote 
epithelial growth and angiogenesis (12). Both cathelicidins and defensins have been 
shown to have the capacity to act as chemokines, substances that attract circulating and 
migrating cells. Defensins can attract dendritic cells and T-lymphocytes to sites of 
infection, and LL-37—the sole human cathelicidin—has the ability to attract 
neutrophils (13, 14). 
 
1.2.2 The complement system 
The complement molecules represent a large group of plasma proteins that act in a self-
activating way. These proteins are secreted by liver cells and monocytes. Activation 
can occur by several means: (1) direct activation on a microbial surface, which is 
known as the alternative pathway, (2) by antibodies bound to foreign surfaces, which is 
known as the classical pathway, and finally (3) by the lectin pathway, which is induced 
by an interaction between microbial carbohydrates and mannose-binding lectins 
(MBLs) in plasma.  
 
The nomenclature is derived from the fact that the proteins help (“complement”) the 
antibody response. C3 is the main complement protein and its activation is required for 
both classical and alternative complement activation pathways. When C3 binds to an 
antigen, an enzymatic conversion to C3b occurs. Since macrophages have receptors for 
C3b, the foreign microbe will either be opsonized or C3b can act as a focus for other 
soluble plasma factors. C3b induces formation of a membrane attack complex (MAC), 
which kills the microbe by cellular lysis. Other results of complement activation can be 
recruitment of inflammatory cells and stimulation of B-lymphocytes to produce 
antibodies (15). 
 
1.2.3 Cells of the innate immune system 
Neutrophils and macrophages are two main types of phagocytes in the innate immune 
system. They share the same function—to engulf and kill microbes. The phagocytic 
process is enhanced by stimulation of receptors for antibodies and complement. The 
characteristics of neutrophilic granulocytes are a multilobed nucleus and the presence 
of granules in the cytoplasm. The granules contain molecules required for successful 
elimination of microbes. The macrophage, which is the mature form of a monocyte, is 
mononuclear and has migrated from the blood to a tissue. Unlike neutrophils, which 
survive only a few days, the macrophages are long-lived cells and can survive for 
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several weeks. In addition to engulfing particles (cellular debris and microbes), 
macrophages have an ability to present antigen to T-cells. A successful immune 
response depends on a series of specific interactions between a T-cell and an antigen-
presenting cell (APC). Although the first essential step in activating a T-cell is the 
binding of an MHC-peptide complex on an APC (signal 1), this interaction alone is not 
sufficient. Co-stimulatory signals (signal 2) are necessary to ensure an effective 
immune response and they are provided by molecules such as CD80 and CD86 
expressed on the surface on APCs (16). Stimulation by cytokines (signal 3) is also 
essential for T-cell activation. 
 
1.2.4 Dendritic cells 
DCs, named for their probing, treelike or dendritic shapes, are pivotal for both 
recognition of a universe of antigens, and control of an array of responses (17). They 
are specialized to capture and process antigens, converting proteins to peptides that are 
presented on MHC molecules and recognized by T cells. DCs are an important bridge 
between innate an adaptive immunity, and can be divided into different groups. 
Plasmacytoid DCs are found in, for example, bone marrow, blood, and thymus. 
Migratory DCs are found in skin, for example, and resident DCs are mostly located in 
the spleen. All types of DCs are professional APCs since they present antigenic 
peptides to T-helper cells. DCs carry receptors that recognize antigen patterns (18). 
They process the antigens and present it to T-cells in a neighboring lymph node. 
Mature DCs can produce cytokines that affect both the innate and the adaptive immune 
response. Depending on the context, DCs produce different cytokines that in turn affect 
the function of the T-cells. When DCs ingest neutrophils infected with bacteria, they 
secrete TGF-β, IL-6, and IL-23 cytokines, leading to the differentiation of Th17 cells, 
which promote inflammation. In addition, engulfment of uninfected, apoptopic 
neutrophils leads to secretion of TGF-β and IL-10 by DCs, thus promoting in vitro 
differentiation of T cells to induced regulatory T-cells, which suppress immune 
responses (19, 20).  
 
1.2.5 NK-cells 
Natural killer cells are lymphocytes that comprise 5-10 % of the total lymphocyte 
fraction. They are characterized by the surface expression of CD56 and CD16, while 
lacking CD3. The role of this cell type is to attack and kill virus-infected cells in 
addition to certain types of tumour cells. NK-cells differ from other lymphocytes since, 
without antigen specific recognition, they can kill the target (21). Their activation is 
controlled by inhibitory receptors on their cell surface, which recognize molecules of 
MHC class I (22). This means that NK-cells are prevented from killing healthy host 
cells but they do kill cells that are infected by a virus or that are cancerous, since those 
cells do not express MHC class I molecules in a normal way. For killing, NK-cells use 
the granzyme and perforin granule exocytosis pathway or they express ligands for 
death receptors on the target cell (23). Another killing mechanism used by NK-cells is 
antibody-dependent cellular cytotoxicity (ADCC). NK-cells express a low-affinity 
receptor for the Fc part of the IgG molecule and can therefore destroy cells via 
antibodies (24). In addition, NK-cells can stimulate the immune response by release of 
different cytokines. 
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1.2.6 Inflammasomes 
The inflammasome is expressed in myeloid cells, and is a component of the innate 
immune system. It is a large cytoplasmic complex responsible for activation of 
inflammatory processes (25), and has been shown to induce pyroptosis, a programmed 
cell death that requires the function of caspase-1 (26). 
 
1.3 ADAPTIVE IMMUNITY 
The adaptive immune system comprises two major cell types: B-lymphocytes and T-
lymphocytes. Compared to innate immunity, the adaptive immunity often needs several 
days to fully mature. The memory of the adaptive immune system persists after the 
infection has been eradicated, which guarantees a more effective and rapid immune 
response if the host is reinfected with the same type of microbe. 
 
1.3.1 Cytokines 
Most cytokines are small- to medium-sized proteins or glycoproteins, which have 
potent biological effects on many cell types. They are released by several cells in the 
immune system and in general the function of cytokines is to coordinate the action of 
different cell types participating in the immune and inflammatory responses. 
 
1.3.2 T-lymphocytes 
T-cells can be broadly divided into T-helper cells (CD4+) and cytotoxic T-cells 
(CD8+). Other important T- lymphocytes are Th17 cells and regulatory T-cells. All T- 
cells express the co-receptor complex CD3. The development of T-cells does not take 
place in the bone marrow. Instead, undifferentiated progenitors migrate from the bone 
marrow to the thymus, where they develop into T-cells. The immunological function of 
the thymus was first described in 1961 (27). During development in the thymus, T-cells 
undergo positive and negative selection. In positive selection, the T-cells are licensed to 
be able to recognize but not react against autologous molecules. In negative selection, 
potentially self-reactive T-cells are destroyd (28). After this selection, T-cells that 
survive are able to recognize “self” molecules but will not react against themselves   
(i. e. there is a tolerance). The T-cells that have passed the selection will migrate to the 
periphery and to the secondary lymphoid organs. The T-cell receptor is special in that it 
is only able to identify an antigen when it is associated with a major histocompatibility 
complex (MHC) molecule on the surface of the cell. MHC class I molecules are found 
on all nucleated cells and class II molecules are found on all APCs. 
 
1.3.3 CD4+ cells 
CD4+ cells have the capacity to recognize MHC class II-associated peptides—for 
example, foreign antigens presented by a dendritic cell. After stimulation, CD4+ cells 
start to produce cytokines that will initiate an immune response. T-helper cells are 
subdivided into two distinct populations, Th1 and Th2 types, defined by the array of 
cytokines being produced (29). The Th1 type mainly secretes IL-2, TNF-β, and 
interferon (IFN)-gamma, and the Th2 type IL-4, IL-5, IL-6, IL-10, and IL-13. Th1 cells 
have the capacity to activate macrophages and therefore the cell-mediated immune 
defence. Th2 cells activate B-cells and enhance production of antibodies. Each of these 
Th subtypes suppresses the other, because IFN-gamma from Th1 cells inhibits 
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proliferation of Th2 cells while IL-10 from Th2 cells impairs cytokine secretion from 
Th1 cells (30, 31). 
  
Th17 cells (32) are a CD4+ cell type that produces IL-17 and IL-22. These cytokines 
induce tissue cells to produce AMPs and chemokines, which leads to recruitment of 
inflammatory cells such as granulocytes and macrophages (33). Th17 cells develop 
from naïve CD4+ cells under the influence of a number of inflammatory cytokines such 
as IL-1, IL-6, and TGF-β (34). Th17 cells were first defined by their expression of IL-
17 (IL-17A), but during the last few years they have also been reported to preferentially 
express IL-22, as well as IL-17F, IL-21, and GM-CSF (35, 36). Data have accumulated 
to suggest that Th17 cells play an important role in autoimmune diseases, different 
types of infections, and the adaptive immune response (37, 38). The polarization of 
Th17 cells is dependent on the action of IL-23 secreted by APCs (39, 40). An example 
of a primary immunodeficiency with a defect in differentiation of Th17 cells is hyper-
IgE syndrome. This disease is mainly the result of a mutation in STAT3 (signal 
transducer and activator of transcriptor 3) and leads to an increased susceptibility to 
fungi and extracellular bacteria. 
 
1.3.4 CD8+ cells 
This is a type of T-lymphocyte that provides defence against intracellular pathogens 
and different types of virus infections. They eliminate target cells that present foreign 
peptide molecules (cytosolic pathogens) bound to MHC class I molecules on the cell 
surface. The release of granule contents accounts for most of the cytotxic activity of 
CD8 effector T-cells and Th 1 cells play an important role as helpers during CD8 T-cell 
responses.  
 
1.3.5 Regulatory T-cells (Tregs) 
To prevent autoimmune reactions in the body, most of the self-reactive T-cells are 
destroyed in the thymus. Nevertheless, some of these cells escape from the thymus and 
start to circulate out to the periphery. In mediation of peripheral tolerance and for 
control of the adaptive immune responses that may cause damage to self-tissues, 
regulatory T-cells have an important role (41). Naturally occurring CD4+CD25+ Tregs, 
characterized by the transcription factor  FOXP3, are essential for prevention of 
autoimmune diseases by inhibiting T-cell proliferation. Type 1 Tregs, a subtype of 
Tregs that are inducible, exert their suppressive activity mainly through the release of 
IL-10. The primary task of type 1 Tregs is to inhibit T-cell responses (41). 
 
1.3.6 B-lymphocytes 
B-cells are lymphocytes that produce antibodies and recognize foreign antigens. 
Immature B-cells develop from lymphoid progenitor cells in the bone marrow. Later 
on, they migrate to secondary lymphatic tissue and an interaction with antigens and T- 
cells takes place. Resting mature B-cells express IgD and IgM on their surface. After 
activation, the B-cells switch to a specific isotype production of IgM, IgA, IgG, or IgE. 
The different antibodies serve as B-cell receptors that recognize antigens. When an 
antigen binds to an antibody on the B-cell surface, it will induce transmission of signals 
into the cell. The B-cell then processes the antigen, delivers it to intracellular sites, and 
 6 
then presents the peptide bound to MHC class II molecules on the surface for 
detection/recognition by T-cells. Most antigens are not able to stimulate B-cells without 
the help of CD4+ T-cells. The foreign peptides bound to MHC class II molecules on 
the B-cell surface are recognized by T-cells, which became activated and express 
molecules, such as CD40L on their surface. The B-cell molecule CD40 binds to 
CD40L and stimulates antibody switching in the B-cell. 
 
After activation, some B-cells become memory cells, resting in the bone marrow, while 
other cells turn into plasma cells, which can produce and secrete large amounts of 
specific antibodies (42). It is important that a significant proportion of them remain as 
memory B-cells since these cells are vital when the body becomes re-exposed for the 
antigen. Common variable immune deficiency (CVID) is a heterogeneous group of 
primary immunodeficiencies characterized by insufficient serum levels of 
immunoglobulin and a high incidence of repeat infections. 
 
1.4 TRANSPLANTATION IMMUNOLOGY 
There are several different types of transplantation, named after the relationship 
between the recipient and the donor. An autologous transplant uses the recipient's own 
cells, whereas an allogeneic transplant is a transplant between two individuals from the 
same species. Syngeneic grafts are genetically identical with the host—for example, 
stem cell transplantation between monozygotic twins. Transplantation across species 
barriers is called xenotransplantation.  
 
As mentioned above, the immune system has the capacity to distinguish self from non-
self. In a transplantation situation, the graft will be considered as non-self by the 
immune system of the host. The main reason for the host immune defence reacting 
against the transplanted cells is non-self HLA/MHC molecules. The immunological 
mechanisms that affect the graft are mostly mediated by the adaptive immune response 
in the host, i.e. T- and B-lymphocytes. When an allogeneic haematopoietic stem cell 
transplantation is performed, there is a risk that the immune cells in the graft will react 
against the host, which is called graft-versus-host disease (GVHD).  
 
MHC genes are the most polymorphic of all mammalian genes. Since there are so 
many variants of each MHC gene, it is very difficult to find two unrelated individuals 
that share an identical set. The immune response to allogeneic MHC molecules is not 
fully understood.  
 
There are two theories about the molecular mechanisms involved in direct 
allorecognition of MHC molecules. The “high determinant density” model proposes 
that alloreactive T-cells recognize the exposed polymorphic antigen directly on the 
allogeneic MHC molecule. If every allogeneic MHC molecule can serve as a ligand for 
an allospecific T-cell, then the density of antigen on the cell surface would be 
extremely high. The much higher ligand density available to the alloreactive T-cell 
means that receptors with a low affinity can respond to the foreign MHC molecule (43, 
44). The second model, called the “multiple binary complex” hypothesis, suggests that 
the anti-MHC alloresponse is a conventional self-restricted immune response. This 
means that the response is mediated by T-cells that are specific for peptide/MHC 
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complexes. In this case, the peptide is a naturally processed peptide and the MHC 
molecule is allogeneic (45, 46). The set of peptides bound by an allogeneic MHC 
molecule often differs considerably from that bound by a self-MHC molecule. If each 
allo-MHC complex is recognized by a different alloreactive T-cell, then a single MHC 
incompatibility can stimulate numerous of alloreactive T-cells. Probably both of the 
above-mentioned models are involved in the overall allo-response.  
 
Indirect allo-recognition is defined as the stimulation of T-cells by the recognition of 
processed peptides of the allogeneic MHC molecules themselves presented by self-
MHC molecules (47, 48). 
 
Apart from MHC proteins, other molecules are important in provoking a rejection or  
GVHD. Minor histocompatibility antigens (mHAg) are known to be derived from 
polymorphic non-MHC proteins that are presented by MHC molecules. Reactions to 
this type of antigen could be found as a transplant rejection or GVHD in MHC-matched 
transplants (49). An example of a well-known mHAg is a set of proteins on the male- 
specific Y chromosome. 
 
The first year after HSCT is characterized by considerable immune deficiency, which is 
then followed by recovery. The deficiency starts with the conditioning regimen that 
destroys haematopoietic and mucosal progenitor cells. The patients lose T- and B-cell 
mediated immune memory, which results in a shortened duration of immunity unless a 
new antigenic challenge is given. The recovery of B- and T-cells will last for at least 
one or two years after transplantation (50, 51).  
 
1.5 ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION 
The first allogeneic haematopoietic stem cell transplantation (HSCT) was performed 
over 50 years ago, and became feasible after the discovery of the HLA complex. 
E. Donnall Thomas et al. performed the first clinical HSCT studies in the 1950s, and 
they  performed the first allogeneic bone marrow transplantation in humans in 1957 
(52). Unfortunately, the early results were very disappointing (53). Many patients were 
in the late stages of leukaemia and did not survive long enough for evaluation. At the 
beginning of the era, it was also noted that engraftment could sometimes be obtained, 
but a lethal immunological reaction of the graft against the host emerged. Several years 
later, this lethal immunological reaction was known as GVHD. Dausset at al. (54) and 
van Rood et al. (55) discovered the HLA system in the 1960s and the ability to perform 
typing of HLA was a breakthrough in HSCT. Later on, in the 1970s, Thomas and his 
colleagues successfully performed bone marrow transplantations, using marrow from 
HLA-identical siblings, in patients with end-stage leukaemia (56). The occurence of 
GVHD was also discovered to have a positive effect in some cases, since it reduced the 
incidence of leukaemic relapse (57, 58).  
 
The aim of transplantation is to replace a defective or diseased immune/ haematopoietic 
system with a new one from a healthy donor. 
 
The procedure involves taking haematopoietic stem/progenitor cells from the donor, 
either from the bone marrow or from peripheral blood, and then transfusing them 
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intravenously into the patient. Haematopoietic stem cells (HSCs) are characterized by 
the ability to differentiate into all types of blood lineages. The most primitive HSCs 
express the molecule CD34 on their surfaces, and these are the target cells that are 
collected when both peripheral blood and bone marrow are used as the stem cell source.  
 
Indications for HSCT include both malignant and non-malignant conditions, and more 
than 25,000 transplantations are performed every year with the purpose of treating 
lymphoma, leukaemia, immune-deficiency disorders, metabolic defects, sickle-cell 
anaemia, beta thalassaemia, and many other diseases (59).  
 
Several serious main problems—GVHD, relapse, and infections — must be considered 
after HSCT. 
 
1.5.1 Conditioning 
Before HSCT, a conditioning therapy is given. The original aim of this treatment was to 
eradicate malignant cells but also to prevent rejection of the graft by suppressing the 
host immune system. Initial studies on animals investigated the threshold for total body 
irradiation (TBI), to achieve an immunosuppressive effect in order to permit allogeneic 
marrow engraftment. The conditioning regimens differ depending on the diagnosis and 
the local traditions of the hospital. In the 1970s, TBI and high-dose cyclophosphamide, 
which had been used earlier as two separate approaches, were combined to reduce the 
risk of relapse (60, 61). Follow-up studies showed promising results; more than half of 
the initial patients were free from disease five years after the transplant (62). In the 
1980s busulfan offered an alternative to TBI (63). By individual dose adjustment and 
prophylactic treatment with anti-convulsants, side effects such as liver toxicity and 
proconvulsive effects were prevented (64). Attempts were made during the 1980s to 
combine different types of chemotherapy with TBI, to elevate the doses, and to add a 
third chemotherapeutic agent, but without success. Unfortunately, these efforts resulted 
in higher transplant-related mortality (TRM) and a significant increase in toxicity, and 
the overall survival of the patients did not increase at all (65-67).  
 
Over the years, researchers have been able to show that transplantation of allogeneic 
stem cells—except the effect of myeloablative conditioning—also has an additional 
anti-leukaemic effect (57, 68). Studies have shown that the potent anti-leukaemic effect 
is due to an on-going reaction between malignant cells in the host and the transplanted 
allogeneic immunological cells (57, 58, 68, 69). Based on these results, a new era with 
reduced-intensity conditioning (RIC) started for older patients and for patients with 
poor medical conditions. RIC protocols where associated with significantly lower risk 
of TRM due to reduced organ toxicity. This protocol relies mainly on tumour cell 
killing (the graft-versus-leukaemia effect) and to a lesser extent on chemo-radiation 
therapy (70-73). However, the frequency of rejection of the graft increased when RIC 
therapy was introduced, and new combinations of chemotherapy drugs have therefore 
been tried (74). 
 
There is an increased risk of GVHD and graft rejection when using unrelated donors 
(75, 76). The main reason is probably an increased alloreactivity due to differences in 
minor histocompatibility antigens and other tissue antigens. To overcome these 
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obstacles, at many centres the patients are treated with anti-thymocyte globulin (ATG) 
(77). These antibodies to T-cells reduce the number of—and modulate the function 
of—T-cells. Their main effect is to prevent rejection by inhibiting the host immune 
response, but they also reduce the risk of GVHD by their influence on donor T-cells. 
By adding ATG to the pre-transplant conditioning protocol, acute GVHD and early 
mortality of unrelated donor (URD) HSCT have been reduced to levels similar to those 
in matched, related HSCT (77, 78). Different doses and types of ATG are used today. 
However, the common mechanism of action is depletion of alloreactive T-cells in both 
the recipient and the graft, so-called in vivo T-cell depletion. Both the type and dose of 
ATG appear to be important for the outcome (79). There are basically three different 
types of ATG: thymoglobulin (TMG), Campath, and ATG-Fresenius.  
 
TMG consists of rabbit immunoglobulins, and is produced by immunizing rabbits with 
fresh human thymocytes. The immunoglobulin fraction contains polyclonal antibodies 
to multiple cell-surface antigens (80, 81). TMG binds to T-cells and has a direct effect 
on them, resulting in T-cell depletion via opsonization and lysis following complement 
activation. To a lesser extent, TMG also binds to B-cells, macrophages, monocytes, and 
neutrophils (80, 81). 
 
Campath is a humanized monoclonal antibody to human CD52, an antigen expressed 
on T-, B- and NK-cells, but (in contrast to TMG) not on other haematopoietic cells 
(82). 
 
As with TMG, ATG-Fresenius consists of rabbit immunoglobulin. The rabbits are 
immunized with a lymphoblastic Jurkat T-cell line. Jurkat is a cell line of immortalized 
T-lymphocytes, originally from a 14-year-old boy with T-cell leukaemia. ATG-
Fresenius, as TMG, binds not only to T-cells but also to other human cell-surface 
molecules (83). This agent is produced and mainly used in Germany. 
 
Despite the proven effectiveness of the above-mentioned ATGs, their area of use is 
somewhat limited by the increase in infections and relapse that is associated with them. 
 
1.5.2 Graft-versus-host disease 
GVHD is one of the major challenges in patients after HSCT, and it is initiated by 
alloreactive donor lymphocytes recognizing the foreign histocompatibility complex of 
the host (84). Three criteria  were defined by Billingham in 1966: (a) the graft must 
contain immunologically competent cells, (b) the host must—due to differences in 
transplantation antigens—be recognized as foreign to the graft, and (c) the host must be 
unable to initiate an immunological reaction against the graft (85).  
 
The main organs that are usually affected are the skin, liver, gastrointestinal tract, and 
lymphatic organs (86). GVHD can be graded clinically according to the degree of 
involvement of the gut, liver, and skin. It occurs in up to 85% of patients, and is 
classified as either acute or chronic. Acute GVHD is graded I-IV and chronic GVHD is 
graded mild, moderate and severe.  
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Acute GVHD usually appears within the first 100 days after HSCT and can involve all 
the above mentioned tissues (86, 87). Disease stage, patient age, disparity in HLA 
antigens, GVHD prophylaxis, and donor-recipient sex mismatch (i.e. female donor for 
male recipients recognizing antigens associated with the Y chromosome) are risk 
factors for GVHD (75, 88, 89). The pathophysiology of acute GVHD is divided into 
three phases (90). The first phase involves damage of the tissue caused by underlying 
disease, conditioning treatment, and infections. In the second phase, activation of donor 
T-lymphocytes emerges. Recipient/host or donor APCs that have migrated to the lymph 
nodes present peptides from recipient antigens to donor T-lymphocytes and thereby 
induce donor T-cell activation (91, 92). The third phase of acute GVHD involves the 
inflammation and cellular damage caused by mature and activated graft T-cells. The 
result of this phase is sustained inflammation and further tissue damage. 
 
Chronic GVHD is one of the most frequent late complications after HSCT, affecting 
30–50% of patients. It differs from acute GVHD not only regarding timing but also in 
clinical appearance. Chronic GVHD develops with manifestations such as hepatic 
dysfunction, dermatitis, keratoconjunctivitis, and oral mucositis. 
 
GVHD Pathophysiology
(I) 
Recipient
conditioning
(II) 
Donor 
T‐cell activation
(III) 
Effector
Host tissue damage:
IL‐1
IL‐6      LPS(intestine)
TNF‐α
HostAPC
Donor T‐cell Th1
IFN‐γ
IL‐2
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NK
Target cell
apoptosis
TNF‐α
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Figure 1. The pathophysiology of GVHD.                                                                                                                  
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The immune pathogenesis of the two different diseases in not fully understood, 
although T-lymphocytes play a central role in both acute and chronic GVHD (93). 
Donor-derived T-cells may initiate a graft-versus-host reaction once they come into 
contact with antigen on the surface of the host APCs, such as macrophages and 
dendritic cells in the lymphoid organs, Langerhans cells in the skin, or Kupffer cells in 
the liver. The engrafted T-cells may recognize the hosts peptide-MHC complex (allo-
antigens) as foreign, if they are different, or they may recognize minor 
histocompatibility antigens. Acute GVHD usually has a strong inflammatory 
component, whereas chronic GVHD shows a more fibrotic and autoimmune pattern. 
The important role of T-cells in acute GVHD is supported by the total abolition of 
GVHD following T-cell depletion of the graft, a treatment that is very effective in 
preventing acute GVHD. Acute GVHD was thought to be a process driven mainly by 
Th1 and Th17 cells, whereas chronic GVHD was thought to be predominately 
mediated by Th2-type immune responses (94). However, this paradigm has been 
challenged and is not absolute (95, 96).  
 
Over the years, several research groups have provided evidence for the crucial effect of 
different cytokines in the context of GVHD: 
 
Interleukin-2: This cytokine has been suggested to be a key molecule involved in the 
process of GVHD. It has a central role as a T-cell growth factor, and cyclosporine is 
known to inhibit IL-2 secretion. Experimental data have shown that IL-2 production by 
T-cells is an early event in GVHD (97). The precursor frequency of host-specific IL-2 -
producing T-cells has been suggested to predict the occurrence of GVHD after 
transplantation between HLA-identical siblings (98).   
                                                                                                  
Interleukin-1: One group has put forward  evidence for a correlation between 
cytoplasmic IL-1 in peripheral blood and GVHD (99). Another model showed that 
administration of this cytokine to hosts in a murine model increased the mortality from 
what appeared to be an accelerated form of GVHD (100).  
                                                                                                                      
TNF-α: The first group to demonstrate that this cytokine is imperative as a mediator of 
GVHD was Piguet and colleagues (101). Infusion of TNF-α mimics most 
manifestations of GVHD. It has been shown that primed, activated macrophages in 
mice with GVHD secreted TNF-α, and that the mortality could be reduced by 
neutralization of TNF-α (102).  
                            
Interferon (IFN): During experimental GVHD, elevated IFN-gamma production has 
been noted (103, 104). Another study has shown that in the clinical situation, a large 
proportion of T-cells isolated from GVHD patients produce IFN-gamma (105).  
                                          
Interleukin-10: This is an anti-inflammatory cytokine that inhibits the production of 
inflammatory cytokines such as TNF-α, IL-1, and IFN-gamma, and it also has the 
ability to inhibit MHC class II expression on APCs. Nevertheless, in experimental 
models IL-10 was not found to protect GVHD mice from GVHD mortality but caused a 
notable reduction in serum TNF-α or IL-1 (106, 107). 
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 Interleukin-12: IL-12 is an inducer of both Th1 cell activity and NK cell function. One 
study has revealed that human macrophages stimulated with LPS in vitro produced 
increased levels of IL-12 in patients with GVHD, but not in those without (108). On the 
other hand, in a mouse model, another research group showed that a single injection of 
IL-12 inhibited GVHD but preserved the graft-versus-leukaemia (GVL) effect (109). 
 
Despite its major side effects, the standard primary treatment for GVHD is systemic 
corticosteroid therapy. Other current therapeutic treatments that are routinely used to 
prevent GVHD, e.g. ATG, are broad-spectrum approaches that target T-cells. 
Unfortunately, these agents also have a negative effect on GVL responses and immune 
reconstitution.  
 
More selective approaches that specifically influence the activation, function, or 
survival of allo-reactive T-cells should avoid some of the adverse side effects of global 
immunosuppressive therapy (94). In mouse studies, the depletion of B-cells from the 
graft resulted in a reduced incidence of acute GVHD, perhaps owing to the effect of B-
cells on host APCs (94, 110). In the clinical setting, incorporating rituximab—a CD20-
specific monoclonal antibody that depletes B-cells—in the conditioning regimen 
reduces the severity and incidence of acute GVHD (94). Recent investigations have 
demonstrated the importance of regulatory mechanisms, including Tregs. The results 
have suggested a relationship between the incidence and severity of GVHD and the 
levels of circulating Tregs (111, 112). 
 
1.5.3 Relapse 
The last three decades have witnessed a significant improvement in survival rates, 
probably due to improvements in supportive care (113, 114), greater availability of 
suitable donors, and modulation of conditioning regimens (115). Despite this, the risk 
of relapse has not changed considerably (116, 117). Patients transplanted at the early 
stages of acute leukaemia have an incidence of relapse of around 20–30%. In patients 
with more advanced disease, studies have shown a higher incidence of relapse—
reaching 40–70% (118, 119). 
 
Generally speaking, leukemic relapse mainly occurs in recipient-derived cells and this 
is probably due to incomplete killing of the leukaemic cells or inadequate graft-versus-
leukemia effect. Some studies have demonstrated recurrent leukaemia in donor cells 
(120-124). Occasionally, leukaemia can occur in donor cells as a de novo event, 
masquerading as a relapse (125, 126). Transplant factors with an increased risk of 
relapse are high patient age (acute leukaemias), refractory disease at transplantation, 
HLA-identical donor, type of GVHD prophylaxis, and donor chimaerism (127). The 
lowest relapse rates are seen in patients who are transplanted in first complete remission 
(128). Other factors that are associated with an increased risk of relapse are less or no 
GVHD at all, and T-cell depletion of the stem cell product (129-131). 
 
Traditionally, a morphological or haematological relapse is the case if the bone marrow 
or blood sample from the patient shows a significant amount of blast cells. Since the 
sensitivity of this method is low, new ways of detecting relapse at an early stage have 
been developed the last three decades. Some malignancies are characterized by specific 
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chromosomal changes and—with cytogenic analysis—cells containing these 
abnormalities can be identified. The translocation of the Philadelphia chromosome, 
t(9;22), is probably the most well-known example and it is present in chronic myeloid 
leukaemia, in some forms of acute lymphoblastic leukaemia, and in a few cases of 
acute myeloid leukaemia (132, 133). Certain combinations of surface antigens on 
malignant cells can be detected with flow cytometry and monoclonal antibodies in an 
immuno-phenotypic analysis. Certain leukaemias are accompanied by rearranged T-cell 
receptors and typical immunoglobulin genes, and these changes can be detected with 
real-time quantitative polymerase chain reaction (PCR). Compared to the other 
techniques, this method offers a very high sensitivity and gives the opportunity to 
detect a low number of transformed cells (134-136). Occurrence of residual recipient 
cells after HSCT can also be detected with real-time quantitative PCR. This specific 
assessment is referred to as a chimerism analysis, and studies have shown that an 
increased proportion of host-derived cells in the leukaemia-affected cell line strongly 
correlates with imminent relapse of disease (137-139). One study has concluded that 
monitoring of leukaemia lineage-specific chimerism is of utmost importance for DLI 
response after allogenic HSCT (140). 
 
1.5.4 Infectious complications 
Immunosuppressive treatment in combination with an immature immune system of 
donor origin give rise to several infectious complications that are important causes of 
morbidity and mortality after HSCT (141, 142). Engraftment after allogeneic HSCT 
occurs within 14 to 28 days. The risk of infection is related to the time period after 
transplantation, which according to some researchers can be defined as pre-
engraftment, day 0–30 after HSCT; immediate post-engraftment, 30–100 days after 
HSCT; and late post-engraftment, at more than 3 months. Allogeneic recipients are at 
risk of infection during all of the above-mentioned phases. 
 
To evaluate the patient's individual risk of infection, several factors have to be 
considered. Important elements that must be taken into account are anti-microbial 
prophylaxis, local patterns of antibiotic resistance, isolation routines, type of transplant, 
numbers of given cells, type of conditioning therapy, and the serological status for the 
donor and recipient regarding virus infections. During the first phase, the number of 
granulocytes in peripheral blood is of great interest and the total T-cell (CD3) or CD4 
cell levels can be used as a surrogate marker for T-cell immunity. Even so, there are no 
definitive biomarkers for immune reconstitution that predict infection risk and the need 
for anti-microbial prophylaxis. Consequently, patients require careful monitoring for 
signs or symptoms of infection, and early intervention.  
 
1.5.5 Viral infection 
The most common viruses that cause infection after HSCT are herpes simplex virus 
(HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and varicella-zoster virus 
(VZV). 
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1.5.5.1 Herpes simplex virus infection 
During the aplastic period, reactivation of HSV is common. The virus is categorized 
into two types: herpes type 1 (HSV-1) and herpes type 2 (HSV-2).  Infection with HSV 
has been shown to be associated with an increased risk of invasive bacterial infection 
(143, 144) and also an increased risk of persistent necrotic severe mucocutaneous 
ulcers and deeper infections. Thus, all patients who undergo HSCT and who are 
serologically positive for HSV should be considered for acyclovir prophylaxis (145). 
 
1.5.5.2 Cytalomegalovirus infection 
CMV infection has been one of the most dreaded infections after HSCT (146). 
Approximately 75% of the general population is infected with the virus. The immune 
response to CMV is mainly mediated by the cellular immune system. After the initial 
infection and immune response, the virus establishes life-long latency. Primary 
infection in immunocompetent individuals is often asymptomatic, but infection in 
immunocompromised patients can cause a life-threatening disease. CMV infection or 
reactivation after HSCT can cause pneumonitis, hepatitis, retinitis, colitis, and/or 
suppression of the bone marrow. Risk factors for CMV infection, apart from the receipt 
of a positive graft, are the presence of GVHD and prolonged and persistent 
neutropenia. The risk of CMV infection can be reduced by matching CMV-negative 
donors to CMV-negative recipients. Surveillance with quantitative plasma PCR for 
CMV and introduction of pre-emptive treatment has greatly reduced the risk of fatal 
disease (147-149). Early treatment is preferable to prophylaxis, since anti-viral drugs 
can be toxic, cause neutropenia, and delay recovery of CMV-specific lymphocytes 
(150, 151). For patients with CMV disease in which anti-viral therapy does not work, 
infusions with CMV-specific cytotoxic T-lymphocytes (CTL) may be a successful 
treatment (152, 153). 
 
1.5.5.3 Epstein-Barr virus infection 
90% of the population of the world are infected with EBV. In healthy individuals, EBV 
is a self-limiting primary infection, and the virus remains latent in B-lymphocytes. In 
the PTLD situation, there is an uncontrolled proliferation of EBV-infected B-
lymphocytes. Post-transplant lymphoproliferative disorder (PTLD) is the name of 
numerous B-cell hyperproliferative states. Almost all of these lymphoid proliferations 
are associated with a T-cell dysfunction. Risk factors for PTLD are; HLA-mismatch, 
serological Epstein-Barr virus mismatch (recipient–/ donor+), use of reduced intensity 
conditioning, acute GVHD grade II to IV, splenectomy—pre-transplant, and infusion of 
mesenchymal stromal cells (154). PTLD has high mortality and the reported incidence 
ranges from 0.6% to 10% (155, 156). Histopathologically, it resembles malignant 
lymphoma. PTLD may be treated and prevented with adoptive cellular transfer therapy, 
rituximab, or donor lymphocyte infusion (DLI). 
 
1.5.5.4 Varicella-zoster virus infection 
Due to cellular deficiency after HSCT, there is an increased risk of both primary and 
reactivated VZV infection. Reactivation of latent VZV is observed in about 30% of 
HSCT recipients within the first year after transplantation (157). The most common 
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manifestation is dermatomal herpes zoster (65%), while other patients have a more 
disseminated infection such as meningoencephalitis or visceral infection (35%).  
 
1.5.5.5 Community acquired viral infections 
Mostly during epidemic seasons, respiratory syncytial virus (RSV), influenza A and B, 
parainfluenza (PIV), and adenovirus may be a crucial cause of morbidity and mortality, 
especially in lymphopenic HSCT recipients (158, 159). Patients infected during the 
aplastic phase are at high risk of development of pneumonia, and once pneumonia has 
developed, the mortality is high in spite of treatment with anti-viral drugs (160). 
 
1.5.6 Bacterial infection 
All patients, except  those undergoing a non-myeloablative conditioning, will become 
totally aplastic during the first phase, and will lack measurable numbers of granulocytes 
in peripheral blood (161). During the neutropenic or pre-engraftment period, both 
Gram-positive and Gram-negative bacterial infections from the skin, mouth, and 
gastrointestinal tract are common (162). Gram-negative bacteria from the 
gastrointestinal tract can cross the intestinal barrier and cause severe infections. 
However, due to treatment with broad spectrum antibiotics in the case of fever or 
prophylactic antibiotic treatment, the incidence of these types of infections has 
decreased (141, 163-165).  
 
In the initial post-transplant period, bacterial infections are usually caused by normal 
skin flora (coagulase-negative Staphylococcus) and bacteria from the gastrointestinal 
and oropharyngeal tract (Streptococcus viridans, Enterococcus species, and enteric 
Gram-negative bacilli) (166, 167). Other bacterial species that could be fatal are 
Pseudomonas aeruginosa, Enterobacteriaceae, and Stenotrophomonas maltophilia. 
Infectious diarrhea is also a problem that must be addressed after HSCT, and the most 
common pathogen is Clostridium difficile.  
 
1.5.7 Fungal infection 
Immunosuppressed patients are predisposed to fungal infection. Risk factors for 
invasive fungal infection are prolonged severe neutropenia, use of broad-spectrum 
antibiotics, the presence of acute GVHD, treatment with corticosteroids (168, 169), and 
mucocutaneous damage. The incidence of invasive fungal infection is around 10% in 
patients who have undergone HSCT (170, 171). Both Aspergillus spp. and Candida 
spp. must be taken under consideration during the first aplastic phase, when decisions 
about anti-mycotic treatment are made. Patients who deteriorate despite adequate anti-
microbial treatment should always be considered for a possible invasive fungal 
infection. Invasive aspergillosis in particular is associated with a high mortality rate in 
HSCT patients (169, 172). Diagnosis of invasive fungal infection is difficult and 
complicated. Blood cultures become positive in only a few of the deep-seated 
infections. Positive cultures from other sites may represent colonization rather than 
invasive infection. The contributions from PCR and from serological antibody or 
antigen tests are unsatisfactory (169). In the past, fungal infections have been treated 
with conventional or liposomal amphotericin B with proven effect on mortality in 
neutropenic patients (173). Today, newer agents such as voriconacole (Vfend) and 
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caspofungin (Cancidas) are available for invasive infection and they have been shown 
to be effective against Candida spp. and Aspergillus spp. (174-177). At the Centre for 
Allogenic Stem Cell Transplantation (CAST), Karolinska University Hospital, the 
incidence of invasive fungal infection, has radically been reduced (the last years around 
2.5%) probably due to the use of prophylaxis with posakonazol (personal 
communication with Dr Jonas Mattsson, Karolinska University Hospital, Stockholm). 
To prevent opportunistic infections such as Pneumocystis jirovecii, prophylaxis with 
trimetoprim-sulfametoxazol is used. 
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Figure 2. Common causes and timing of infections post HSCT.                                                                                          
.                                     
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1.6 VITAMIN D DEFICIENCY 
Most vertebrates including reptiles, birds, and lower primates need exposure to UVB 
radiation for their vitamin D production (178). For humans, the association between 
sunlight and health was first appreciated with the industrialization of northern Europe. 
During that time, there was markedly reduced exposure to sun, resulting in a childhood 
epidemic of a condition commonly known as rickets, with bone deformities and severe 
growth retardation (179-182). At the beginning of the twentieth century, observational 
studies showed a relationship between exposure to ultraviolet radiation and cure of 
rickets (183).  
 
During the past decade, major advances have been made in vitamin D research that 
transcend the simple concept that the vitamin is only important in the context of bone 
health. Epidemiological studies have shown an association between low vitamin D 
levels and a variety of respiratory tract infections (184)  (185). For example, vitamin D 
insufficiency is associated with increased risk of developing tuberculosis (186, 187). 
The relationship between vitamin D deficiency and susceptibility to viral respiratory 
tract infections is unclear. Nevertheless, several observational studies have found an 
inverse association between 25(OH)D levels and incidence of respiratory tract 
infections (188, 189).  
 
1.6.1 Sources and metabolism 
Humans get vitamin D mainly through exposure to sunlight and from small amounts in 
the diet or dietary supplements (190). It is almost impossible to obtain adequate levels 
of vitamin D only from dietary intake, but large amounts of oily fish can prevent 
vitamin D deficiency. There are two different forms of vitamin D, vitamin D2 and 
vitamin D3. Vitamin D2 is found naturally in mushrooms such as chanterelles and is 
manufactured through ultraviolet irradiation of ergosterol from yeast. Vitamin D3 is 
found in, for example, fatty fish and it is the metabolite produced when solar ultraviolet 
B radiation (of wavelength 290–315 nm) penetrates the skin. Long-term exposure to 
sunlight degrades pre-vitamin D3 and vitamin D3 into inactive photoproducts, so 
excessive sun-tanning does not cause intoxication. Vitamin D3 is produced 
commercially by exposing 7-dehydrocholesterol from lanolin to ultraviolet radiation.  
 
When vitamin D is transported in the blood, it is bound to a vitamin D binding protein 
(VDBP), and after synthesis it binds to vitamin D receptor (VDR), a member of the 
nuclear receptor superfamily that is expressed by numerous cells in the body. A 
liganded vitamin D receptor mediates the action of active vitamin D by controlling the 
expression of sensitive genes. Vitamin D is fat-soluble and can be stored in and 
released from fat cells, which constitute an endogenous depot (191). Obesity is 
associated with vitamin D deficiency, and it is believed to be due to the sequestration of 
vitamin D by the large pool of body fat (192).  
 
During exposure to UVB radiation from sun-light, 7-dehydrocholesterol in the skin is 
converted to pre-vitamin D3, which— in a heat dependent procedure—is immediately 
converted to vitamin D3 (cholecalciferol) (191, 193, 194).  
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With the help of VDBP, vitamin D3 enters the liver and is converted by the enzyme D-
25-hydroxylase (encoded by the CYP2R1 gene) into 25-hydroxyvitamin D, 25(OH)D. 
This is the major circulating form of vitamin D and is the metabolite considered to best 
reflect the vitamin D status of an individual. 25(OH)D is inactive and must be 
converted a second time, with the help of the enzyme 25(OH)D-1α-hydroxylase 
(encoded by the gene CYP27B1), into 1,25-dihydroxyvitamin D [1,25(OH)2D],which 
is the biologically active form. This last transformation mainly takes place in the 
kidneys, but it also occurs in other cells such as macrophages, monocytes, and 
epithelial cells. After synthesis, 1,25(OH)2D is released into the general circulation and 
binds to the VDR. It is only the kidney CYP27B1 that contributes to the levels of 
1,25(OH)2D in the circulation. 
 
Vitamin D is metabolized to its active form in various tissues and cells for regulating of 
cellular proliferation and differentiation as also to induce AMPs such as the cathelicidin 
LL-37 in macrophages. When a macrophage is stimulated through a Toll-like receptor 
(TLR1/2) by an infectious agent, there is a signal that up-regulates the production of the 
enzyme 25(OH)D-1α-hydroxylase and there is also an increase in the expression of  
vitamin D receptor. 1,25(OH)2 D reduces its own synthesis through negative feedback 
and reduces the synthesis of parathyroid hormone (PTH) by a direct effect on cells in 
the parathyroid glands. 
 
Expression of the catabolizing enzyme 25(OH)D-24-hydroxylase (encoded by the gene 
CYP24A1) is enhanced by 1,25(OH)2D, and it converts both 25(OH)D and 
1,25(OH)2D into  biologically inactive products. The elimination half-life of 25(OH)D 
is approximately 15 days, whereas that of 1,25(OH)2D is about 2–4 h (195). The 
progressively hydroxylated metabolites, including lactones and calcitroic acid (more 
hydrophilic), allow both biliary and renal excretion (196). 1,25(OH)2D enhances 
intestinal calcium absorption in the small intestine by interacting with vitamin D 
receptor, resulting in increased expression of epithelial calcium channels and 
production of calcium binding proteins (calbindin 9K) (191). Receptors on osteoblasts 
bind 1,25(OH)2D, which results in increased  expression of receptor NFкВ ligand 
(RANKL). RANKL binds to RANK on the osteoclasts, and this makes the osteoclasts  
mature (197). The task of a mature osteoclast is to remove calcium and phosphorus 
from bone while maintaining calcium and phosphorus levels in the blood, which is 
essential for healthy bone. Thus, vitamin D deficiency leads to deficient mineralization 
of bone. 
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Figure 3. Vitamin D metabolism.                                                                                                                                           
 
1.6.2 Prevalence, definition, and treatment 
Since 25(OH)D comes from both endogenous and dietary sources of vitamin D, it 
reflects the vitamin D status of the patient in the most correct way. Vitamin D 
inadequacy appears to be a widely spread global problem in all age groups. The major 
cause of vitamin D deficiency is inadequate exposure to sunlight (198-201). Wearing a 
sunscreen with a sun-protection factor of 30 reduces vitamin D synthesis in the skin by 
more than 95% (202). 
 
Much debate has taken place over the definition of vitamin D deficiency. Vitamin D 
deficiency could be defined as a 25(OH)D below 50 nmol/liter (20 ng/ml) and vitamin 
D insufficiency as a 25(OH)D of 50-75 nmol/liter (21-29 ng/ml) (203). This is based on 
the observation that intestinal calcium absorption is maximized above 80 nmol/liter, in 
postmenopausal women (204) and that parathyroid hormone (PTH) concentrations in 
adults continue to decline and reach their nadir at 75-100 nmol/liter (204-206). This 
means that it is an inverse relation between 25(OH)D and parathyroid hormone.  
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Figure 4. Correlation between P-PTH levels and P-25(OH)D levels.                                                                        
                   
 
Risk factors for vitamin D deficiency include dark skin pigmentation, living at a 
northern latitude, lack of direct exposure to sunlight, osteoporosis, kidney disease, 
malabsorption syndromes, obeseity, pregnancy, lactation, and hyper-parathyroidism.  
 
The most common way to treat vitamin D deficiency in northern Europe is by oral 
supplementation of vitamin D3. 1,25(OH)2D is not the first-line treatment, except in 
patients with chronic kidney disease, because its renal effects increase the risk of both 
cholelithiasis and hypercalcaemia due to its influence on calcium metabolism.  
 
The optimal regimen for treatment of vitamin D deficiency is controversial because of 
an on-going discussion about the level of 25(OH)D at which there is a need for 
supplementation, and for what kinds of symptoms. There is also an on-going debate 
about which dose is optimal to achieve a high enough serum level to provide the 
numerous health benefits that can be associated with vitamin D. One must remember 
that individuals with malabsorption or other risk factors for vitamin D deficiency may 
require higher chronic doses to maintain optimal levels (207, 208). One study has 
suggested that healthy men consume/metabolize 3,000–5,000 IU vitamin D3 per day, 
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meeting > 80% of their winter cholecalciferol needs with cutaneously synthesized 
accumulations from solar sources during the preceding summer months (209). The 
recommendations from the Endocrine Practice Guidelines committee for patients at risk 
of vitamin D deficiency are as follows: in children up to 1 year of age, 2,000 IU/day; in 
children up to 13 years of age, 4,000 IU/day; and in adults, doses between 4,000 and 
10,000 IU/day are required. For individuals with no risk factors for deficiency, the 
committee recommends 1,000–3,000 IU/day for children and 4,000 IU/day for adults 
(203).  
 
It has been proposed that declining vitamin D levels during winter time may explain the 
increased prevalence of respiratory tract infections during that part of the year. One 
relatively recent prospective cohort study suggested that supplementation with vitamin 
D to raise the concentrations of 25(OH)D to 95 nmol/l could release the burden of 
illness from viral infections in adults living in temperate climates (210). 
  
Toxicity due to excess vitamin D intake is rare, but it has been reported in a few cases 
and generally with doses exceeding 10,000 IU/day (211, 212) for extended periods. 
Acute vitamin D toxicity that involved hypercalcaemia has been found in cases with an 
intake of vitamin D exceeding 40,000 IU/day (211-213). It has been estimated that 
circulating levels of 25(OH)D of > 250–375 nmol/l could possibly give signs of 
hypercalcaemia (214), which can include weakness, nausea, bone pain, and headache. 
No adverse effects have been seen in healthy individuals consuming daily doses of 
vitamin D up to 10,000 IU (213, 214). Daily intake markedly exceeding this amount for 
several months is required to maintain a vitamin D level above 250 nmol/l (214). 
 
1.6.3 Non-skeletal effects of vitamin D 
There is increasing evidence to suggest that optimal vitamin D levels throughout one's 
whole life—even in utero—may be essential. It may be crucial not only in maintaining 
good bone health, but also in protection against, for example, autoimmune diseases, 
cardiovascular diseases, and cancers (215, 216). Many tissues in the body express the 
nuclear receptor for 1,25(OH)2D, including skin, brain, colon tissues, prostate, breast 
and also different cells in the immune system, such as T- and B-lymphocytes and 
macrophages (190, 194). Active vitamin D is present in the circulation for a very short 
time period only, and local activation in target immune cells is imperative for vitamin 
D-mediated effects on the immune defence (217). 1,25(OH)2D is involved in regulation 
of more than 200 genes controlling cell proliferation, differentiation, and apoptosis 
(179, 218), and the non-skeletal biological effects of vitamin D are thought to be 
involved in several disease processes (194). 
 
1.6.3.1 Association with susceptibility to infection 
The link between vitamin D deficiency and susceptibility to infections of the 
respiratory tract has been suggested for many years, but it has not yet been definitively 
proven. A systematic review of clinical studies by Jolliffe et al. (2013) has shown 
broadly consistent associations between vitamin D deficiency and susceptibility to 
respiratory infection (219). In contrast, vitamin D supplementation trials have not 
demonstrated consistent protective effects against respiratory infection. Clinical trials 
that show no effect may have had a low prevalence of baseline vitamin D deficiency in 
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participants, or sub-optimal doses of vitamin D. Another meta-analysis and systematic 
review, published by Bergman et al. (2013), of randomized controlled trials indicated 
that vitamin D has a protective effect against respiratory tract infection and that dosing 
once-daily appears to be most effective (220). 
 
As mentioned below, several clinical trials in different populations have given mixed 
results. 
 
Murdoch et al. compared 100,000 IU/month of oral vitamin D for 18 months or 
placebo in 322 healthy adults in New Zealand (221). No effects on the incidence or 
severity of RTIs were seen. In this study, those included had a mean vitamin D level of 
75 nmol/l at baseline and this means that the participants did not have a vitamin D 
deficiency (221). In addition, a recent study performed by Rees et al. concluded that 
supplementation with 1,000 IU/day did not significantly reduce the incidence or 
duration of upper RTI in adults with a baseline 25(OH)D level of 61 nmol/l (222). The 
finding that vitamin D has no effect on RTIs is consistent with two other randomized 
controlled studies that unfortunately had weaknesses in the design, with short duration 
or too small dose of vitamin D, and both of these studies were underpowered (223, 
224). In the United States, Li-Ng et al. reported no effect on respiratory tract infections 
in 162 adults given 2,000 IU/day vitamin D for 12 weeks, compared with placebo 
(223). This trial may have been underpowered, and too short to allow vitamin D levels 
to reach a steady state. Laaksi et al. included 164 healthy Finnish soldiers who were 
randomly assigned to the intervention group, which received 400 IU vitamin D3 daily, 
or the control group, which received placebo. This study was performed for 6 months, 
between October to March (224), and the participants reported an average of 2.2 days 
missed from work due to respiratory tract infection in the vitamin D group and 3.0 in 
the placebo group. One weakness of this study was that there are indications that 
additional supplementation with 400 IU/day is not sufficient to maintain an adequate 
level of vitamin D through the winter (225). 
 
It is possible that an effect will only be observed in a population with a high prevalence 
of vitamin D deficiency, as occurred in a recent trial of vitamin D substitution with the 
aim of reducing exacerbations of chronic obstructive pulmonary disease (226). In that 
study, supplementation of vitamin D significantly reduced exacerbations only in 
individuals with levels less than 25 nmol/l at the time of inclusion. Two other recent 
studies have shown contrasting effects of vitamin D supplementation in children. In one 
randomized trial, researchers gave vitamin D supplementation to Mongolian school 
children in winter time and noted a 50% reduction in acute respiratory infections in the 
study population that had an average vitamin D level of less than 25 nmol/l (227). In 
The Lancet, Semira Manaseki-Holland and colleagues reported contradictory results of 
supplementation of bolus-dose vitamin D (228). In that study, the addition of vitamin D 
did not influence the incidence of first episode of pneumonia in children in 
Afghanistan, which is actually a population with a high prevalence of vitamin D 
deficiency (228). The researchers randomly assigned 3,046 infants aged 1–11 months 
to receive a quarterly dose of 100,000 IU vitamin D3 or placebo over 18 months. An 
editorial comment, written by A.R. Martineau, about this study has been published in 
The Lancet (229). The author wrote that some issues have to be considered when 
interpreting the results of the Afghanistan study. One must consider the possibility that 
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the pharmacokinetics of vitamin D3 administered in large doses quarterly and 
malnutrition in the study population could interfere with the outcome of the study. 
Another explanation of the study result would be that a subgroup of participants might 
have benefited from the supplementation but that this effect was concealed by a larger 
group of non-responders. 
 
A cross-sectional trial from Greenland showed that both low (< 75 nmol/l) and high 
serum concentrations of vitamin D (> 140 nmol/L) were associated with an increased 
risk of tuberculosis (230). Similarly, molecular studies have suggested the presence of 
feedback systems that effectively block the activation of vitamin D at several levels 
when large supraphysiological doses are given (231-233).  
 
Low levels of 25(OH)D are associated with an elevated risk of tuberculosis (234-236). 
It has been found that through activation of a Toll-like receptor, Mycobacterium 
tuberculosis initiates expression of 25(OH)D-1α-hydroxylase and VDR genes in the 
cell. If there is not enough 25-hydroxyvitmain D available to the 1α-hydroxylase, as is 
the case  in vitamin D deficiency (237), then insufficient 1,25(OH)2D will be present 
locally. This, in turn, will reduce binding of 1,25(OH)2D to the macrophage VDR, 
thereby limiting the activation of VDR-dependent anti-microbial genes and the 
subsequent killing of microbes (238). 
 
In one study, β-defensin, which has a bactericidal effect on S. aureus, has been shown 
to be induced by vitamin D; moreover, it has been suggested that low levels of vitamin 
D are associated with an increased risk of being colonized with this bacterium (9, 239).  
 
There is both mechanistic and clinical evidence to suggest that vitamin D can prevent 
viral infections (210, 240-243). The ability of viruses to activate TLR-induced 
pathways similar to those activated by mycobacteria and bacteria suggests that 
induction of immune responses to vitamin D may also promote anti-viral effects. It has 
been proposed that vitamin D has effects on cytokine production and suppression of 
inflammation (244), and it may therefore have the ability to reduce the severity of viral 
pneumonia (245). 
 
The link between vitamin D deficiency and increased susceptibility to infections has 
grown stronger in recent years.  
 
1.6.3.2 Muscle strength 
Skeletal muscles have a vitamin D receptor, and probably require vitamin D for optimal 
function (179, 246). Lack of vitamin D has been shown to cause muscle weakness (194, 
247, 248). Several studies have supported the hypothesis that vitamin D inadequacy 
contributes to age-related muscle weakness (249, 250) and falls (251, 252). A meta-
analysis of randomized controlled trials on vitamin D supplementation showed an 
approximately 20% reduced risk of falls in ambulatory or institutionalized older 
individuals treated with vitamin D supplements (253). 
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1.6.3.3 Cancer 
There is a latitude gradient for several different malignancies in adults, including 
Hodgkin’s lymphoma as well as prostate, ovarian, colon, breast, pancreatic, and other 
cancers (246, 254-260). Both prospective and retrospective epidemiological studies 
have suggested that levels of 25(OH)D less than 50 nmol/l may be associated with a 
30–50% higher risk of breast, prostate, and colon cancer (254, 257, 258, 261, 262). 
There are some experimental data to suggest that 1,25 (OH)2D in a malignant cell can 
induce apoptosis and prevent angiogenesis, and thereby reduce the capacity of 
cancerous cells to grow (194, 263). 
 
1.6.3.4 Autoimmune diseases, diabetes, and inflammation 
Some studies have indicated that living in areas with less sunlight increases the risk of 
type 1 diabetes, Crohn’s disease, and multiple sclerosis (264, 265). Women whose 
intake of vitamin D was more than 400 IU/day showed a significantly reduced risk of 
developing rheumatoid arthritis (266, 267). In addition, 10,366 children in Finland 
received 2,000 IU vitamin D per day during the first year of life were followed for 31 
years and showed a reduced risk of type 1 diabetes by approximately 80% (268). 
Vitamin D3 has also been shown to suppress the Th2 response in allergic broncho-
pulmonary aspergillosis (269). In addition, experimental studies have shown that 
1,25(OH)2D has broad anti-inflammatory effects on the adaptive immune system by 
shifting the T-helper cell pool from a Th1/Th17 response to a mainly Th2/Treg-
predominant response (270, 271). 
 
1.6.3.5 Cardiovascular disease 
Earlier studies have shown an association between living at a higher latitude and an 
increased risk of hypertension and cardiovascular disease (272, 273). In a group of 
patients with hypertension who were treated with UVB radiation 3 times a week for 3 
months, it was found that 25(OH)D levels increased by approximately 180% and blood 
pressure, both systolic and diastolic, was reduced by 6 mmHg (274). 
 
1.6.3.6 Mental health 
One group has pointed out that it could be important for the foetus that pregnant 
women achieve a satisfactory vitamin D level in the circulation, since vitamin D is 
probably essential for  transcriptional activity of receptors in the brain, for brain 
development, and for maintenance of mental function later in life (275). In different 
studies, lack of vitamin D has been associated with an increased incidence of 
depression, schizophrenia, and autism (276-278). 
 
1.6.4 Vitamin D and HSCT 
Vitamin D deficiency is common following HSCT. In both adults and children who 
have experienced HSCT, several studies have suggested that there is a high incidence 
of vitamin D deficiency or insufficiency at baseline (70–89%) (279-282).  
For several reasons, HSCT patients are potentially at increased risk of having low 
vitamin D levels after transplant. Factors that could possibly contribute to post-HSCT 
vitamin D deficiency are reduced uptake from the intestines because of GVHD, 
bacterial overgrowth in the bowel, and increased catabolism because of the use of 
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glucocorticoids (281-285). IFN-gamma, a distinct stimulator of macrophage 1α-
hydroxylase expression, is often down-regulated by glucocorticoids and other 
immunosuppressive agents (286). Transplanted patients may also have reduced 
exposure to direct sunlight because of hospitalization and convalescence. 
 
How vitamin D interferes with the responsiveness of the human immune system, in the 
context of HSCT, is of great interest, but to date findings are contradictory. It has been 
described that vitamin D might prevent GVHD, and since GVHD is one major obstacle 
to successful HSCT, great efforts are being made to prevent—and to deepen our 
understanding of—this complication. T-lymphocytes and DCs are well known to play a 
central role in the pathogenesis of GVHD, and it is known that their function can be 
modified by vitamin D.  
 
Several preclinical trials have been performed to investigate this subject in greater 
detail. It has been shown that vitamin D inhibits the maturation of DCs and polarizes 
the T-cell population towards the expression of Th2 cytokines rather than Th1 
cytokines. This in turn gives a reduced allogeneic T-cell proliferation in response to DC 
stimulation. These data suggest that vitamin D supplementation could result in 
immature DC populations that skew toward tolerizing T-cells rather than stimulatory 
populations (287). One study has shown less signs of GVHD in mice treated with a 
vitamin D analogue, probably due to down-regulation of T-lymphocytes and weakened 
inflammatory response (288). In addition, in vitro studies have shown that active 
vitamin D inhibits mixed lymphocyte cultures in a dose-dependent manner (289). 
Active vitamin D has also been suggested to alter the surface phenotype and 
morphology of DCs, which may compromise contacts between DCs and T-
lymphocytes and thereby diminish interaction and T-lymphocyte cytokine secretion 
(290). In a vitamin D receptor knock-out mouse model, it was shown that vitamin D-
mediated suppression of DC maturation was lost, resulting in an altered ability to 
stimulate allogeneic T-cell proliferation (291). DCs that are generated in the presence 
of vitamin D have a reduced production of IL-12 and they induce hypo-responsiveness 
of allogeneic T-cells (292, 293). It has also been shown that vitamin D enhances 
apoptosis of mature DCs, resulting in inhibition of T-cell alloreactivity (294). One 
study has concluded that the net result of the action of 1,25(OH)2D on T-cells, thereby 
also having a possible effect on GVHD, is to block the induction of Th1 cell cytokines, 
especially IFN-gamma , while promoting Th2 cell responses (295). Taking all these 
results together, the main effect of vitamin D on GVHD is modulation of the T-cell 
response. 
 
A clinical study performed by Rosenblatt et al. found two cases of improvement in 
adult patients suffering from a steroid-refractory GVHD when the patients were given 
vitamin D supplementation (287). In addition, earlier clinical studies have shown 
evidence of a linkage between sufficient vitamin D levels and less chronic GVHD in 
adult patients (296, 297).  
 
There is also emerging evidence that vitamin D may play a role in immunomodulation 
of other parts of the immune system. For more than 20 years, it has been known that 
vitamin D can suppress immunoglobulin production (298). In earlier studies, vitamin D 
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has been shown to suppress the proliferation of B-lymphocytes, the differentiation of 
plasma cells, and the secretion of antibodies (299, 300).  
 
The possible effect of vitamin D on the outcome after HSCT is not well documented. 
Nevertheless, the effects of vitamin D in HSCT deserve greater attention. 
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2 AIMS OF THE PRESENT STUDY 
 
The overall objective of the present thesis was to deepen our understanding of the 
panorama of infections in patients undergoing HSCT and in patients with antibody 
deficiency or increased susceptibility to infections.  
 
Specific aims of the present thesis were: 
 
1. To study the association between IgG levels and the outcome after   
allogeneic HSCT. 
 
2. To compare the effects of conditioning with Campath and 
Thymoglobulin on the clinical outcome of allogeneic HSCT. 
 
3. To determine whether treatment with vitamin D could reduce 
infectious symptoms and antibiotic consumption in patients with antibody 
deficiency or frequent RTI. 
 
4. To determine the prevalence of vitamin D deficiency in children after 
allogeneic HSCT and to relate vitamin D status to clinical outcomes. 
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3 MATERIALS AND METHODS 
 
3.1 PATIENTS AND MATERIALS IN STUDY I, II, AND IV 
Patients included in studies I, II, and IV of this thesis were transplanted at Karolinska 
University Hospital, Huddinge, Sweden between 1995 and 2011. Studies I, II, and IV 
were approved by the local ethics committee at Karolinska University Hospital, 
Huddinge (DNR 425/97). The patient characteristics are summarized in Table 1: 
 
Table 1. Abbreviations: BM: bone marrow, CB: umbilical cord blood, CsA: cyclosporine A, MAC: myeloablative 
conditioning, MDS: myelodysplastic syndrome,  MM: HLA mismatched donor, MMF: mycophenolate mofetil,  
MTX: methotrexate, MUD: HLA matched unrelated donor, NC: Nuclear cells, PBSC: peripheral blood stem cells , 
RIC: reduced intensity conditioning, TBI: total body irradiation 
 
 
Study I  Study II  Study IV 
Number  179  108  123 
Sex (Male/Female)  102/77  54/54  83/40 
Mean age  35 (10‐65)  55 (<1‐67)  9 (<1‐19) 
Children (<18y)  35 (20%)  4 (4%)  119 (97%) 
Diagnosis:       
Acute Leukaemia  83 (46%)  25 (23%)  38 (31%) 
Chronic Leukaemia  53 (30%)  21 (19%)  3 (2%) 
MDS  5 (3%)  40 (37%)  20 (16%) 
Other malignancy  22 (12%)  14 (13%)  5 (4%) 
Non‐Malignant   16 (9%)  8 (7%)  57 (46%) 
Disease stage 
(Early/Late) 
111/57  30/78  78/45 
Donor:       
Sibling  91 (51%)  32 (30%)  43 (35%) 
MUD  76 (42%)  67 (62%)  57 (46%) 
MM  12 (7%)  9 (8%)  23 (19%) 
Donor age  35 (5‐62)  34 (21‐71)  22 (0‐55) 
Female to Male  32 (18%)  11 (10%)  28 (23%) 
Stem cell source:       
BM/PBSCs/CB  85/94/0  19/89/0  84/21/18 
NC dose (x108/kg)  4.5 (0.5‐27.6)  11.1 (1.0‐54.5)  4.5 (0.3‐36.9) 
CD34+ dose (x106/kg)  5.3 (0.3‐25.5)  7.6 (0.6‐26.0)  4.8 (0.1‐43.8) 
Conditioning:       
MAC/RIC  146/33  17/91  82/41 
TBI‐based  101 (56%)  19 (18%)  37 (30%) 
Chemo‐based  78 (44%)  89 (82%)  86 (70%) 
ATG/Campath  109/1 (61%)  72/36 (100%)  94/2 (78%) 
GVHD prophylaxis:       
CsA+MTX  157 (88%)  95 (88%)  81 (66%) 
CsA+MMF  12(7%)  0  0 
Tacrolimus+Sirolimus  0  13 (12%)  21 (17%) 
Other  10 (6%)  0  21 (17%) 
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3.2 PATIENTS AND MATERIALS IN STUDY III 
In study III,  patients were included from the Immunodeficiency Unit, Karolinska 
University Hospital, Huddinge, Sweden, between March and June 2010. Inclusion 
criteria were age 18–75 years and an increased susceptibility to respiratory tract 
infection; that is, > 42 days with symptoms from the respiratory tract over a 12-month 
period prior to inclusion. Study III was approved by the local ethics committee in 
Stockholm (DNR 2009/1678-31/4 and 2010/498-32). Baseline data and patient 
characteristics are summarized in Table 2: 
 
  Vitamin D  Placebo 
Number  70  70 
Mean age  55.4  50.8 
Female  52/70  50/70 
Male  18/70  20/70 
IgG replacement  39/70  42/70 
Smoking  4/70  6/70 
25(OH)D levels (mean, nmol/l)  51.5  46.9 
Immunological diagnosis     
    IgA deficiency  9/70  9/70 
    IgG subclass deficiency  27/70  30/70 
    CVID  6/70  4/70 
    ND  28/70  27/70 
Concomitant disease     
    No other disease  16/70  18/70 
    Lung: Asthma  27/70  25/70 
    Lung: BE  5/70  7/70 
    Lung: COPD  5/70  4/70 
    Other disease*  17/70  16/70 
 
Table 2. * other disease includes: hypertension, body pain, hypothyroidism and gastritis as most common 
diagnosis. Abbreviations: BE: bronchiectasis, COPD: chronic obstructive pulmonary disease, CVID: 
common variable immunodeficiency, ND: increased susceptibility to infections without a defined 
immunological disorder 
 
3.3 METHODS IN STUDY I, II, AND IV 
3.3.1.1 Conditioning 
In study I, II and IV, Myeloablative conditioning regimens (MAC) consisted of 
cyclophosphamide (Cy) (60 mg/kg daily) for 2 days in combination with either TBI 
(single dose 10 Gy or fractionated 4x3 Gy) or busulfan (Bu) (4 mg/kg daily) for 4 days 
(301, 302). Patients with aplastic anaemia and sibling donor received 200 mg/kg of Cy 
and ATG.  
Reduced intensity conditioning regimens (RIC) consisted of fludarabine (Flu) (30 
mg/m2 daily) for 3–6 days, combined with 2 Gy TBI, Cy alone (30 mg/kg daily) for 
two days, Cy (60 mg/kg) and 2x3 Gy TBI, Treosulfan (12-14g/m2 daily) for 3 days or 
Bu (4 mg/kg daily) for 2 days (71, 303, 304). 
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Patients with unrelated or mismatched donors, and all patients with non-malignant 
disorders, were treated with ATG 2 mg/kg/day for 2–5 days or Campath 30 mg/day for 
1–3 days before transplantation. (305). Both antibodies were given with the last dose on 
the day before infusion of the cells. 
 
3.3.1.2 GVHD prophylaxis 
Most of the patients received CsA combined with a short course of methotrexate 
(MTX) as prophylaxis against GVHD (306, 307). In the absence of GVHD, in patients 
with malignancies CsA was discontinued after 3 months when HLA-identical sibling 
donors were used and after 6 months when unrelated donors were used.  CsA was 
discontinued after 12–24 months in patients with non-malignant disorders. No GVHD 
prophylaxis was given after syngeneic transplants. Other protocols included CsA alone, 
T-cell depletion, and CsA combined with either prednisolone or mycofenolate mofetil. 
A few patients received sirolimus and tacrolimus.  
 
3.3.1.3 Supportive care 
Supportive care has been described in detail previously (308-310). During the 
pancytopenic phase, adult patients received prophylactic treatment with ciprofloxacin 
in combination with anti-fungal therapy until the absolute neutrophil count exceeded 
0.5 × 109/l. During the first six months after engraftment, trimethoprim-sulfametoxazol 
was administered against Pneumocystis jirovecii  infection. In study IV, in children 
who developed plasma IgG < 4 g/L after HSCT, IgG substitution was used (311).  
 
3.3.1.4 Definitions 
Engraftment was defined as stable absolute neutrophil counts of > 0.5 × 109/l for three 
consecutive days. Diagnosis of acute and chronic GVHD was made based on clinical 
symptoms and/or biopsies according to established criteria (86, 312). For the diagnosis 
of bacteraemia, at least one positive blood culture was required. Invasive fungal 
infection was defined as positive blood culture and/or positive cultures from at least 
two organs for Candida or Aspergillus species. Aspergillus pneumonia was defined as 
pulmonary infiltrates and positive cultures of bronchoalveolar lavage fluid, sputum, or 
autopsy samples. In study I, patients with IgG values below 4 g/L were defined as 
significantly deficient according to the existing guidelines for antibody-replacement 
therapy (313, 314). In study IV, vitamin D insufficiency was defined as ≤ 50 nM/L 
25(OH)D at baseline.  
 
3.3.1.5 Cell-surface markers and immunoglobulin 
Relative numbers of T- (CD3+) and B- lymphocytes (CD19+) and NK-cells (CD56+) 
were determined by flow cytometry (FACS). Serum IgG was analyzed routinely by 
nephelometry at the Department of Clinical Chemistry, Karolinska University 
Laboratory. 
 
3.3.1.6 Statistics 
Continuous variables were compared using Mann-Whitney test or Kruskal-Wallis test, 
and proportions were compared using Fisher’s exact test or chi-square test. The 
Kaplan-Meyer method was used to estimate the probability of overall survival and 
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relapse-free survival while TRM, relapse, and GVHD were calculated using a 
nonparametric estimator of cumulative incidence curves. Univariate and multivariate 
analyses were performed using Gray’s test or Cox proportional hazard regression 
models. A p-value < 0.05 was considered to indicate a significant difference between 
the groups being compared. Only factors at the 10% level from the univariate analysis 
were assessed in the multivariate (stepwise) analysis. 
 
3.4 METHODS IN STUDY III 
3.4.1.1 Study design 
Study III was a prospective, randomized, double-blind placebo-controlled study of 
vitamin D supplementation in patients with increased susceptibility to respiratory tract 
infections. The study was registered at www.clinicaltrials.gov (NCT01131858, 
eduraCT nr: 2009-011758-16) before inclusion of the first patient. 
 
3.4.1.2 Sample size calculation  
The sample size was based on the assumption that treatment with vitamin D would 
reduce the number of days with symptoms from the respiratory tract, from 42 to 28 
days. Given this assumption, a sample size of 60 patients per study group was predicted 
to provide the study with 90% power at a significance level of p = 0.02. To compensate 
for exclusion of participants, the two arms were increased to include 70 patients per 
treatment arm. Importantly, the only reason for using p = 0.02 was to ensure that there 
was a sufficient number of participants. The conventional significance level of p = 0.05 
was used for all statistical analysis of the results. 
 
3.4.1.3 Interventions 
The patients were randomized to 12 months of supplementation with vitamin D (4,000 
IU daily) or placebo oil. The participants were instructed to mark their daily symptoms 
in a diary. Every month, they sent their filled-out diary to the study site by regular mail. 
The following data were recorded in the diary: symptoms from the respiratory tract, 
ears and sinuses, treatment with antibiotics, numbers of bacterial cultures, times of and 
reasons for visits to hospitals, frequency of travelling abroad, and adherence to the 
study drug. 
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Figure 6. The infection diary used in study III. 
 
3.4.1.4 Outcomes 
The primary outcome was a composite infectious score, based on the diary mentioned 
above, and included five parameters: (1) symptoms from the respiratory tract, (2) 
symptoms from the ears, (3) symptoms from the sinuses, (4) malaise, and (5) use of 
antibiotics. All the participants were asked to only report those symptoms that they felt 
were caused by an infection in the respiratory tract (i.e. not allergy, wounds etc).  
  
Secondary outcomes were serum levels of 25(OH)D (at baseline and after 3, 6, 9, and 
12 months), numbers of bacterial cultures, microbiological findings, and amounts of 
AMPs (LL-37 and HNP1-3) in nasal fluid (at baseline and after 6 and 12 months). In 
addition, analyses for single nucleotide polymorphisms (SNPs) were performed for 
VDR (Taq1 and Foq1), CYP27B1, CYP24A1, CYP2R1, and vitamin D binding protein 
(GC).  
 
3.4.1.5 Statistics 
In the statistical analysis, continuous variables were analyzed using Mann-Whitney U 
test or linear regression. Dichotomous variables were analyzed by Fisher’s exact test or 
logistic regression. Regressions of log-transformed infectious scores were performed 
both unadjusted and with adjustment for potential confounders such as underlying 
diseases or differences in SNPs for VDR. Because of severe skewing, scores were log-
transformed before analysis. Furthermore, the randomization had resulted in age 
distribution that could possibly impinge upon the study result, and a multivariate 
analysis was therefore added to the original analysis plan, adjusting for potential 
confounders.  
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A multivariate model was used in which an effect size of 1 indicated identical outcome 
in the study groups. To explore potential divergent effects on different organ systems, 
both adjusted and unadjusted analyses were repeated separately for each individual part 
of the infectious score. In addition, the temporal dimensions of the vitamin D effect 
were investigated by dividing the study period into four 90-day periods. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I — IGG LEVELS AFTER HSCT 
Because of complications associated with GVHD, infections, and patient age, the B-
cell repertoire is often belated after HSCT. Patients who develop chronic GVHD may 
never have a revitalized, normal immune function (50, 315). It usually takes 3–6 
months for serum IgM levels to return to normal ranges whereas recovery of serum IgG 
levels may be delayed up to one year or longer (316, 317). In earlier studies, 
impairment of antibody immunity after HSCT has been found to be correlated with an 
increased risk of infections, mostly due to encapsulated bacteria (318). 
 
In paper I, we determined the clinical influence of IgG levels after HSCT in 179 
patients who received transplants between 1995 and 2002. Only patients with at least 
two IgG levels measured during the first 12 months post-transplantation were included 
in the study. Because of difficulties in estimating immunoglobulin levels in patients 
with myeloma, in patients treated with intrevenous immunoglobulin (IVIG), and in 
children less than 10 years of age, these patient groups were excluded.  
 
Serum samples for measurement of IgG were collected 3, 6, 9 and 12 months after 
transplantation and then annually until 5 years post-transplantation. In this study, IgG 
levels after HSCT increased throughout the study period, especially from 6 to 12 
months. 
 
Multivariate analysis was performed to evaluate different factors that could be 
associated with low IgG levels (< 4 g/L) after HSCT. Acute and chronic GVHD, 
patient age, donor age, HLA mismatch, treatment with ATG, and conditioning regimen 
were included as variables. Factors influencing IgG levels three months after 
transplantation were acute GVHD of grades I–IV and patient age ≤ 30. Six months after 
HSCT, acute GVHD of grades I–IV, patient age ≤ 30 years, and no treatment with 
ATG were associated with low IgG levels. One year after HSCT, three variables were 
associated with low IgG levels: acute GVHD of grades I–IV, female donor to male 
recipient, and GVHD prophylaxis with CsA + MTX. 
 
In paper I, we also studied IgG levels and the relationship to survival and transplant-
related mortality. Patients with IgG levels of < 4 g/L on at least two occasions during 
the first year after HSCT showed a reduced cumulative proportion of survival and an 
increased risk of TRM compared to patients with moderately low or normal IgG levels. 
Patients with low IgG levels had an increased incidence of infections when they died, 
but this finding was borderline-significant (p = 0.056). 
 
Discussion 
The combination of immunosuppressive treatment and an immature immune system 
gives rise to a variety of complications after HSCT. All patients undergo a period of 
both humoral and pronounced cellular immunodeficiency. Haematopoietic stem cells 
are characterized by the ability to self-renew and differentiate into all mature blood 
lineages. After the cells have been transfused into the patient’s circulation, the 
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immunological function gradually increases. Most of the patients were 
immunologically competent within 2 years (316, 319). Even so, some patients—
especially those who suffer from GVHD—do not show reconstitution of the immune 
system. In study I, we found that IgG levels after HSCT increased throughout the study 
period, which is in accordance with earlier studies (320). We found five factors that had 
a negative effect on IgG levels in our study: acute GVHD, patient age ≤ 30 years at the 
time of transplantation, lack of treatment with ATG, female donor to male recipient, 
and treatment with CsA and MTX as GVHD prophylaxis. Our hypothetical model is 
that many of these factors can increase GVHD and, because of this, decrease 
immunological revitalization. In addition, in multivariate analysis we found that low 
IgG levels were significantly correlated with higher TRM and inferior survival. These 
results indicate that a reasonably high level of IgG in peripheral blood after HSCT is 
one important factor for a good outcome after transplantation. 
  
It is known that patients who have undergone HSCT are highly susceptible to all kinds 
of infections. The major indication for IVIG treatment is primary immune deficiency, 
but there are also indications for IVIG treatment in various autoimmune disorders and 
infections in immunocompromised patients. Different studies performed during the last 
few years have found contradictory results regarding beneficial effects of IVIG 
treatment. IVIG has been shown to have a positive effect on bacterial infections (321). 
It has also been suggested that IVIG could have immunomodulatory effects in vivo, a 
treatment that decrease the risk of acute GVHD after HSCT (322). In contrast, other 
studies have found no effect of IVIG treatment on either GVHD or survival after 
transplantation (317, 323). In a retrospective study, prophylactic IVIG treatment after 
HSCT was shown to have no effect on overall survival, but the incidence of death due 
to infections was lower in the patients treated with IVIG (323). In another study, IVIG 
was shown to reduce proliferation of B-lymphocytes and immunoglobulin production 
by co-ligation of the B-cell antigen receptor and the Fc-γ RIIb receptor mediating the 
Fc receptor off signal (324). In addition, in one study it was concluded that both IgM 
and IgG profiles become less heterogeneous in patients treated with IVIG after HSCT, 
and that this effect remains months to years after accomplished IVIG treatment (325). 
In summary, there is no consensus on whether or not IVIG treatment is beneficial after 
HSCT. 
  
4.2 PAPER II — CAMPATH AND THYMOGLOBULIN AS PART OF 
CONDITIONING 
GVHD is a major cause of morbidity and mortality after HSCT. Many centres add 
ATG to reduce the risk of GVHD and rejection. The risk of rejection is increased when 
an unrelated donor is used. By adding ATG to the pre-transplant protocol when using 
an unrelated donor, both acute GVHD and early mortality have declined to levels 
similar to those in HSCT with matched, related donors (78, 309). 
 
In paper II, we retrospectively compared 36 patients given Campath (alemtuzumab) as 
part of the conditioning with a matched cohort of 72 patients who received 
thymoglobulin (TMG).  
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There was a higher incidence of invasive fungal infections in the Campath-treated 
patients in this study, but this was not statistically significant. The incidence of 
bacteraemia and CMV reactivation was the same in the two groups; nor could any 
differences be noted in HSV and VZV reactivation. Three cases of PTLD occurred in 
the Campath group and one case occurred in the control group. 
 
The cumulative incidence of any grade of acute GVHD was 34% in the Campath-
treated patients, as compared to 53% in patients given TMG (p = 0.09). The cumulative 
incidence of chronic GVHD was 46% and 25% in patients who received Campath and 
TMG, respectively (p = 0.09). 
   
There was no significant difference in TRM in the two groups. No disparity was seen in 
the two groups when we compared the risk of relapse and survival. The 5-year 
cumulative incidence of relapse was 26% in the Campath-treated patients and 34% in 
patients given TMG (ns). The 5-year overall survival was 53% and 58% in patients 
who received Campath and TMG, respectively (ns).  
 
No difference in erythrocyte and platelet transfusions between the two groups was seen. 
Of the Campath-treated patients, 17% were given granulocyte transfusion as compared 
to 4% in the TMG group (p = 0.024). Time to neutrophil and platelet engraftment was 
similar in the two groups. When we compared cell-surface molecules (CD3+ T-
lymphcytes, CD19+ B-lymphocytes, and CD56+ NK-cells) and IgG levels in the two 
groups, no significant disparity was found. Chimerism data for the donor CD3+ cell 
line were available for 106 of the 108 patients. Of the TMG-treated patients, 60% 
reached full donor chimerism (DC) within 90 days, 67% reached full DC within 6 
months, and 72% reached it within 1 year. For the Campath-treated patients, the 
corresponding numbers were 44% at 90 days, 53% at 6 months, and 56% at 1 year (p = 
0.12). No significant differences were seen in median time to full DC in the CD3+, 
CD33+, and CD19+ cells in the groups compared. 
 
Discussion 
Both Campath and TMG have been developed to achieve so-called in vivo T-cell 
depletion.  In study II, we were able to show that Campath was associated with less 
overall acute GVHD but more chronic GVHD. Whether this was due to a greater effect 
of Campath than of ATG, in terms of early depletion of alloreactive T-cells of graft 
origin, is not known. Our findings correspond well with an earlier study (326) in which 
GVHD was well controlled in the majority of patients treated with Campath. The 
finding of more chronic GVHD in the Campath-treated patients in this study could have 
been due to the small number of patients included. There may be a correlation between 
the cell dose of the graft and chronic GVHD, but this was not found in the present 
study. However, patients in the Campath group received a higher CD34+ cell dose and 
had more chronic GVHD. 
 
Considering all types of infections, no difference was found between the Campath 
group and the TMG group. Nevertheless, there was a trend of more fungal infections in 
the patients treated with Campath (p = 0.057). This finding is supported by a study that 
showed that treatment with Campath increases the risk of invasive infection with 
Aspergillus after RIC HSCT (169). In addition, 17% of the patients in the Campath 
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group and 4% of the patients in the TMG group were given granulocyte transfusions as 
treatment for infections that had not responded to conventional anti-microbial therapy. 
These findings may indicate that patients treated with anti-CD52 antibodies are more 
susceptible to severe infections.  
 
Our small study revealed no differences in T- and B-lymphocyte levels during the first 
year after HSCT. This is not in accordance with another small study that showed that 
patients who receive Campath have a very slow recovery of the CD4+ T-cell subset 
(327). This can result in a long-lasting impairment of anti-viral immunity, which is in 
turn associated with significant morbidity and mortality (328, 329). Previous 
pharmacokinetic analysis in Campath-treated patients showed that the CD52 antibody 
is detectable in lympholytic serum concentrations for up to 56 days after transplantation 
(330). TMG may be found in serum up to 35 days after HSCT (331). Taking these 
results together, one could speculate that since Campath can be found in the 
bloodstream for a longer time after administration than TMG, this drug may have a 
longer immunosuppressive effect. 
 
Our group found in an earlier study that a low dose of TMG (4 mg/kg in total) 
increased the risk of severe acute GVHD, whereas 10 mg/kg increased the risk of death 
from infection. Medium doses of TMG (6–8 mg/kg) gave the lowest TRM and the best 
survival (332). Taking this observation into consideration, an additional factor that may 
have an influence on both GVHD and infections is the dose given to the patients. In this 
study, we found a dose effect of both preparations on acute and chronic GVHD. 
 
When using anti-T-cell antibodies, the increased incidence of PTLD is of great concern. 
Surprisingly, in study II we found a low incidence of PTLD; and we could not detect a 
difference in development of PTLD between the two drugs. Earlier studies have shown 
a statistcally significantly increased risk of PTLD when using anti-T-cell antibodies 
(333). The low incidence of PTLD in our study might be explained by one of the 
limiting factors: that is, the small number of patients included.  
 
4.3 PAPER III — VITAMIN D SUPPLEMENTATION IN PATIENTS WITH  
INCREASED SUSCEPTIBILITY TO INFECTIONS 
In paper III, 140 patients were included in a double-blind, randomized controlled trial. 
Inclusion criteria were age 18–75 years and an increased susceptibility to respiratory 
tract infections, i.e. more than 42 days with symptoms from the respiratory tract during 
a 12-month period prior to study start. 85 of the patients included had an antibody 
deficiency (selective IgA deficiency, common variable immune disorder, or IgG 
subclass deficiency) (see Table 2 in Materials and Methods). The aim of the study was 
to investigate whether supplementation with vitamin D could reduce infectious 
symptoms and antibiotic consumption in patients with frequent RTI. Vitamin D (4,000 
IU) or placebo was given daily for 1 year. The primary endpoint was an infectious 
score based on five parameters: symptoms from the respiratory tract, ears, and sinuses, 
malaise, and antibiotic consumption. Secondary endpoints were serum levels of 
25(OH)D, microbiological findings, and levels of AMPs in nasal fluid. 
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One year of treatment with vitamin D was significantly associated with a reduced total 
infectious score. In the temporal analysis, we concluded that the effect of vitamin D 
supplementation increases with time. When the individual items of the infectious score 
were analyzed separately, all point estimates indicated a reduction in the treatment 
group, although only the total score and antibiotic consumption reached statistical 
significance. The absolute values were 33 days on antibiotics for the placebo group and 
16 days for the vitamin D group, i.e. a reduction of 17 days/patient/year in the 
intervention group. Figure 7A, B. 
 
The mean 25(OH)D level at study start in the intervention group was 51.5 nmol/l and in 
the placebo group it was 46.9 nmol/l, which means that there was no significant 
difference between the two groups at baseline. After 3 months, the vitamin D group had 
a significantly higher mean vitamin D level: 133 nmol/l as compared to 67 nmol/l. This 
increase remained throughout the study. 
 
 
Figure 7. Primary endpoint. The adjusted total relative infectious score (A) is expressed ´per quarter`(3-
month periods). The adjusted 1-year scores (total score, airway, malaise, ear, sinus and antibiotics) are 
depicted in a Forest-plot (B) together with 95% CI. Effects are presented as relative scores (total score, 
airway and malaise) or OR (ear, sinus, antibiotics and indicated with asterisks). 
 
   39 
During the study, 173 microbiological samples were obtained in the vitamin D group 
and 301 in the placebo group. The number of samples with at least one positive finding 
was higher in the placebo group (p = 0.052). The fraction of positive samples was the 
same for both groups. 
 
There were no differences between the groups for respiratory pathogens such as 
Haemophilus influenza, Moraxella catharralis, and Streptococcus pneumonia, but there 
were significantly fewer findings of Staphylococcos aureus, Candida spp. and 
Aspergillus spp. in the treatment group. A trend was seen—although not significant—in 
that patients with asthma in the intervention group produced fewer bacterial cultures 
and fewer positive cultures than placebo-treated asthmatics (p = 0.080 and p = 0.052, 
respectively). 
 
No statistically significant differences were noted between the vitamin D group and the 
placebo group when LL-37 and HNP1-3 were analyzed in nasal fluids. After 1 year, 
there was a non-significant trend for placebo-treated patients to have higher levels of 
AMPs than patients treated with vitamin D. We also found that after 12 months, no 
primary pathogens could be detected in nasal swabs from patients in the vitamin D 
group. 
 
There was not reported more adverse events in the intervention group compared to the 
placebo group.  
 
Discussion 
All five components of the primary endpoints favoured the vitamin D group, and a 
statistically significant effect was seen both on the probability of treatment with 
antibiotics and on the total score. The overall infectious score was significantly 
reduced, mainly as a result of the large effect on the antibiotic parameter. These 
findings suggest that vitamin D supplementation may prevent respiratory tract 
infections and reduce antibiotic consumption, especially in patients with an increased 
susceptibility to infections.  
 
One could speculate that the dose of vitamin D, the dosing interval, and the study 
length could be of importance with regard to prevention of infections. Other trials using 
lower doses of vitamin D (400–2,000 IU/day) have mainly shown no beneficial effects 
on infections (223, 225). Interestingly, a recent meta-analysis showed that the dosing 
interval also appears to be a key factor since the intervention studies using daily doses 
of vitamin D showed a better therapeutic effect than studies where participants were 
given large bolus doses of vitamin D at intervals of between 1 and 3 months (220). In 
addition, earlier studies that have shown no preventive effect of vitamin D 
supplementation on infections have been performed only during winter season or 
during shorter periods (of 6–12 weeks) (224, 334-336). One strength of our study was 
that a relatively large dose of vitamin D (4,000 IU) was administered daily for one year. 
Our study was the first to cover all four seasons, which is probably important in 
Sweden where there is known variation in 25(OH)D levels during a one-year period. 
Another strength was that the patients included had deficiency in vitamin D at the start 
of the study (mean 50 nmol/l). One study conducted by Murdoch et al., showing no 
effect of vitamin D supplementation on respiratory tract infections, had healthy 
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participants with a normal mean vitamin D level at baseline (72 nmol/l) (221). Taking 
the earlier findings together, it seems plausible that only individuals with a deficiency 
in vitamin D and symptoms of infection benefit from supplementation. 
 
The mechanisms of the effects observed in study III are not fully understood. Earlier 
studies have suggested that vitamin D modulates the immune response at many levels, 
such as induction of AMPs, skewing of T-cells from Th1/Th17 to Tregs, and general 
anti-inflammatory effects (337).  
 
It has already been shown that 1,25(OH)2D induces AMPs in immune cells (338). 
However, an unexpected finding in our study was that we noted a trend of higher 
AMPs in the placebo group. To explain this, one could argue that this may be due to an 
effect of microbes on the mucosal production of AMP, which was recently shown in a 
study from our unit (339). Vitamin D may have the capacity to eliminate pathogens and 
thus reduce the trigger for AMP production. Given that vitamin D induces AMPs in 
epithelial cells, we expected a reduction in bacterial pathogens such as H. influenza, M. 
catharralis and S. pneumoniae in the participants treated with vitamin D. Notably, the 
frequency of these bacteria was not reduced; instead, we found a reduction in S. aureus 
and fungal species. A possible explanation could be that vitamin D reduces antibiotic 
consumption, and thereby also decreases the risk of growth of antibiotic-related 
colonization bacteria such as S. aureus and fungal species. Furthermore, vitamin D has 
been shown to modulate cytokine production induced by C. albicans (340). 
Alternatively, it is possible that vitamin D can prevent mainly viral infections. This is 
supported in earlier studies that put forward both mechanistic and clinical evidence for 
this proposition (210, 242, 243). 
 
Interestingly, we observed a trend that adverse events were being reported more often 
in the placebo group, suggesting that vitamin D could possibly be efficient against other 
diseases. This was evident for cardiovascular diseases in particular. 
 
A potential problem with study III was that the primary endpoint might be questioned, 
since it relied solely on patient-reported information. Another limitation was that the 
patient population was heterogeneous with regard to immune deficiency and 
concomitant diseases. We tried to adjust for these factors in the multivariate analysis of 
the primary endpoint, but unfortunately the sample sizes in each subgroup were too 
small to be able to draw any conclusions. Thus, the results from our study cannot be 
applied directly to the general population. 
 
4.4 PAPER IV — VITAMIN D IN PAEDIATRIC HAEMATOPOIETIC STEM 
CELL TRANSPLANTATION 
The main objective of study IV was to determine the clinical importance of vitamin D 
deficiency in children after HSCT. We wanted to investigate whether vitamin D is 
associated with short- and long-term outcome parameters in paediatric SCT. 
 
123 patients who underwent HSCT between 2004 and 2011 were included in this 
retrospective study, and were followed for up to eight years with regard to their vitamin 
D status. The patients were divided into two groups based on serum 25(OH)D level at 
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baseline: low level (< 50 nmol/l) and sufficient level (≥ 50 nmol/l). The median vitamin 
D level at baseline was 33 nmol/l in the low-level group and 63 nmol/l in the sufficient-
level group. 25(OH)D levels remained significantly higher in the sufficient-level group 
during follow-up of at least 6 months after transplantation. 
 
In the group with sufficient vitamin D levels, moderate-to-severe acute GVHD 
occurred more frequently than in the low-level group (47 % vs. 29 %, p = 0.07). When 
comparing the patients with moderate-to-severe chronic GVHD to those without 
chronic GVHD, there was a significantly increased risk in the low-level group. 
Neutrophilic granulocytes and lymphocyte numbers rose significantly faster during the 
first 3 months post-transplantation in patients with sufficient vitamin D levels at 
baseline. When comparing patients with the highest baseline levels of vitamin D (> 75 
nmol/l) to the others, significantly lower IgG levels were observed in the group with 
high levels. The number of clinical infections observed was not significantly different, 
except for a finding of lower incidence of HSV and VZV 3 months after transplantation 
in the sufficient-level group (p = 0.05 and p = 0.04, respectively). Overall survival (OS) 
in all patients was not significantly different between the groups. When focusing only 
on patients with malignant disease, sufficient levels were associated with better OS (p = 
0.01). Relapse was found to be more common in patients in the low-level group (p = 
0.03). 
 
Discussion  
Based on previous reports, we chose to define hypovitaminosis as levels of 25(OH)D 
below 50 nmol/l (203). Currently, there is no consensus regarding sufficient levels, but 
several authors claim that 75 nmol/l or higher is sufficient in both children and adults. 
Levels for optimal influence on immunological processes may be even higher. Patients 
who undergo HSCT are more prone to develop vitamin D deficiency due to lack of UV 
exposure, hospitalization, corticosteroid treatment, diminished uptake from the 
intestines affected by GVHD, and bacterial overgrowth (281, 282, 285). Duncan et al. 
followed 67 paediatric HSCT patients and found that 37% were deficient at baseline, 
but in the subgroup of patients ≥ 11 years of age 67% were deficient (282). This is in 
accordance with our findings (69%). The lowest levels in our study were found in 
patients who were transplanted during winter and early summer, which is the time of 
year before exposure to sun in Sweden is sufficient to raise vitamin D levels in serum. 
 
In study IV, we found that the frequency of acute GVHD was higher and that of 
chronic GVHD was lower in patients with vitamin D levels > 50 nmol/l at baseline. 
These findings may highlight the different pathogenetic processes in the two forms of 
GVHD, but they may also indicate that vitamin D has dual roles—both immune-
inhibitory and stimulatory. The link between vitamin D deficiency and increased risk of 
chronic GVHD is supported by earlier studies on adult haematopoietic stem cell-
transplanted patients (296, 297). In our material, we found that the frequency of acute 
GVHD was higher in the patient group with sufficient levels of vitamin D. In contrast, 
Pakkala et al. have shown that a vitamin D analogue reduced signs of acute GVHD in 
mice, probably due to down-regulation of both T-lymphocyte activation and 
inflammatory effector mechanisms (288). Since T-cells have a main role in 
development of GVHD, it is interesting that an earlier study has shown that active 
vitamin D inhibits mixed lymphocyte cultures in a dose-dependent manner and affects 
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DC maturation, resulting in a Th2-polarized T-lymphocyte population (287). This 
finding may indicate that administration of high doses of vitamin D to transplanted 
patients can induce an immune-inhibitory effect and therefore reduce the risk of 
GVHD. Nevertheless, it is important to remember that it is crucial to maintain a fully 
activated Th1 type of response to maintain control of viral infections. 
 
The effect of vitamin D on immune reconstitution is not well understood. In our 
material, neutrophil and lymphocyte counts were significantly higher first 3 months 
after HSCT in the sufficient-level group. One can speculate that in this case vitamin D 
may have an immune-stimulatory effect in the early phases of immune recovery. This 
is certainly an interesting observation since, as described above, acute GVHD was seen 
more frequently in the sufficient-level group in our study. A faster normalization of 
immune cell counts might have implications for susceptibility to infections, but no 
significant effect was seen in our material. One reason for us not being able to see any 
effect on infections could be that the baseline levels of vitamin D were generally low, 
and that any influence on infections are not apparent unless the levels of 25(OH)D are 
above 75 nmol/l.  
 
In study IV, we could also conclude that patients with the highest vitamin D levels at 
baseline had the lowest IgG levels and more often received IgG replacement. This is in 
accordance with other studies in which vitamin D has been shown to suppress B-
lymphocyte proliferation, plasma cell differentiation, and IgG secretion (299, 300). We 
concluded that in all patients overall survival (OS) did not differ in the two groups, 
probably because of the good survival rate in patients with non-malignant diseases. In 
patients transplanted due to malignancies, however, we noted that OS was significantly 
higher in patients with sufficient vitamin D levels. We could also conclude that in the 
patient group with vitamin D levels > 50 nmol/l, relapse was significantly less 
common. 
  
It should be noted that there may be a “healthy patient bias” here, where a high vitamin 
D level constitutes a surrogate marker for well-being at the start of HSCT. Moreover, 
since study IV was a retrospective and observational study, no causuality could be 
inferred from these associations. However, our findings may suggest that vitamin D has 
a beneficial role. The triad of more acute GVHD, better overall survival, and less 
relapse may indicate that vitamin D has immune-stimulatory effects mediating 
expansion of alloreactive cells, including those with an ability to kill malignant cells 
(the graft-versus-leukaemia effect). Additional studies where a randomized, blind 
approach is taken are highly warranted in this field. 
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5 CONCLUSION AND FUTURE PLANS 
 
The results presented in this thesis show that a better understanding of the panorama of 
infections in immunocompromised patients gives new views on treatment strategies in 
this patient group.  
 
In study I, we concluded that a very strong predicting factor for death after HSCT is a 
low IgG level (< 4 g/L), measured twice during the first year after transplantation. In 
our view, our results provide evidence enough for us to continue examining IVIG 
treatment after HSCT. To further evaluate the importance of IgG levels after 
transplantation regarding survival, a prospective study in patients with low IgG levels 
after SCT should be conducted where the benefit of IVIG treatment in that specific 
patient group is examined. 
 
One conclusion that can be drawn from study II, after comparing Campath and 
Thymoglobulin as part of a conditioning treatment before HSCT, is that both drugs 
must be taken into consideration to reduce the risk of GVHD and rejection after 
transplantation with alternative donors. There was no difference in IgG levels between 
the two groups. Campath was associated with an increased risk of fungal infections, 
which may have been due to a more immunosuppressive effect compared to TMG. This 
study was small (a comparison of 36 patients given Campath with a matched cohort of 
72 patients receiving TMG), and we believe that larger prospective randomized studies 
will be needed to evaluate the clinical value of the drugs. 
 
Study III showed that treatment with vitamin D reduced symptoms and antibiotic 
consumption in patients with an increased frequency of respiratory tract infections. 
Thus, vitamin D supplementation could provide an alternative strategy to reduce 
antibiotic use in high consumers, and it may—indirectly—also have an impact on 
emerging problems with bacterial resistance.  
 
In study IV, we concluded that vitamin D status affected the clinical course in children 
undergoing HSCT. Vitamin D deficiency at baseline was associated with an increased 
risk of death, relapse, and chronic GVHD over an 8-year follow-up period. Patients 
with the highest levels of vitamin D at baseline had the lowest IgG levels after 
transplantation. Further studies are needed to evaluate our findings and to establish 
whether vitamin D and treatment with IVIG affect immunological processes in HSCT, 
and to investigate the subsequent outcome. 
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6 SAMMANFATTNING PÅ SVENSKA 
 
Människan har under evolutionen utvecklat ett immunologiskt försvar i syfte att skydda 
oss mot mikroorganismer som skulle kunna vara skadliga. Immunförsvaret består av 
många olika komponenter, exempelvis: 
• Hud och slemhinnor utgör en första barriär mot främmande smittämnen.  
• Granulocyter är en typ av vita blodkroppar som oskadliggör mikroorganismer. 
• Komplementsystement utgörs av olika proteiner som hjälper till i vårt immunförsvar. 
• T- och B-celler är vita blodkroppar som försvarar oss mot virus-, bakterie- och 
svampinfektioner.  
• Antikroppar (immunglobuliner, t ex IgG), som bildas av B-cellerna, deltar i försvaret 
mot infektioner. 
 
Det är mycket som kan gå fel i människans komplicerade infektionsförsvar. Vissa 
personer har en medfödd defekt i immunförsvaret, till exempel en oförmåga att bilda 
antikroppar, vilket ofta innebär en ökad benägenhet för luftvägsinfektioner. Ibland 
moduleras immunförsvaret medvetet, exempelvis i samband med 
stamcellstransplantation. I de fyra studierna, beskrivna i den här avhandlingen, har vi 
studerat infektionspanoramat hos patienter som genomgått stamcellstransplantation 
eller haft en ökad benägenhet att insjukna i infektioner. Ett särskilt fokus har lagts på 
vitamin D och dess effekter på immunförvaret. 
 
Vid hematopoetisk stamcellstransplantation (HSCT), transplanteras de blodbildande 
stamcellerna (röda- och vita blodkroppar samt blodplättar) som finns i benmärgen. 
HSCT är idag en etablerad behandlingsmetod vid flera olika sjukdomar såsom 
leukemier och svåra immunbristtillstånd. Själva transplantationen innebär inte någon 
operation utan genomförs som en blodtransfusion. HSCT brukar indelas i två olika 
typer: autolog HSCT som innebär transplantation med egna benmärgsceller och allogen 
HSCT som innebär transplantation med benmärgsceller från en donator. De mest 
fruktade komplikationerna efter transplantation är återfall i grundsjukdomen, GVHD 
(graft-versus-host disease), infektion samt avstötning av de transplanterade cellerna. 
GVHD är en reaktion där de transplanterade cellerna reagerar mot patientens egen 
vävnad. Alla patienter som genomgår HSCT har på grund av avsaknad av vita 
blodkroppar, innan de transplanterade immunförsvarscellerna börjar fungera, en ökad 
risk att drabbas av infektioner. I samband med transplantation föreligger alltid en risk 
för avstötning d.v.s. att patientens eget immunförsvar dödar de transplanterade cellerna. 
 
Alla patienter som genomgår HSCT behandlas innan själva transplantationen med 
cellgifter och/eller strålning i syfte att förgöra de sjuka cellerna i kroppen samt för att 
undvika att patientens immunförsvar stöter bort transplantatet. De nya 
benmärgscellerna har i sig en kraftfull effekt mot till exempel en leukemi-sjukdom. 
Patienter som genomgår allogen HSCT får ofta behandling med ett 
immunsupprimerande läkemedel som kalls för ATG (anti thymocyt globulin). Detta 
läkemedel ges ofta i syfte att förebygga GVHD och minska risken för avstötning.  
 
Vitamin D bildas i huden under inverkan av solljus. I Sverige sker detta bara under 
sommarhalvåret eftersom UVB-strålningen är för svag under den mörka årstiden för att 
någon produktion skall kunna ske i huden. Globalt sett är vitamin D-syntesen från UVB 
viktigare än det vitamin D vi får i oss från kosten. De flesta svenskar har brist på 
vitamin D, särkilt under vinterhalvåret. Det mest kända tillståndet som orsakas av 
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allvarlig vitamin D-brist är rakit (Engelska sjukan) som ger skelettabnormiteter. 
Kroppens slemhinnor är utrustade med ett antimikrobiellt system som bygger på 
kontinuerlig produktion av antimikrobiella peptider (AMP). AMP kan frisättas av 
vitamin D och har en förmåga att döda invaderande mikroorganismer. Vitamin D har, 
förutom att påverka produktionen av AMP, också visat sig kunna både stimulera och 
hämma immunförsvaret i stort. Forskning har visat att det finns receptorer, 
mottagarmolekyler, för vitamin D i många av kroppens celler och att brist på vitamin D 
skulle kunna ge upphov till en rad sjukdomstillstånd. Tidigare studier har visat ett 
samband mellan låga koncentrationer av vitamin D och flertalet 
”vällevnadssjukdomar”, såsom cancer och hjärt- och kärlsjukdomar men också en ökad 
benägenhet för infektioner. 
 
I studie I undersökte vi retrospektivt (en studieform där man tittar tillbaka på det som 
skett) vuxna patienter, som genomgått HSCT, i syfte att utvärdera IgG-nivåer efter 
transplantation. Vi fann att IgG successivt ökade efter transplantationstillfället samt att 
låga nivåer av IgG var en riskfaktor för att dö efter transplantation. 
 
I studie II jämförde vi retrospektivt två olika typer av ATG: Campath och TMG 
(thymoglobulin). Med hjälp av journalanteckningar och laboratorielistor jämförde vi 
hur patienterna mådde efter transplantationstillfället. Det visade sig inte vara någon stor 
skillnad mellan de två olika läkemedlen förutom att Campath troligen ger en något 
ökad risk för svåra infektioner jämfört med de patienter som behandlas med TMG. 
 
I studie III undersökte vi om vitamin D-behandling kan minska infektionssymtom och 
antibiotikakonsumtion hos patienter med antikroppsbrist eller ökad benägenhet för 
luftvägsinfektion. 140 patienter, med problem med återkommande luftvägsinfektioner, 
inkluderades i vår studie som varade i ett år. 70 patienter fick placebo och 70 patienter 
fick 4000 IU vitamin D dagligen. Vi fann att både infektionssymtom från luftvägarna 
samt antibiotikakonsumtionen minskade hos de patienter som fick vitamin D. 
 
I studie IV undersökte vi retrospektivt barn, som genomgått HSCT, i syfte att se om det 
fanns något samband mellan vilket vitamin D-värde patienterna hade vid 
transplantationen och hur de sedan mådde efteråt. Vi upptäckte att vitamin D-brist hos 
de studerade barnen gav en ökad risk att dö efter transplantation. Vi noterade också en 
ökad risk för GVHD och återinsjuknande i grundsjukdomen hos patienter med låga 
vitamin D-nivåer i blodet vid transplantationstillfället. 
 
Förhoppningsvis har de genomförda studierna, presenterade i min avhandling, gett en 
bättre förståelse för vilka typer av infektioner som föreligger hos patienter med 
försvagat immunförsvar samt utvidgat kunskaperna runt betydelsen av 
immunglobulinbrist och vitamin D-brist hos denna patientkategori. 
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Allogeneic stem cell transplantation: low immunoglobulin levels associated
with decreased survival
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The aim of this study was to evaluate the effects and
kinetics of IgG levels after allogeneic stem cell transplant-
ation (SCT). This study retrospectively examines 179
consecutive patients undergoing SCT between 1995 and
2002. Diagnoses included acute and chronic leukemia
(n¼ 136), solid tumors (n¼ 11), other malignancies
(n¼ 16) and non-malignant diseases (n¼ 16). Standard
myeloablative conditioning was given to 146 patients, and
33 patients received reduced intensity conditioning. Serum
samples for measurement of IgG levels were collected 3,
6 and 12 months after SCT, and then yearly. IgG levels
increased after SCT throughout the study period. Factors
that were associated with low IgG levels after SCT were
acute graft-versus-host disease (GVHD), patient agep30
years, female donor-to-male recipient, not receiving anti-
thymocyte globulin and type of GVHD prophylaxis.
Compared to patients with moderately low or normal
levels as measured twice during the ﬁrst year after
transplantation, patients with low IgG levels (o4 g/l)
showed a decreased survival rate (54 vs 71%, P¼ 0.04)
and an increased incidence of transplant-related mortality
(27 vs 9%, Po0.01). IgG levels generally increase after
SCT. Persistent low levels of IgG are a risk factor for
death after SCT.
Bone Marrow Transplantation (2008) 41, 267–273;
doi:10.1038/sj.bmt.1705892; published online 12November 2007
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Introduction
Reconstitution of the immune system after allogeneic stem
cell transplantation (SCT) depends on the conditioning
regimen before SCT, graft-versus-host disease (GVHD)
and time after SCT.1,2 Parts of the innate immune system,
such as granulocytes, monocytes and NK cells, recover
within 2–6 months after SCT.3 Patients who develop
chronic GVHD after SCT may never recover normal
immune function.4 After SCT, the reconstitution of the
B-cell repertoire is often delayed because of complications
associated with GVHD, age and infections.5,6 Normal
B-cell counts are reached between 6 and 9 months after
SCT and after more than 12 months if GVHD has
occurred.7 Antibody production is also impaired after
SCT. Serum IgM levels return to normal usually within 3–6
months, whereas recovery of serum IgG levels may be
delayed up to one year or longer.4,7 Impairment of antibody
immunity correlates with an increased risk of infections
after SCT primarily due to encapsulated bacteria.8,9 In a
randomized trial of long-term administration of intrave-
nous immunoglobulin (IVIG), no differences in chronic
GVHD or infections were shown between patients receiving
IVIG and controls;9 however, in this study patients with
IgGo4 g/l received IVIG even if randomized to the control
arm. It has also been suggested that immunization of the
recipient and the donor before SCT may improve antibody
immunity after SCT.10,11
In this study, we evaluated the clinical inﬂuence of IgG
levels after SCT in 179 patients who received transplants
between 1995 and 2002. This study evaluates the inﬂuence
of IgG levels on incidence of infections, transplant-related
mortality (TRM), and survival.
Patients and methods
Patients
This study retrospectively examines 179 consecutive
patients who had undergone allogeneic SCT at Karolinska
University Hospital Huddinge between 1995 and 2002.
The ethical committee at the Karolinska Institute
(Karolinska University Hospital Huddinge) approved all
aspects of this study. Only patients with at least two IgG
levels measured during the ﬁrst 12 months were included in
the study. This study excluded patients with myeloma,
patients treated with IVIG and children younger than 10
years. Our experience is that the ability to produce IgG
in children younger than 10 years can be very diverse
and therefore difﬁcult to evaluate. The indications for
Received 26 January 2007; revised 31 August 2007; accepted 7 September
2007; published online 12 November 2007
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transplantation included acute leukemia (n¼ 83), chronic
leukemia (n¼ 53), solid tumor (n¼ 11), other malignancies
(n¼ 16) and non-malignant disease (n¼ 16). Table 1
summarizes the patients’ demographics.
Donors and tissue typing
Unstimulated bone marrow (BM) and peripheral blood
stem cells (PBSC’s) were obtained from 85 and 94 donors
respectively. The donors of PBSC’s were treated with
granulocyte-colony-stimulating-factor (10mg/kg/day) be-
fore the donation.12 Pre-transplant histo-compatibility
testing of donors and patients consisted of HLA class I
and II typing by allele level PCR single-stranded poly-
morphism.13 The majority of patients had an HLA-
identical sibling donor or a HLA-A, -B and -DRb1
identical unrelated donor, but 12 with mismatched donors
were also included.
Conditioning
Myeloablative conditioning regimens consisted of cyclo-
phosphamide (60mg/kg daily) for 2 days in combination
with either 7.5–10Gy single dose total body irradia-
tion (TBI) (n¼ 65), 12Gy (4� 3Gy) of fractionated
TBI (n¼ 31), or busulfan (1mg/kg daily) for 4 days
(n¼ 45).14,15 Six patients with aplastic anemia received
200mg/kg of cyclophosphamide and anti-thymocyte glo-
bulin (ATG). All patients with unrelated or mismatched
donors were treated with ATG (2–5mg/kg daily) for 2–5
days before transplantation.16 The reduced intensity con-
ditioning (RIC) was ﬂudarabine (30mg/m2 daily) for 3–6
days, combined with 2Gy TBI (n¼ 5), 60mg/kg cyclopho-
sphamide (n¼ 9) or busulfan (4mg/kg daily) for 2 days and
ATG (2mg/kg daily) for 4 days (n¼ 18).17–19
GVHD prophylaxis
The majority of patients (88%) received cyclosporine (CsA)
combined with four doses of methotrexate (MTX) as
prophylaxis against GVHD.20,21 If GVHD did not occur,
CsA was discontinued after 6 months for patients who
received a matched unrelated donor (MUD) or mismatched
grafts, and 3 months in the case of sibling transplants. No
GVHD prophylaxis was used following the four syngeneic
transplants. Other protocols included CsA (n¼ 2), T-cell
depletion (n¼ 3) and CsA combined with either predniso-
lone (n¼ 1) or mycofenolate mofetil (n¼ 12).18 Four
patients received mycofenolate mofetil and tacrolimus.
Supportive care
During the pancytopenic phase, all patients received
prophylactic treatment with oral ciproﬂoxacin (500mg
twice daily), ﬂuconazole (100mg daily) and nystatin
(200 000 IU 4 times daily) until the absolute neutrophil
count exceeded 0.5� 109/l. During the ﬁrst six months after
engraftment, trimethoprim–sulfametoxazol was adminis-
tered as prophylaxis against Pneumocystis carinii infection.
Patients with a herpes simplex virus IgG that exceeded
10 000 (determined by enzyme-linked immunosorbent
assay; ELISA) received oral or intravenous acyclovir
prophylaxis during the pancytopenic period.
If patients had a fever, empirical antibiotic therapy was
initiated immediately after samples for culture had been
obtained. The primary antibiotic regimen used was
trimethoprim–sulfamethoxazole combined with an amino
glycoside (amikacin) except in patients with known
hypersensitivity to sulfonamides. Treatment was adjusted
according to bacterial susceptibility as soon as the etiology
had been established in cultures. If a patient had an
Table 1 Characteristics of patients included in the study of IgG
levels after allogeneic hematopoietic stem cell transplantation
All patients
(n¼ 179)
Two low IgG
(n¼ 26)
Normal IgG
(n¼ 153)
Sex (M/F) 102/77 16/10 86/67
Age 35 (10–65) 29 (10–60) 37 (10–65)
Children
(10–18 years)
35 (20%) 5 (19%) 30 (20%)
Donor sex (M/F) 108/71 14/12 94/59
Donor age 35 (5–62) 34 (14–62) 35 (5–61)
Diagnose
Non-malignant 16 (9%) 2 (8%) 14 (9%)
Acute leukemia 83 (46%) 13 (50%) 70 (46%)
Chronic leukemia 53 (30%) 7 (27%) 46 (30%)
Other
malignanciesa
16 (9%) 3 (12%) 13 (8%)
Solid tumor 11 (6%) 1 (4%) 10 (7%)
Disease stage
(early/late)b
111/57 17/8 94/49
Donor
Sibling 91 (51%) 12 (46%) 79 (52%)
MUD 76 (42%) 13 (50%) 63 (41%)
Mismatch 12 (7%) 1 (4%) 11 (7%)
Fem D to Male R 32 (18%) 6 (23%) 26 (17%)
Stem-cell source
(BM/PBSC)
85/94 11/15 74/79
NC dose (� 108/kg) 4.5 (0.5–27.6) 6.2 (1.1–25.6) 4.1 (0.5–27.6)
CD34+ dose
(� 106/kg)
5.3 (0.3–25.5) 6.2 (0.7–9.5) 5.2 (0.3–25.5)
G-CSF after SCT 129 (72%) 20 (77%) 109 (71%)
Conditioning
TBI based 96 (54%) 16 (61%) 80 (52%)
Non-TBI based 50 (28%) 7 (27%) 43 (28%)
RIC 33 (18%) 3 (12%) 30 (20%)
ATG 110 (61%) 14 (54%) 96 (63%)
GVHD prophylaxis
CsA+MTX 157 (88%) 25 (96%) 132 (86%)
Other
combinations
22 1 (4%) 21 (14%)
Acute GVHD
No 55 (31%) 5 (19%) 50 (33%)
I 85 (47%) 14 (54%) 71 (46%)
II 33 (18%) 4 (15%) 29 (19%)
III–IV 6 (3%) 3 (12%) 3 (2%)
Chronic GVHD 99 (55%) 20 (77%) 79 (52%)
Abbreviations: ATG¼ anti-thymocyte globuline; BM¼ bone marrow;
CsA+MTX¼ cyclosporine+methotrexate; Fem D to Male R¼ female
donor-to-male recipient; G-CSF¼ granulocyte colony-stimulating factor;
GVHD¼ graft-versus-host disease; MUD¼HLA-A, -B and -DR identical
unrelated donor; NC¼ nucleated cell; PBSC¼peripheral blood stem cells;
RIC¼ reduced intensity conditioning; TBI¼ total-body irradiation.
aIncluding lymphoma 9, MDS 5 and myeloﬁbrosis 2.
bEarly, CR/CP1 and non-malignant diseases, late; later stages.
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antibiotic-resistant fever lasting for more than 4–5 days,
empirical antifungal therapy was initiated with i.v. ampho-
tericin-B (0.3–0.8mg/kg daily) or i.v. liposomal ampho-
tericin-B (1–3mg/kg daily).
Blood samples were tested weekly for cytomegalovirus
(CMV ) reactivation until 14 weeks after SCT. This test was
done using a semi-quantitative PCR or quantitative real-
time PCR for detection of CMV-DNA in peripheral blood
lymphocytes.22,23 Deﬁnition and treatment of CMV disease
after hemopoietic stem cell transplantation have been
previously described.24,25
To achieve faster engraftment after transplantation,
granulocyte colony-stimulating factor was administered to
129 patients until 2001. This treatment ended when an
association with increased risk for acute GVHD was
found.26
Deﬁnitions
Diagnosis and grading of acute and chronic GVHD were
performed based on clinical symptoms and/or biopsies
according to established criteria.27,28 For the diagnosis of
bacteremia, at least one positive blood culture was
required. Invasive fungal infection was deﬁned as positive
blood culture and/or positive cultures from at least two
organs for Candida or Aspergillus species. Aspergillus
pneumonia was deﬁned as pulmonary inﬁltrates and
positive cultures of bronchoalveolar lavage ﬂuid, sputum
or autopsy samples. Patients with serum IgG values below
4 g/l were deﬁned as signiﬁcantly deﬁcient according to the
existing guidelines for antibody-replacement therapy.29,30
Measurement of IgG Levels
Serum samples for measurement of IgG levels were
collected 3, 6, 9 and 12 months following hemopoietic
stem cell transplantation and then at yearly intervals until 5
years posttransplantation. Serum IgG was analyzed routi-
nely by nephelometry at Karolinska University Labora-
tory, Department of Clinical Chemistry. Reference levels
were 6–15 g/l.
Statistics
Variables related to the patients, donors, disease and
transplant were analyzed for their potential prognostic
value on overall survival and TRM. Univariate and
multivariate Cox proportional hazard regression models
were used to identify independent risk factors for death.
Relapse and TRM were competing events. For this reason,
assessment of factors predicting TRM were based on the
proportional hazard model for sub-distribution of compet-
ing risk. Univariate and multivariate analyses were
performed using Gray’s test and the proportional sub-
distribution hazard regression model developed by Fine
and Gray. A stepwise backward procedure was used to
construct a set of independent predictors. All predictors
with a P-value below 0.10 in the univariate analysis were
included in the multivariate analysis. All tests were two-
sided.
The multiple linear regression method was used in the
analysis of factors affecting IgG levels at different time
points . Factors tested by univariate analysis were: patient
and donor sex and age, sex mismatch, type of donor,
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Figure 1 IgG levels at different time points after SCT in 179 patients.
Mean795% CI. Dotted line indicates lower reference level for the lab.
***Pp0.001 vs IgG levels at 3 months.
Table 2 Results from the multivariate analysis of factors
associated with IgG levels at different time points after SCT in 179
patients
Factor RH 95% CI P-value
3 months
Acute GVHD
No 1
Grades I–IV 0.79 0.66–0.94 o0.01
Age (years)
p30 1
430 1.25 1.04–1.49 0.015
6 months
Acute GVHD
No 1
Grades I–IV 0.67 0.58–0.70 o0.001
ATG
No 1
Yes 1.22 1.06–1.40 o0.01
Age (years)
p30 1
430 1.23 1.07–1.42 o0.01
12 months
Acute GVHD
No 1
Grades I–IV 0.79 0.68–0.93 o0.01
Sex match
Other 1
Fem D to Male R 0.82 0.70–0.97 0.017
GVHD prophylaxis
CsA+MTX 1
Other 1.20 1.02–1.40 0.026
Abbreviations: ATG¼ anti-thymocyte globuline; CI¼ conﬁdence interval;
CsA+MTX¼ cyclosporine and methotrexate; Fem D to Male R¼ female
donor-to male-recipient; GVHD¼ graft-versus-host disease; RH¼ relative
hazard.
(If RHo1 indicates an association to low IgG levels and if RH41 indicates
an association to high IgG levels).
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GVHD prophylaxis, disease stage, nucleated cell-dose, type
of conditioning (TBI/non-TBI, RIC/conventional), ATG in
the conditioning, GVHD and type of graft (BM/PBSC).
Chronic GVHD were analyzed in a time-dependent
manner, where only patients who developed GVHD were
assessed as having GVHD from the time point when they
developed GVHD. All analyses were carried out using the
cmprsk package (developed by Gray, June 2001) on Splus
2000 software and Statistica software.
Results
Reconstitution of IgG levels after SCT
IgG levels were not available for every patient at each time
point. After SCT, IgG levels increased throughout the
study period, especially from 6 to 12 months (Figure 1). In
37 patients, only 2 samples were available; 64 patients had
3 samples; 50 patients had 4 samples; and 28 patients had
more than 4 samples.
Factors inﬂuencing IgG levels after SCT
Multivariate analysis was performed to further evaluate the
factors associated with low antibody levels after transplant-
ation. The following variables were included in the model:
acute and chronic GVHD, patient age, donor age, HLA
mismatch, treatment with ATG and conditioning therapy.
Two factors were associated with low IgG levels three
months after SCT: acute GVHD grades I–IV (Po0.01) and
patient age p30 years (P¼ 0.015). Six months after SCT
acute GVHD grades I–IV (Po0.001), patient age p30
years (Po0.01) and no treatment with ATG (Po0.01) were
associated with low IgG levels. One year after SCT, three
variables were associated with low IgG levels: acute GVHD
grades I–IV (Po0.01); female donor-to-male recipient
(P¼ 0.017); and GVHD prophylaxis with CsAþMTX
(P¼ 0.026) (Table 2, Figures 2a–e).
IgG levels and its relation to survival and TRM
Figure 3 shows IgG levels after SCT and its correlation to
survival and TRM. Patients with low IgG levels (o4 g/l),
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measured twice during the ﬁrst year after transplantation,
exhibited a decreased cumulative proportion of survival
and an increased risk of TRM compared to patients with
moderately low or normal levels. Multivariate analysis
showed that low IgG levels, TBI-based conditioning, acute
GVHD grades II–IV and CMV infection were signiﬁcantly
correlated with higher TRM (Table 3). Factors associated
with a lower overall survival were low IgG levels, higher
patient age and acute GVHD grades II–IV (Table 3).
Causes of death in the group with low IgG levels were
relapse 5(19%), GVHD 1(4%), infection 4(15%) and
others 2(8%). Causes of death in the group with normal
IgG levels were relapse 26(17%), GVHD 5(3%), infection
7(5%) and others 7(5%). Patients with low IgG levels had a
borderline (P¼ 0.056) signiﬁcant increased incidence of
infections when they died.
Discussion
Following allogenic SCT, the patient undergoes a period
of pronounced cellular and humoral immunodeﬁciency.
Although immunological function gradually increases,
some patients, particularly those who suffer from GVHD,
do not exhibit reconstitution of the immune system. Most
of the patients were immunologically competent within
2 years.2,4,31–33
In this study, IgG levels after SCT increased throughout
the study period. Five factors had a negative effect on IgG
levels after SCT: acute GVHD, patient age p30 years at
the time of transplantation, lack of treatment with ATG, a
female donor-to-a male recipient and treatment with CsA
and MTX as GVHD prophylaxis. We hypothesize that
some of these factors increase GVHD and thereby decrease
immunological reconstitution. On multivariate analysis,
low IgG levels signiﬁcantly correlated with higher TRM
and inferior survival. These results suggest that a reason-
ably high level of IgG in peripheral blood after SCT is one
important factor for a good outcome post-SCT.
Several serious problems—GVHD, relapse and infec-
tions—need to be considered after SCT. Patients who have
undergone SCT are very susceptible to viral, bacterial and
fungal infections. A way of overcoming the problem of
severe infections is to give prophylactic treatment with high
doses of IVIG. There are contradictory ﬁndings in the
literature regarding the beneﬁcial effects of IVIG treat-
ment.34 IVIG has been shown to have a positive effect on
bacterial infections.35 Some studies suggest that IVIG could
have immunomodulatory effects in vivo, a treatment that
decreases the risk of acute GVHD post-SCT.32,33 Other
studies, however, conclude that IVIG treatment after
SCT does not signiﬁcantly affect GVHD or survival.7,36
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Figure 3 Different outcome variables in patients depending on IgG
levels. ‘Low IgG’ indicates patients with at least two IgG levels o4 g/l at
two occasions during the ﬁrst year after SCT. ‘Normal’ indicates all other
patients with at least two measured IgG levels during the ﬁrst year after
hemopoietic stem cell transplantation. (a) Overall survival and (b)
transplant-related mortality (TRM).
Table 3 Results from the multivariate analysis of factors
associated with various outcome variables in 179 SCT patients
Transplant Related Mortality
Factor RH 95% CI P-value
IgG-levels
Normal 1
Two low levels 3.32 1.25–8.85 0.017
Conditioning
Non-TBI 1
TBI 4.62 1.30–16.4 0.019
Acute GVHD
Grades 0–I 1
Grades II–IV 2.72 1.13–6.55 0.028
CMV infection
No 1
Yes 3.10 1.07–8.94 0.035
Death
IgG-levels
Normal 1
Two low levels 2.47 1.30–4.76 0.006
Age
Continuous 1.03 1.01–1.05 0.003
Acute GVHD
Grades 0–I 1
Grades II–IV 2.08 1.17–3.67 0.012
Abbreviations: CI¼ conﬁdence interval; GVHD¼ graft-versus-host
disease; RH¼ relative hazard; TBI¼ total-body irradiation.
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A retrospective clinical evaluation of prophylactic IVIG
treatment post-SCT showed that the overall survival was
unaffected, but the incidence of death due to infections
was lower in the IVIG-treated group.36 Although fewer
patients treated with IVIG compared to non-IVIG-treated
patients died due to infections, more IVIG-treated patients
died of veno-occlusive disease of the liver.37 One study
concludes that IVIG reduces proliferation of B-lympho-
cytes and immunoglobulin production by co-ligation of the
B-cell antigen receptor and the Fc-g RIIb receptor
mediating the Fc receptor off signal.38 In addition, one
study notes that both IgG and IgM proﬁles become less
heterogeneous in patients who have been treated with IVIG
after SCT and that this effect persists months to years after
the IVIG treatment has been completed.33 In summary, we
think that these earlier studies show both advantages and
disadvantages of IVIG treatment.
We believe that our results, showing a strong correlation
between persistent low levels of IgG and death after SCT,
provide enough evidence to continue examining IVIG
treatment after SCT. Do patients with low IgG levels post
transplant beneﬁt from IVIG treatment? In previous
studies, IVIG was given regardless of IgG levels post-
transplant. Our results raise one main question: is it
possible that treatment with immunoglobulin during the
ﬁrst year post-SCT can increase survival? The major
indication for IVIG treatment is primary immune deﬁ-
ciency, but there are also indications for IVIG treatment in
various autoimmune disorders and infections in immuno-
compromised patients. Our present results suggest an
evaluation of IVIG treatment post-SCT for patients with
low IgG levels. We have found no evidence that a low IgG
level in itself increases mortality. A low IgG level may be a
surrogate marker for other adverse prognostic indicators.
Nevertheless, our data show that a very strong predicting
factor for death after SCT is a low IgG level (o4 g/l)
measured twice during the ﬁrst year after transplantation.
To further evaluate the importance of IgG levels after SCT
with respect to survival, researchers should conduct a
prospective study in patients with low IgG levels post-SCT
and examine the beneﬁt of IVIG treatment in that speciﬁc
patient group.
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II

A comparison of Campath and Thymoglobulin as part of the
conditioning before allogeneic hematopoietic stem cell
transplantation
Anna-Carin Norlin, Mats Remberger
Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
Hematopoietic stem cell transplantation (HSCT) is a
potentially curative treatment for patients with hemato-
logic malignancies, bone marrow (BM) failure syndrome,
and some inherited metabolic disorders. However, graft-
versus-host disease (GVHD) is still a major cause of
morbidity and mortality (1, 2). The risk of rejection is
higher in unrelated donor (URD) HSCT and when a less
toxic, reduced-intensity conditioning (RIC) is used. To
reduce the risk of GVHD and rejection after HSCT,
many centers add anti-thymocyte globulin (ATG) to the
conditioning protocol when using URDs (3–7). Some
RIC protocols also include ATG independently of donor
(8). By adding ATG to the pretransplant conditioning
protocol, acute GVHD and early mortality of URD
HSCT have been reduced to levels similar to those of
matched related HSCT (5, 9). The mechanism of action
is depletion of alloreactive T cells in both the recipient
and the graft, so-called in vivo T-cell depletion. Many
different doses and types of ATG are used today.
In this retrospective study, we compared patients who
were given Campath as part of the conditioning protocol
with a matched cohort of patients given Thymoglobulin
(TMG).
Patients and methods
Patients
This study included 36 consecutive patients receiving
Campath (Genzyme, Cambridge, MA, USA) as part of
Abstract
Background: In vivo T-cell depletion with anti-thymocyte globulin is a commonly used strategy for the
prevention of graft-versus-host disease (GVHD) and to avoid rejection after hematopoietic stem cell trans-
plantation (HSCT). Methods: We compared 36 patients given Campath (alemtuzumab) as part of the
conditioning with a matched cohort of 72 patients receiving Thymoglobulin (TMG). Most patients had a
hematologic malignancy beyond first remission. Median age was 55 (1–67). The majority of patients had
an unrelated donor (70%) and 82% were given peripheral blood stem cells. Most patients received
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conditioning before HSCT between November 2002 and
October 2009 at Karolinska University Hospital. Median
age was 52 yr (range 2–67). Most patients had a hemato-
logic malignancy, while three had a metabolic disorder.
Twenty-six patients (72%) were beyond CR1 (complete
remission) ⁄CP1 (chronic phase) and were considered to
be at high risk.
As controls, we selected 72 patients receiving TMG
(Genzyme) instead of Campath. The controls were selected
out of 289 patients given TMG during the same time per-
iod and matched according to age, diagnosis, stage of dis-
ease, donor, conditioning, and GVHD prophylaxis.
Patient and donor demographics are listed in Table 1.
The study was approved by the local ethical committee
and was performed in accordance with the declaration of
Helsinki. Informed consent was obtained from all
patients included in the study.
Donors
Among the Campath-treated patients, 13 patients had an
HLA-identical sibling donor while 20 had an HLA-A,
HLA-B, and HLA-DR matched URD (MUD) and three
had an allele-mismatched URD (mmURD) (10). There
were 14 male donors and 22 female donors with a med-
ian age of 35 yr (range 21–71).
In the control group, 19 patients had an HLA-identi-
cal sibling donor while 47 had an MUD and 6 had an
mmURD (10). There were 45 male donors and 27 female
donors with a median age of 34 yr (21–71).
HLA typing
All patients and donors were typed using PCR-sequence-
speciﬁc primers high-resolution typing for both HLA
class I and II antigens (11, 12).
Conditioning
In the Campath group, most patients received reduced-
intensity conditioning (RIC) with ﬂudarabine (Flu)
(30 mg ⁄m2 for 3–5 d) in combination with oral busulfan
(Bu, 4 mg ⁄kg ⁄d for 2 d) (n = 19) (8), 2x3 Gy fraction-
ated total-body irradiation (fTBI) and cyclophosphamide
(Cy, 30 mg ⁄kg ⁄d for 2 d) (n = 7) (13), Cy alone at
30 mg ⁄kg ⁄d for 2 d (n = 4) (14), or Treosulfan at
14 g ⁄m2 ⁄d for 3 d (n = 1) (15). Five patients received
full-dose conditioning with busulfan (4 mg ⁄kg ⁄d for 4 d)
and cyclophosphamide (60 mg ⁄kg ⁄d for 2 d) (16). Cam-
path was given at a dose of 30 mg ⁄d for 1 (n = 25), 2
(n = 3), or 3 (n = 8) days (17).
In the control group, 41 patients received RIC consisting
of Flu ⁄Bu, 12 received Flu ⁄ fTBI ⁄Cy, two received Flu ⁄Cy
and ﬁve patients received Flu ⁄Treosulfan. Conventional
conditioning with Bu ⁄Cy was given to 12 patients. TMG
was given at a dose of 2 mg ⁄kg ⁄d for 3 (n = 31) or 4
(n = 41) days. Both antibodies were given with the last
dose on the day before infusion of the cells (6).
GVHD prophylaxis
Most patients received GVHD prophylaxis with cyclo-
sporine (CsA) and four doses of methotrexate (MTX)
(18, 19). During the ﬁrst month, blood CsA levels were
kept at 100–150 ng ⁄mL in patients with sibling donors
Table 1 Patient and donor characteristics for patients treated with
two different anti-T-cell antibodies after hematopoietic stem cell trans-
plantation
Campath Thymoglobulin
N 36 72
Diagnosis
Acute leukemia 6 19
CML ⁄CLL 1 ⁄ 6 10 ⁄ 4
MDS ⁄MPS 16 24
Other hematologic malignancy 4 10
Metabolic disorder 3 5
High-risk disease 26 (72%) 52 (72%)
Sex (M ⁄ F) 14 ⁄ 22 40 ⁄ 32
Age 52 (2–67) 55 (1–67)
Donor
Sibling 13 19
MUD 20 47
Allele mmURD 3 6
Donor sex (M ⁄ F) 20 ⁄ 16 45 ⁄ 27
Donor age 35 (21–65) 34 (21–71)
Stem cell source (BM ⁄ PBSC) 4 ⁄ 32 15 ⁄ 57
NC dose 12.2 (2.5–31.0) 10.2 (1.0–54.5)
CD34 dose 9.4 (0.6–21.9) 7.1 (0.8–26.0)**
Conditioning
Busulfan + Cy 5 12
RIC 31 60
GVHD prophylaxis
CsA + MTX 35 60
Tacrolimus + rapamycin 1 12
G-CSF 4 (11%) 12 (17%)
Acute GVHD
No 24 (67%) 34 (47%)
I 3 (8%) 18 (25%)
II 6 (17%) 16 (22%)
III–IV 3 (8%) 4 (6%)
Chronic GVHD 14 ⁄ 33 17 ⁄ 66§
Follow-up (yr) 3.3 (0.7–7.7) 4.0 (0.7–9.8)
§P = 0.09, **P = 0.01.
URD, unrelated donor; CML, chronic myeloid leukemia; CLL, chronic
lymphoid leukemia; MDS, myelodysplastic syndrome; MPS, myelopro-
liferative syndrome; High-risk disease, beyond CR1 ⁄CP1 or in MDS
not RA; MUD, matched URD; mmURD, mismatched; BM, bone
marrow; PBSC, peripheral blood stem cells; NC, nucleated cell; Cy,
cyclophosphamide; RIC, reduced-intensity conditioning; CsA, cyclo-
sporine; MTX, methotrexate; GVHD, graft-versus-host disease; G-CSF,
granulocyte colony-stimulating factor.
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and at 200–300 ng ⁄mL in those with URDs. In the
absence of GVHD, CsA was discontinued after 3 months
using HLA-identical sibling donors and after 6 months
using URDs (5, 20).
Supportive care
As prophylactic gut decontamination, the patients
received ciproﬂoxacin 500 mg twice daily in combination
with oral amphotericin-B. Granulocyte colony-stimulat-
ing factor (G-CSF) was given to all patients after HSCT
until neutrophil engraftment (>0.5 · 109 ⁄L) until
August 2001 (21). Thereafter, prophylactic G-CSF was
not given because we found that there was an increased
risk of acute GVHD of grades II–IV with this drug (22).
Stem cell source
Stem cells from peripheral blood (PBSCs) were given to
32 and 57 patients in the Campath and control group,
respectively, while four and 15 patients received BM
(23). Before aphaeresis, all donors of PBSCs were treated
subcutaneously once a day with G-CSF (Rhoˆne-Poulenc
Rorer, Lyon, France or Amgen-Roche Inc., Thousand
Oaks, CA, USA), 10 lg ⁄kg ⁄d for 4–6 d.
Diagnosis and treatment of GVHD
Acute and chronic GVHD was diagnosed on the basis of
clinical symptoms and ⁄or biopsies (skin, liver, gastroin-
testinal tract, or oral mucosa) according to standard
criteria (24). The patients were treated for grade-I acute
GVHD with prednisolone, starting at 2 mg ⁄kg ⁄d, which
was tapered after the initial response (25). In more severe
cases, ATG, methylprednisolone, MTX, psoralene, and
UV light (PUVA) or mesenchymal stem cells were used
(26, 27). Chronic GVHD was initially treated with CsA
and steroids.
Cell-surface markers and immunoglobulin
Relative numbers of T (CD3+) and B lymphocytes
(CD19+) and NK cells (CD56+) were determined by
ﬂow cytometry (FACS) at 3, 6, and 12 months after
HSCT. Serum samples for measurement of IgG levels
were collected 3, 6, and 12 months following HSCT.
Serum IgG was analyzed routinely by nephelometry at
the Department of Clinical Chemistry, Karolinska Uni-
versity Laboratory. Reference levels were 6–15 g ⁄L.
Definitions
Engraftment was established by chimerism analysis using
PCR ampliﬁcation of variable numbers of tandem
repeats (until 2003) and short tandem repeats (28).
Leukemia relapse was deﬁned as >20% blasts in BM.
Cytogenetic relapse was reappearance of cells with the
Philadelphia chromosome seen by conventional karyo-
typing analysis.
Bacteraemia was deﬁned as the ﬁrst positive blood cul-
ture related to a febrile episode during the ﬁrst 30 d after
transplantation (29).
Cytomegalovirus (CMV) reactivation was determined
weekly by PCR of leukocyte DNA. CMV disease was
deﬁned according to previous deﬁnitions (30, 31). Herpes
simplex virus (HSV) and varicella zoster virus (VZV)
infections were deﬁned as a positive PCR ﬁnding from
the affected area. Invasive fungal infection was deﬁned
as positive blood culture and ⁄or positive cultures from at
least two organs for Candida or Aspergillus species.
Aspergillus pneumonia was deﬁned as pulmonary inﬁl-
trates and positive cultures of bronchoalveolar lavage
ﬂuid, sputum, or autopsy samples.
Engraftment was deﬁned as stable absolute neutrophil
counts of >0.5 · 109 ⁄L for three consecutive days, and
platelet engraftment was deﬁned as platelet counts of
>30 · 109 ⁄L for seven consecutive days without transfu-
sions.
Statistics
The analysis was performed in July 2010. The probabili-
ties of overall survival and relapse-free survival (RFS)
were estimated using the Kaplan–Meyer method and
compared with the log-rank test (32). The incidence of
GVHD, transplant-related mortality (TRM), and relapse
was estimated non-parametrically by cumulative inci-
dence curves (33, 34). Patients were censored at the time
of death, relapse, or last follow-up. Predictive analyses
for GVHD, TRM, and relapse were based on the pro-
portional hazards model for subdistribution of compet-
ing risks. Univariate and multivariate analyses were then
performed using Gray’s test, and the proportional sub-
distribution hazard regression model was developed by
Fine and Gray (34). A stepwise backward procedure was
used to construct a set of independent predictors for
each end-point. All predictors with a P-value below 0.10
were considered, and sequentially removed if the P-value
in the multiple model was above 0.05. All tests were two-
sided. The type-I error rate was ﬁxed at 0.05 for factors
potentially associated with time-to-event outcomes. Fac-
tors analyzed in the univariate analysis included patient
and donor sex and age, sex-mismatch, disease stage, con-
ditioning (TBI-based), G-CSF, CMV serology, nucleated
and CD34+ cell dose, type of antibody, antibody dose
and GVHD. A Campath total dose of 30 mg and a
TMG total dose of 6 mg ⁄kg were considered as a low
dose. Analyses were performed using the cmprsk soft-
ware package (developed by Gray, June 2001), Splus 6.2
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software (Insightful Corp., Seattle, WA, USA), and
Statistica software (StatSoft, Tulsa, OK, USA). The
Mann–Whitney U test was used to compare continuous
variables, and Fisher’s exact test was used to compare
the distribution of categorical variables.
Results
Transfusions
No difference in erythrocyte and platelet transfusions
between the two groups was seen. The median number
of erythrocyte and platelet transfusions in patients with
Campath and TMG was 4 (range 0–18), 2 (0–22), 2 (0–
48), and 1 (0–28), respectively. Of the Campath-treated
patients, six were given granulocyte transfusion when
compared to three in the TMG group (P = 0.024).
Engraftment
All patients had engraftment initially, but three and six
patients in the Campath and TMG group suffered from
graft failure (GF) at a median of 137 d (range 40–211)
after transplantation. GF tended to occur earlier in Cam-
path-treated patients (days 40, 41 and 137) than in TMG
patients (days 49, 125, 147, 182, 207 and 211)
(P = 0.09). Time to neutrophil and platelet engraftment
was similar in the two groups (Table 2).
Infections
The incidence of bacteraemia was 25% and 21% (ns),
and the incidence of CMV reactivation was 61% in both
groups. CMV reactivation occurred at a median of 37 d
(24–242) and 34 d (9–410) after HSCT in patients treated
with Campath and TMG, respectively. CMV disease
occurred in three and four patients, respectively, in the
two groups. No differences in HSV and VZV reactiva-
tions were seen between the two groups. However, there
was a non-signiﬁcant higher incidence of invasive fungal
infections in the Campath-treated patients (16.7% vs.
4.2%, P = 0.057). Post-transplant lymphoproliferative
disease (PTLD) occurred in one and three patient in the
two groups, respectively.
Graft-versus-host disease
In the Campath-treated patients, the cumulative inci-
dence of any grade of acute GVHD was 34% when com-
pared to 53% in patients given TMG (P = 0.07)
(Fig. 1A). The cumulative incidence of acute GVHD of
grades II–IV was 25% and 28% (ns) and the cumulative
incidence of chronic GVHD was 46% and 25%
(P = 0.09) (Fig. 1B) in patients who received Campath
and TMG, respectively. We found dose effect of ATG
and Campath on the incidence of acute GVHD
(P = 0.057) (Fig. 1C).
In the multivariate analysis, Campath (RH 1.31, 95%
CI 1.03–1.67, P = 0.02) and low antibody dose (2.14,
1.05–4.35, P = 0.03) were associated with chronic
GVHD.
Transplant-related mortality
There was no signiﬁcant difference in TRM between the
two groups: 8% and 7% at 100 d, and 28% and 18% at
1 yr in patients given Campath and TMG, respectively
(Fig. 2A).
In multivariate analysis, higher patient age (in decades)
(1.70, 1.06–2.72, P = 0.028) and TBI-based conditioning
(2.59, 1.12–5.99, P = 0.029) were associated with TRM.
Relapse
Thirty patients (28%) had a leukemia relapse at a med-
ian of 285 d (60–2227) after the transplant. The 5-yr
cumulative incidence of relapse was 26% in the
Campath-treated patients and 34% in patients given
TMG (ns) (Fig. 2B). If patients with chronic lymphoid
leukemia were removed from the analysis, the incidences
of relapse were 21% and 33%, respectively (P = 0.24).
In multivariate analysis, higher patient age (1.88, 1.22–
2.89, P = 0.004) and G-CSF given after HSCT (2.59,
1.14–5.87, P = 0.023) were associated with relapse.
Donor lymphocyte infusions
Donor lymphocyte infusions (DLI) were given to 50
patients: 22 (41%) in the Campath group and 28 (39%)
in the TMG group. Reasons for DLI treatment were
relapse (n = 4), GF (n = 1) and increasing recipient
Table 2 Time to engraftment, transfusions and graft failure (GF) in
patients treated with two different anti-T-cell antibodies after hemato-
poietic stem cell transplantation
Campath Thymoglobulin P-value
Time to ANC >0.5 · 109 ⁄ L 19 (10–34) 18 (11–50) NS
Time to platelets >30 · 109 ⁄ L 14 (0–46) 13 (0–160) NS
Time to platelets >50 · 109 ⁄ L 15 (9–76) 15 (0–170) NS
No. of RBC transfusions 3.5 (0–18) 2 (0–48) NS
No. of Platelet transfusions 1.5 (0–22) 1 (0–28) NS
Granulocyte transfusions 6 patients 3 patients 0.024
GF 3 6 NS
Time to GF (d) 41 (40–137) 164 (49–211) 0.09
PTLD 1 3 NS
ANC, absolute neutrophil count; RBC, red blood cells; PTLD, post-
transplant lymphoproliferative disease; NS, not significant.
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chimerism (n = 17) in Campath-treated patients, and
GF (n = 2), relapse (n = 6), and chimerism (n = 20) in
TMG patients. All patients received escalating doses of
DLI with a median of two doses (range 1–5) given in
each group. The escalations in doses were performed in
steps of 0.5–1 log starting between 1 · 105 to 1 · 106
CD3+ cells per kilo, depending on the type of donor,
degree of HLA match, and history of GVHD in the reci-
pient. DLI was given at a median of 138 d (35–504) and
132 d (35–1922) after HSCT in the two groups, respec-
tively. DLI-induced GVHD occurred in 11 (50%) Cam-
path patients and 13 (46%) TMG patients and was
severe (grades III–IV) in three patients in each group.
Survival
The 5-yr overall survival was 53% and 58% in patients
who received Campath and TMG, respectively (ns)
(Fig. 2C). RFS at 5 yr was 39% and 43%, respectively
(ns) (Fig. 2D).
Causes of death in patients who received Campath
and TMG were relapse in 6 and 13 cases, respectively,
infections in 6 and 11 cases, GVHD in four and one
case, and other causes in one and three cases.
In multivariate analysis, higher patient age (2.09, 1.48–
2.97, P < 0.001) and acute GVHD II–IV (1.81, 0.97–
3.39, P = 0.06) were associated with inferior survival.
Higher patient age (2.05, 1.48–2.86, P < 0.001) was the
only factor affecting RFS in the multivariate analysis.
Cell-surface molecules and IgG
No differences in levels of CD3+ T lymphocytes and
CD19+ B lymphocytes were seen (Fig. 3A–B), although
levels of CD3+ lymphocytes tended to be higher in
TMG-treated patients compared to in Campath-treated
patients. No signiﬁcant difference in NK-cell (CD56+)
levels was seen between the two groups. IgG levels were
determined in 83 patients. No signiﬁcant difference
between the two groups was seen. In 13 patients, low lev-
els of IgG (<4 mg ⁄L) were seen. Overall survival for
these 13 patients was signiﬁcantly inferior to that for
patients with normal IgG levels (35% vs. 72%,
P < 0.01).
Chimerism
Chimerism data for the CD3+ cell line (T cells) were
available in 106 of the 108 patients. Of the TMG-treated
patients, 43 (60%) reached full donor chimerism (DC)
within 90 d, 48 (67%) reached full DC within 6 months,
and 52 (72%) within 1 yr. For the Campath-treated
group, the corresponding ﬁgures were 15 (44%) at 90 d,
18 (53%) at 6 months, and 19 (56%) at 1 yr, P = 0.12.
Median time to full DC in the CD3+ cell line was 49
(14–530) days (n = 54) and 49 (15–925) days (n = 21)
in the TMG and Campath groups, respectively (ns).
Median time to full DC in CD33+ cells was 28 (14–504)
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Figure 1 Cumulative incidence of acute GVHD grades I–IV (A),
chronic GVHD (B) and (C) acute GVHD grades II–IV after allogeneic
hematopoietic stem cell transplantation in patients treated with TMG
or Campath. TMG LD, Thymoglobulin low dose, 6 mg ⁄ kg; TMG HD,
Thymoglobulin high dose, 8 mg ⁄ kg; Camp LD, Campath low dose,
30 mg; Camp HD, Campath high dose, 60–90 mg; GVHD, graft-ver-
sus-host disease.
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days (n = 62) and 28 (14–400) days (n = 24) in patients
who received TMG and Campath (ns). Median time to
full DC in CD19+ cells was 35 (14–504) days (n = 64)
and 48 (17–365) days (n = 24) in patients who received
TMG and Campath (P = 0.14).
Discussion
In this study, we evaluated the effect of two different
drugs, Campath and TMG, which have both been devel-
oped to achieve a so-called in vivo T-cell depletion. We
compared 36 patients given Campath as part of condi-
tioning with a matched cohort of 72 patients who
received TMG. In vivo T-cell depletion with ATG is a
commonly used strategy for the prevention of GVHD
and to avoid rejection after HSCT. Many protocols have
been used, and comparisons between different drugs have
been performed in some studies (6, 35–39). Campath is a
humanized monoclonal antibody to human CD52, an
antigen that is expressed on B, T, and natural killer
(NK-) cells, but not on other hematopoietic cells (40). In
contrast, TMG consists of rabbit immunoglobulins and
is produced by immunizing rabbits with fresh human
thymocytes. The immunoglobulin fraction contains poly-
clonal antibodies to multiple cell-surface antigens (41,
42). TMG binds to T cells and has a direct effect on T
cells, resulting in T-cell depletion via opsonization and
lysis following complement activation. TMG also binds
to B cells, monocytes, macrophages, and neutrophils, but
to a lesser extent (41, 42).
In the present study, we were able to show that
Campath was associated with less overall acute GVHD
(43) but more chronic GVHD. Whether this was attrib-
uted to a greater effect of Campath than of ATG, in
terms of early depletion of alloreactive T cells of graft
origin, remains unclear. Our result is supported by data
from the studies of Hale et al. (44) in which GVHD was
well controlled in the majority of patients treated with
Campath. More chronic GVHD in Campath-treated
patients were not translated into a lower relapse rate in
this study (45). Probably the size of the study is the main
reason for this ﬁnding. It may be a correlation between
the cell dose of the graft and chronic GVHD, but this
was not found in this study. However, Campath-treated
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Figure 2 Cumulative incidence of transplant-related mortality (A), relapse (B), probability of survival (C), relapse-free survival (D) in patients receiv-
ing Thymoglobulin or Campath during conditioning before allogeneic hematopoietic stem cell transplantation.
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patients received a higher CD34 cell dose and had more
chronic GVHD.
Regarding bacterial and viral infections, we did not
see any difference between the Campath and the TMG
groups. There was a trend (P = 0.057) of more fungal
infections in the patients treated with Campath. In an as
yet unpublished study, we have shown that treatment
with Campath increases the risk of invasive infection
with Aspergillus after RIC HSCT (46). Furthermore, six
(17%) Campath-treated patients compared to three
(4%) TMG-treated patients were given granulocyte
transfusions as treatment for infections that did not
respond to conventional treatment. This may indicate
that patients treated with Campath are more susceptible
to severe infections. In our retrospective study, no dif-
ferences in T- and B-lymphocyte levels were found dur-
ing the ﬁrst year after HSCT. Previous pharmacokinetic
analysis, by Morris et al. (47), of patients treated with
Campath revealed that the antibody is detectable in
lympholytic serum concentrations for up to 56 d after
transplantation. TMG may be detected in serum up to
5 wk after HSCT (48). Another study has shown that
patients who receive Campath have a poor immune
reconstitution, particularly with very slow recovery of
the CD4 T-cell subset (49). This leads to a strong and
long-lasting impairment of antiviral immunity, which is
associated with signiﬁcant morbidity and mortality (50,
51). Taking the results of these studies together, one
could speculate that because Campath can be detected
in blood for a longer time after administration com-
pared to TMG, this drug may have a longer immuno-
suppressive effect.
No signiﬁcant difference in IgG levels was seen
between the two groups during the ﬁrst year after trans-
plantation. An important observation made earlier by
our group (6) is that a low dose of TMG (4 mg ⁄kg in
total) increased the risk of severe acute GVHD, whereas
10 mg ⁄kg increased the risk of death from infection.
Medium doses of TMG (6–8 mg ⁄kg) resulted in the low-
est TRM and best survival. Considering this observation,
an additional factor that could probably interfere with
both GVHD and infections is the dose of Campath and
TMG. In this study, we found a dose effect of both
preparations on acute and chronic GVHD.
The increased incidence of PTLDs is a concern when
using anti-T-cell antibodies. In this study, we could see
no difference regarding the incidence of PTLDs. This is
a surprisingly low incidence, since earlier studies by
Lynch et al. (52) have shown a statistically signiﬁcant
increase in the incidence of PTLD in patients treated
with anti-T-cell antibodies. While depletion of B cells by
ex vivo treatment of the marrow with anti-B-cell anti-
bodies may reduce the risk of PTLD, a protective effect
of in vivo B-cell-depleting therapies following bone-
marrow transplantation has not been well established
(53–55).
One must remember that this is a small study, and
the conclusions that we can draw are therefore some-
what limited. Even so, we believe that both TMG and
Camath are drugs that must be taken into consideration
to reduce the risk of GVHD and rejection after HSCT
with alternative donors. Prospective randomized studies
are needed to evaluate the positions of the drugs. A
number of recent studies (1, 2) suggest that there may
be a limited use of in vivo purging agents, in alternative
donors with RIC. Therefore, we believe that this is a
central issue to address in studies that are in the
planning stage. We also believe that in further studies a
larger number of patients have to be included. We sug-
gest that studies in the future should focus partly on
GVHD, because any attempt to reduce GVHD may be
offset by a higher risk of relapse, and the results should
be interpreted with caution.
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ABSTRACT
Background: Low serum levels of 25-hydroxyvitamin
D3 are associated with an increased risk of respiratory
tract infections (RTIs). Clinical trials with vitamin D3
against various infections have been carried out but
data are so far not conclusive. Thus, there is a need for
additional randomised controlled trials of effects of
vitamin D3 on infections.
Objective: To investigate if supplementation with
vitamin D3 could reduce infectious symptoms and
antibiotic consumption among patients with antibody
deficiency or frequent RTIs.
Design: A double-blind randomised controlled trial.
Setting: Karolinska University Hospital, Huddinge.
Participants: 140 patients with antibody deficiency
(selective IgA subclass deficiency, IgG subclass
deficiency, common variable immune disorder) and
patients with increased susceptibility to RTIs
(>4 bacterial RTIs/year) but without immunological
diagnosis.
Intervention: Vitamin D3 (4000 IU) or placebo was
given daily for 1 year.
Primary and secondary outcome measures: The
primary endpoint was an infectious score based on five
parameters: symptoms from respiratory tract, ears and
sinuses, malaise and antibiotic consumption.
Secondary endpoints were serum levels of
25-hydroxyvitamin D3, microbiological findings and
levels of antimicrobial peptides (LL-37, HNP1–3) in
nasal fluid.
Results: The overall infectious score was significantly
reduced for patients allocated to the vitamin D group
(202 points) compared with the placebo group
(249 points; adjusted relative score 0.771, 95% CI
0.604 to 0.985, p=0.04).
Limitations: A single study centre, small sample size
and a selected group of patients. The sample size
calculation was performed using p=0.02 as the
significance level whereas the primary and secondary
endpoints were analysed using the conventional
p=0.05 as the significance level.
Conclusions: Supplementation with vitamin D3 may
reduce disease burden in patients with frequent RTIs.
INTRODUCTION
Vitamin D was discovered when it was noted
that rachitic children were improved by expos-
ure to sunlight.1 It was later shown by Holick
et al2 that vitamin D3 is synthesised in the skin
under the inﬂuence of ultraviolet light.
Vitamin D3 is further hydroxylated in the liver
ARTICLE SUMMARY
Article focus
▪ Recent evidence suggests that vitamin D3 has
potent extraskeletal effects, such as suppression
of inflammation and strengthening of mucosal
immunity by induction of antimicrobial peptides.
▪ Data from observational studies suggest that low
levels of 25-hydroxyvitamin D3 are associated with
an increased risk of respiratory tract infections.
▪ Results from a limited number of randomised
controlled trials on the protective role of vitamin
D3 against respiratory tract infections are incon-
clusive and thus additional studies are warranted.
Key messages
▪ Therefore we designed and carried out a rando-
mised controlled trial where a large dose (4000 IU)
of vitamin D3 was given to patients with an
increased susceptibility to infections for 1 year.
▪ The main conclusion is that vitamin D3 supple-
mentation reduces symptoms and antibiotic con-
sumption among patients with an increased
frequency of respiratory tract infections. Thus,
vitamin D3 supplementation may be an alternative
strategy to reduce antibiotic use among patients
with recurrent respiratory tract infections.
Strengths and limitations of this study
▪ A high daily dose of vitamin D3 was used, the
study time was a full year covering all seasons
and patients with an increased frequency of
respiratory tract infections were studied.
▪ A single study centre, small sample size (n=140)
and a selected group of patients.
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to 25-hydroxyvitamin D3, which is considered to reﬂect
the vitamin D status of an individual patient.3 The ﬁnal
activation to the active form 1,25-dihydroxyvitamin D3
(1,25(OH)D3) requires 1-α-hydroxylase activity. This
enzyme (also designated CYP27B1) is expressed in the
kidney but also in many other cell-types, including epithe-
lial and immune cells.4 The active vitamin D3 (1,25(OH)
D3) binds to the vitamin D receptor (VDR), which
belongs to the nuclear receptor family. Active vitamin D3
is only present in minute amounts in the circulation and
local activation in target cells is crucial for vitamin
D-mediated effects on the immune system.5
Low levels of 25-hydroxyvitamin D3 are associated with
an increased risk of tuberculosis6–8 and respiratory tract
infections.9 The mechanism is not fully elucidated but
vitamin D3 has been shown to induce antimicrobial
peptides in immune cells.10 In addition, active vitamin
D3 (1,25(OH)D3) has broad anti-inﬂammatory effects
on the adaptive immune system by shifting the T helper
cell pool from a Th1/Th17-response to a Th2/
Treg-dominated response.11 12 Vitamin D3 has also been
shown to suppress the Th2-response in allergic broncho-
pulmonary aspergillosis.13 Thus, vitamin D3 modulates
both the adaptive and innate immune system.14 The bulk
of data on vitamin D3 and infections stems from in vitro
experiments and retrospective observational studies.
Results from randomised controlled trials (RCTs) where
the effects of vitamin D3 on infections have been investi-
gated (reviewed by Yamshchikov et al15) are not conclu-
sive and larger clinical trials are therefore warranted.
We designed a study to test the hypothesis that
4000 IU of vitamin D3 given daily to patients with anti-
body deﬁciency and frequent respiratory tract infections
for 1 year could prevent or ameliorate infections. In add-
ition, we investigated whether genetic polymorphisms in
genes involved in the effect and/or metabolism of
vitamin D3 have an inﬂuence on the outcome of vitamin
D3 supplementation.
METHODS
Study design
A prospective, randomised, double-blind placebo-
controlled study of vitamin D3 supplementation in
patients with an increased susceptibility to respiratory
tract infections. The study was approved by the local
Ethical Committee and the Swedish Medical Product
Agency and was performed in accordance with the dec-
laration of Helsinki. Written informed consent was
obtained from all study participants. The study was regis-
tered at www.clinicaltrials.gov prior to inclusion of the
ﬁrst patient (NCT01131858). The EudraCT number is
2009-011758-16. The full protocol is available from the
corresponding author upon request.
Sample size calculation
The sample size was based on the assumption that the
intervention would reduce the number of days with
symptoms from 42 (210 points) to 28 days (140 points),
that is, a reduction of the infectious burden by 30%.
Given this assumption, a sample size of 60 patients per
study group was predicted to provide the study 90%
power at a signiﬁcance level of p=0.02 (Student’s t test).
To compensate for predicted exclusion of participants,
the groups were increased to include 70 patients per
treatment arm. Importantly, the signiﬁcance level of
p=0.02 was chosen in the power calculation to ensure
that a sufﬁcient number of patients were recruited in
order to avoid a type II error in the primary analysis.
However, the conventional and widely accepted signiﬁ-
cance level of p=0.05 was used for statistical analyses of
the primary and secondary endpoints.
Participants
Patients at the Immunodeﬁciency Unit, Karolinska
University Hospital, Huddinge, Sweden, were included
between March and June 2010 by the study nurses (SH,
ML and KJ). Inclusion criteria were age 18–75 years and
an increased susceptibility to respiratory tract infections;
that is, >42 days with symptoms from the respiratory tract
during a 12-month period prior to study inclusion.
Patients registered at the Immunodeﬁciency Unit are
closely followed up with a diary of symptoms and anti-
biotic consumption. Thus, the patients are trained and
used to apply such an instrument to assess their infec-
tious status. Data from patients’ standard diary were used
as an instrument in order to assess patients for eligibility,
both via telephone and by the responsible physician (PB
and ACN) prior to inclusion. Patients with selective
IgA-deﬁciency (D80.2), IgG-subclass deﬁciency (D80.3)
and common variable immune disorder (CVID, D83.0)
as well as patients without a deﬁned immunological
diagnosis (D89.9) were included. Exclusion criteria were
prophylactic treatment with antibiotics, history of hyper-
calcaemia or stones in the urinary tract, sarcoidosis,
ongoing supplementation with vitamin D3 exceeding
400 IU/day, HIV-infection and pregnancy.
Interventions
Patients were randomised to 12 months’ treatment with
vitamin D3 (Vigantol, 4000 IU/day, Merck GmbH,
Darmstadt, Germany) or placebo oil. One drop contained
500 IU vitamin D3 or placebo oil (Miglyol oil, Merck
GmbH, Darmstadt, Germany) and the participants were
asked to take eight drops daily. The participants had to
mark their daily symptoms of infection in a diary, which
was sent via regular mail to the study site every month.
The following data were recorded: symptoms from the
respiratory tract, ears and sinuses, treatment with antibio-
tics, numbers of bacterial cultures, times and reasons of
visits to hospitals, frequency of travelling abroad and
adherence to study drug.
Outcomes
The primary outcome was a composite infectious score,
based on a daily patient-reported questionnaire and
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included ﬁve parameters: symptoms from the respiratory
tract, ears and sinuses, malaise and use of antibiotics
(see online supplementary ﬁgure S1), each parameter
gave 1 point/day. The occurrence of x-ray veriﬁed pneu-
monia gave three additional points per day for a period
of 7 days. Thus, a pneumonia resulted in 3×7 points=21
extra points. Patients were speciﬁcally instructed to
record only symptoms related to ongoing respiratory
tract infections. Symptoms related to infections at other
sites (urinary tract, wounds, etc) as well as non-infectious
symptoms were reported as adverse events. Secondary
outcomes were serum levels of 25-hydroxyvitamin D3 (at
baseline and after 3, 6, 9 and 12 months), numbers of
bacterial cultures, microbiological ﬁndings and levels of
antimicrobial peptides (LL-37 and HNP1-3) in nasal
ﬂuid (at baseline and after 6 and 12 months). In add-
ition, six post hoc genotype analyses were performed
in all participants. Analyses of single nucleotide poly-
morphisms (SNPs) were carried out for VDR (Taq1 and
Foq1), CYP27B1, CYP24A1, CYP2R1 and vitamin D
binding protein (GC). Safety tests included plasma levels
of creatine, calcium, phosphate and albumin, measured
at baseline and after 3, 6, 9 and 12 months. At inclusion,
urine-HCG (human chorionic gonadotropin) in women
was measured and p-parathyroid hormone was measured
in both genders. The results of the safety tests were
reviewed by an independent and unblinded consultant
physician. Two blinded physicians (PB and ACN) were
responsible for inclusion and all medical visits to the
study site (Immunodeﬁciency Unit, Karolinska
University Hospital, Huddinge, Sweden).
Randomisation and statistical analysis
Participants were randomised to 12 months’ treatment
with vitamin D3 (Vigantol, 4000 IU/day) or placebo oil.
Block randomisation with a block size of ten was used
to ascertain equal group sizes. Staff at Karolinska Trial
Alliance was responsible for randomisation procedures.
In the statistical analysis, continuous variables were com-
pared using Mann-Whitney U test or linear regression
and dichotomous variables by Fisher’s exact test or logis-
tic regression. Regressions of log-transformed infectious
scores were performed both unadjusted (simple regres-
sion) and with adjustment for potential confounders
(multiple regression).
Statistical methods: primary analysis
The distribution of the infectious score was found to be
skewed, thereby violating the normal assumption of
the prespeciﬁed t test analysis. Hence, scores were log-
transformed prior to analysis. Further, the randomisation
had resulted in age distributions that were not entirely
balanced between the two groups. Since there might
be concerns that such imbalance could inﬂuence
the results of the study, the original analysis plan was
extended with a multivariable analysis adjusting for
potential confounders. In this linear regression model
based on log-transformed values of the primary outcome
(the total infectious score) and its individual compo-
nents, adjustment was made for age, gender, smoking,
type of immune deﬁciency and signiﬁcant comorbidities
(respiratory or non-respiratory). Because of the trans-
formation procedure, the adjusted effect of vitamin D3 is
expressed as a ratio between the score in the vitamin D3
and the placebo group. In this multiplicative model, an
effect size of 1 indicates identical outcome in the two
study groups and statistically non-signiﬁcant results are
recognised by CIs encompassing the value 1.
To explore potential divergent effects on different
organ systems, both adjusted and unadjusted analyses
were repeated separately for each individual item of the
infectious score. In addition, the temporal aspects of the
vitamin D3 effect were investigated by dividing the study
period into four 90-day periods (starting on the ﬁrst day
of treatment) and repeating the analyses separately for
each time period. ‘Ear’ and ‘sinus’ symptoms as well as
‘antibiotic use’ occurred at low frequencies and for
these entities normal distributions could not be achieved
despite data transformation. Thus, the adjusted analyses
of these individual items were based on multivariable
logistic regression, after coding the symptom (or anti-
biotic therapy) as present or absent during the course of
the study. However, this only applies to analysis of the
individual items, and not to the primary analysis of the
total infectious score, where all item scores were added
as originally described.
Most postrandomisation exclusions were due to
patients failing to ﬁll out the symptoms diary. Hence,
no intention-to-treat (ITT) analysis based on actual
outcome data could be performed. However, the poten-
tial impact of dropouts was addressed in an ITT analysis
based on multiple imputation of missing outcome data.
In the imputation process, pooled estimates were
derived from 100 datasets created by means of multivari-
ate imputation by chained equations and predictive
mean matching for the same covariates as in the
adjusted per-protocol analysis.
Detailed descriptions of randomisation and blinding,
sampling of nasal ﬂuid, measurement of antimicrobial
peptides, measurement of 25-hydroxyvitamin D3, geno-
typing and statistical analyses of secondary outcomes are
presented in the supplementary methods section.
RESULTS
Baseline data
A total of 286 patients were ﬁrst assessed for eligibility
but 144 were not included because they did not fulﬁl all
inclusion criteria; <42 days with infection/year (n=35),
lacked other inclusion criteria (n=42), or declined to
participate (n=67). The remaining 142 patients were
further screened and 140 patients were included in the
study. Of these, 70 were randomised to vitamin D3 sup-
plementation and 70 to placebo (ﬁgure 1). The groups
did not differ with regard to gender, IgG replacement
therapy, smoking, baseline 25-hydroxyvitamin D3 levels,
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type of immune defect or comorbidities (table 1).
Patients with subclass deﬁciency, selective IgA deﬁciency
(sIgAD), CVID and patients without a deﬁned immuno-
logical diagnosis (ND) but with >4 bacterial respiratory
tract infections/year were included. IgG replacement
therapy was most common in the CVID group (100%)
and in the subclass deﬁciency group (63%), and also
frequent in the other groups (ND, 54% and sIgAD,
38%, see online supplementary table S1). Patients allo-
cated to the placebo group were slightly younger than
patients in the treatment group (p=0.025, data not
shown). During the course of the study, 16 patients left
the study prematurely (8 patients from each study
group) and consequently 124 patients were included in
the main per-protocol analysis. Reasons for dropout
included elevated parathyroid hormone (n=2), with-
drawn consent (n=5), adverse events (n=1), prescription
of vitamin D outside the study (n=1), failure to complete
diary (n=4) or non-compliance to study medication
(n=3; ﬁgure 1).
Primary endpoint: infectious score
One year of vitamin D3 treatment was associated with
a signiﬁcantly reduced total infectious score both in
the unadjusted (n=124, p=0.024; table 2) and in the
adjusted analyses (n=124, p=0.040; table 2; ﬁgure 2A,B
and see online supplementary table S2). The
Table 1 Baseline data
Vitamin D3 Placebo
Number 70 70
Age (mean) 55.4 50.8
Female 52/70 50/70
Male 18/70 20/70
IgG-replacement 39/70 42/70
Smoking 4/70 6/70
25-OH levels (mean) (nmol/l) 51.5 46.9
Immunological diagnosis
sIgA-deficiency 9/70 9/70
IgG subclass 27/70 30/70
CVID 6/70 4/70
ND 28/70 27/70
Concomitant disease
No other disease 16/70 18/70
Lung: Asthma 27/70 25/70
Lung: BE 5/70 7/70
Lung: COPD 5/70 4/70
Other disease* 17/70 16/70
Mann-Whitney U test was used for comparisons of age and
25-OH vitamin D3. Fisher’s exact test was used for all other
comparisons.
*‘other disease’ includes hypertension, body pain, hypothyroidism
and gastritis as most common diagnoses.
BE, bronchiectasis; COPD, chronic obstructive pulmonary
disease; CVID, common variable immuno deficiency; ND,
increased susceptibility to infections without a defined
immunological disorder.
Figure 1 Study outline.
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unadjusted relative score in the intervention group was
0.754 (95% CI 0.591 to 0.963, p=0.024, n=124) corre-
sponding to a 25% reduction and after adjustment
for potential confounders, the relative score was 0.771
(95% CI 0.604 to 0.985, p=0.04), corresponding to a
23% reduction (table 2). According to the temporal
analysis, the effect of vitamin D3 supplementation
tended to improve with time (ﬁgure 2A). The absolute
unadjusted score per patient was 202 points for the
vitamin D group and 249 points for the placebo group, a
signiﬁcant reduction of 47 points per patient (p=0.023,
Mann-Whitney U test, see online supplementary
table S3).
When the individual items of the infectious score
were analysed separately, all point estimates indicated
a reduction in the treatment group (table 2, see online
supplementary ﬁgure S2), although only antibiotic con-
sumption reached statistical signiﬁcance (ﬁgure 2B and
see online supplementary ﬁgure S2, panel E). The
adjusted OR for antibiotic use was 0.365 (95% CI 0.153
to 0.872, p=0.023, n=124), that is, a 63.5% reduction of
the odds of antibiotic use in the intervention group
(table 2). The absolute values were 33 days on antibiotics
for the placebo group and 16 days for the vitamin D3
group, that is, a reduction of 17 days in the vitamin D3
group (see online supplementary table S3). The tem-
poral trends for speciﬁc symptoms and antibiotic con-
sumption were similar to the total score and reached
statistical signiﬁcance for ‘ear’-symptoms (n=124,
p=0.041) and for ‘malaise’ (n=124, p=0.053) in the
ﬁnal quarter of the study (see online supplementary
ﬁgure S2, panels B and C).
Analysing the primary outcome according to ITT
(n=140) produced results virtually identical to those of
the per-protocol analysis. In the unadjusted ITT analysis,
vitamin D3 reduced the total infectious score by 25%
(relative score 0.752, 95% CI 0.588 to 0.962, p=0.024)
and after adjustment for potential confounders the
reduction was 23% (relative score 0.767, 95% CI 0.599
to 0.982, p=0.036).
Serum levels of 25-hydroxyvitamin D3
Serum 25-hydroxyvitamin D3 levels did not differ between
the groups at baseline (table 1) but already after 3 months
Figure 2 Primary endpoint. The adjusted total relative
infectious score (A) is expressed ‘per quarter’ (3-month
periods). The adjusted 1-year scores (total score, airway,
malaise, ear, sinus and antibiotics) are depicted in a
Forest-plot (B) together with 95% CI. Effects are presented as
relative scores (total score, airway and malaise) or OR (ear,
sinus, antibiotics and indicated with asterisks).
Table 2 Primary endpoint
Endpoint
Univariable regression model (unadjusted
values) Multiple regression model (adjusted values)
Effect 95% CI p Value Effect 95% CI p Value
Total score 0.754 0.591 to 0.963 0.024 0.771 0.604 to 0.985 0.040
Airway 0.857 0.697 to 1.053 0.141 0.871 0.706 to 1.074 0.200
Ear* 0.721 0.352 to 1.465 0.367 0.695 0.320 to 1.501 0.357
Sinus* 0.583 0.280 to 1.198 0.144 0.594 0.265 to 1.328 0.204
Malaise 0.845 0.692 to 1.032 0.098 0.845 0.689 to 1.036 0.108
Antibiotics* 0.355 0.154 to 0.784 0.012 0.365 0.153 to 0.872 0.023
Treatment effect calculated as the ratio between infectious scores in the vitamin D3 and the placebo groups. Due to low frequencies,
endpoints marked with asterisks (*) were coded as binary outcomes (ie, present or absent in each patient) and compared by means of logistic
regression. In these cases, the effect refers to OR of experiencing the outcome at least once during the course of the study (The data are
based on n=124 patients).
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the intervention group had a signiﬁcantly higher level
of 25-hydroxyvitamin D3 (133.4 vs 66.6 nmol/l, p<0.001;
ﬁgure 3). This increase remained throughout the study
(ﬁgure 3).
Bacterial cultures and microbiology
During the course of the study, 173 microbiological
samples were obtained in the vitamin D3 group
(n=62, 2.79/patient) and 301 in the placebo group
(n=62, 4.85/patient; p=0.010; table 3). The number of
samples with at least one positive ﬁnding was higher in the
placebo group, with close to statistical signiﬁcance
(p=0.052), while the fraction of positive samples was
similar for both groups (table 3). Signiﬁcantly more
patients had a microbiological sample taken from the
respiratory tract (≥1 sample) during the study period in
the placebo group; OR 2.63 (95% CI 1.17 to 5.92; table 3).
In total, the vitamin D3 group generated 76 positive
microbiological ﬁndings (bacteria or fungi), compared
with 159 in the placebo group (p=0.023). There was no
difference between the groups for the traditional
respiratory pathogens (Haemophilus inﬂuenza, Moraxella
catharralis and Streptococcus pneumonia), but there were
signiﬁcantly fewer ﬁndings of Streptococcus aureus
(p=0.019) and fungi (p=0.028, Candida spp. and
Aspergillus spp.) in the treatment group (table 4).
Likewise, signiﬁcantly fewer vitamin D3-treated patients
had a bacterial culture positive for S aureus (p=0.019) or
fungal species (p=0.058), although the latter difference
did not reach statistical signiﬁcance (table 4).
Vitamin D treated patients with subclass deﬁciency left
signiﬁcantly fewer bacterial or fungal cultures than
placebo-treated patients with this diagnosis; seven cul-
tures in the vitamin D group (n=22) versus 47 cultures
in the placebo group (n=24) (see online supplementary
table S4). Also the number of patients that had ≥1 bac-
terial culture taken was signiﬁcantly fewer in the placebo
group (12/22 vs 22/24, p=0.0065, see online supplemen-
tary table S4). There was no signiﬁcant effect of other
immunological diagnoses on bacterial cultures or micro-
biology (see online supplementary table S4).
Since concomitant lung disease may be an important
factor for vitamin D mediated effects on respiratory
immunity, we performed a detailed analysis of bacterial cul-
tures and microbiology of patients with asthma, bronchiec-
tasis (BE) and chronic obstructive pulmonary disease
(COPD). The numbers of patients with these diagnoses
were quite small, which preclude any ﬁrm conclusions
regarding any effect. However, there was a trend—however
not signiﬁcant—that vitamin D-treated patients with
asthma produced fewer bacterial cultures (average 2.9 cul-
tures/patient vs 7.0 cultures/patients, p=0.080, see online
supplementary ﬁgure S3) and fewer positive cultures than
placebo-treated asthmatics (average 0.6 positive cultures/
patients vs 2.7/patient in the placebo group, p=0.052, see
online supplementary ﬁgure S3). In addition, vitamin
D-treated asthma patients showed signiﬁcantly fewer cul-
tures positive for fungi (Candida and Aspergillus) compared
with placebo-treated asthmatics (p=0.0476, see online sup-
plementary table S5). For BE or COPD patients there was
no clear trend or signiﬁcant effect in bacterial cultures or
microbiology.
Levels of antimicrobial peptides in nasal fluid
There was no statistically signiﬁcant difference between the
vitamin D3 or placebo groups when nasal ﬂuids were ana-
lysed for the presence of antimicrobial peptides (AMPs).
Initially, the levels of both LL-37 and HNP1-3 tended to be
higher in the placebo group (see online supplementary
ﬁgure S3, panels A and B). However, after 12 months the
microbiological pattern was reversed and no primary
pathogens could be detected in nasal swabs from vitamin
D3-treated patients (n=25, p=0.039; see online supplemen-
tary ﬁgure S4, panel C). The placebo-treated patients
exhibited the same mix between normal ﬂora and primary
pathogens at all three sampling points (0, 6 and
12 months; see online supplementary ﬁgure S4, panel C).
SNP variants and treatment effect
Most genetic variants did not affect the primary end-
point. However, patients carrying the ‘AA’ genotype in
Figure 3 Secondary endpoint. Vitamin D levels. Serum was
collected at days 0, 3, 6, 9 and 12 months and levels of
25-hydroxyvitamin D3 were measured. Values are expressed
as mean±95% CI.
Table 3 Bacterial cultures
Vitamin
D3 Placebo Significance
Number of samples
per patient (mean,
n=62/62)
2.79 4.85 p=0.010*
Number of positive
samples per patient
(mean, n=62/62)
1.01 2.02 p=0.052*
Fraction positive
cultures (%)
63/173
(36%)
125/301
(41%)
p=0.28**
Patients with ≥1
sample taken
38/62
(61%)
50/62
(81%)
p=0.029**
*Mann-Whitney U test.
**Fisher’s exact test.
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the CYP2R1-gene, encoding the 25-hydroxylase enzyme,
had a larger beneﬁt of vitamin D3-supplementation
(–55%) compared to AG or GG carriers (–6%) (n=124,
p=0.046 for interaction, see online supplementary
table S6).
Adverse events
In total, the vitamin D3 group reported 38 adverse
events (AEs) versus 56 AEs in the placebo group. The
most common symptoms in the treatment group were
headache (n=5) and lumbago (n=5), whereas placebo-
treated patients reported paresthesias (n=8), diverticu-
litis (n=4) and urinary tract infection (n=4) as most
frequent AEs (table 5, see online supplementary
table S7). There was a general trend towards the
number of adverse events being higher in the placebo
group. Signiﬁcantly more patients in the placebo group
reported cardiovascular problems, such as heart failure,
hypertonia and thrombosis (p=0.028). For gastrointes-
tinal and other (non-respiratory) infections there was
also a trend favouring the vitamin D3 group (p=0.058
and 0.09, respectively). No clinically relevant changes
in serum levels of calcium, phosphate, creatine or
albumin could be observed (see online supplementary
ﬁgure S5). There was one severe adverse event in each
group (rabdomyosarcoma in the vitamin D3 group and
lung bleeding in the placebo group), both judged as
being unrelated to the study drug.
DISCUSSION
The main conclusion from this long-term RCT is that
vitamin D3 supplementation reduces the total burden of
respiratory tract infections. The primary endpoint was
composed of ﬁve different parameters that patients
recorded daily throughout the study year. All point esti-
mates favoured the vitamin D3 group and a statistically
signiﬁcant effect was seen on both the total score and on
the probability of receiving antibiotics (p<0.05). The
effect on the infectious score was evident both in analysis
per-protocol and according to ITT, and withstood adjust-
ment for potential confounders. In addition, the number
of bacterial cultures and microbiological ﬁndings was sig-
niﬁcantly reduced in the intervention group. These ﬁnd-
ings are potentially important and support that Vitamin
D3 supplementation may prevent respiratory tract infec-
tions and reduce antibiotic consumption, particularly in
patients with hypogammaglobulinaemia or with an
increased frequency of respiratory tract infections.
However, our study has several limitations: First, the
choice of primary endpoint may be questioned since it
relies solely on patient-reported information. To com-
pensate for inherent problems with patient-reported
data, the evaluation instrument was designed to cover
many aspects of an infectious episode, including various
symptoms as well as antibiotic consumption. Together
the reported data formed an ‘infectious score’, which
constituted the primary endpoint of the study. Similar
composite scores have successfully been applied to
different diseases, such as tuberculosis (TB-score16),
pneumonia (CURB-6517) and bacterial meningitis
(BMS-score18). Notably, vitamin D supplementation had
a major effect on the odds of taking antibiotics during
the study period (a reduction by 63.5%). In addition,
the absolute number of days on antibiotics was reduced
by 50% (from 33 days in the placebo group to 16 days in
Table 5 Adverse events
Organ
Vitamin
D3 n (%)
Placebo
n (%) p Value
CNS 11 (29) 10 (18) 1.00
Gastrointestinal 4 (11) 12 (21) 0.058
Cardiovascular 0 (0) 6 (11) 0.028
Infections (other than RTI) 2 (5) 8 (14) 0.09
Musculoskeletal 10 (26) 10 (18) 1.00
Respiratory (non-infectious) 2 (5) 4 (7) 0.68
Skin 5 (13) 2 (4) 0.44
Other 4 (10) 4 (7) 1.00
Total 38 56
Number of reports. Fisher’s exact test was used for between
group comparison (the data are based on AE-reports from n=62
patients/arm).
CNS, central nervous system, RTI, respiratory tract infection.
Table 4 Microbiological findings
Microorganism
Number of findings (total) Number of patients
Vitamin D3 Placebo MW-U Vitamin D3 Placebo Fisher
Haemophilus influenzae 28 27 p=0.46 10/62 13/62 p=0.64
Moraxella catharralis 8 17 p=0.39 7/62 10/62 p=0.60
Streptococcus pneumoniae 7 6 p=0.74 4/62 5/62 p=1.00
Staphylococcus aureus 6 33 p=0.010 4/62 14/62 p=0.019
Enterobacteriacae 8 8 p=0.39 4/62 7/62 p=0.53
Pseudomonas aeruginosa 8 15 p=0.68 3/62 4/62 p=1.00
Fungal infection 11 53 p=0.028 4/62 12/62 p=0.058
Total 76 159 p=0.023
Mann-Whitney U test was used to analyse the total number of findings, whereas Fisher’s exact test was used for analysis of the number of
patients (fraction) with a specific finding.
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the intervention group), which was statistically signiﬁ-
cant both in the adjusted and unadjusted analyses
(table 1). However, despite the relatively modest reduc-
tion for the other components of the primary endpoint
the overall infectious score was signiﬁcantly reduced—
mainly as a result of the large effect on the antibiotic
parameter—both in the unadjusted and in the adjusted
analyses (table 1 and ﬁgure 2). It is important to inter-
pret the statistical signiﬁcance in light of our power cal-
culation, which was based on a signiﬁcance level of
p=0.02. In the power calculation, the signiﬁcance level
was reduced from 0.05 to 0.02 in order to increase the
statistical power at the p=0.05 level. This approach was
incorrect, and the targeted power (at the p=0.05 level)
should instead have been increased without altering the
p-value threshold. However, we have used the widely
accepted signiﬁcance level p=0.05 in the statistical ana-
lyses for both the primary and secondary endpoints,
respectively. Another potential problem was that the
patient population was very heterogeneous with regard
to immune deﬁciency and concomitant diseases. We
adjusted for these factors in the multivariable analyses of
the primary endpoint, but the sample sizes in each sub-
group were too small to draw any conclusions of effects
in speciﬁc disease groups. However, a detailed post
hoc analysis of the relation between immunological
diagnosis, concomitant lung disease and the secondary
endpoints ‘taken bacterial cultures’, ‘positive bacterial’
cultures and ‘microbiological ﬁndings’ was performed.
There was a clear trend that vitamin D-treated patients
with subclass deﬁciency and/or asthma produced fewer
bacterial cultures, fewer positive cultures and fewer
fungal cultures (see online supplementary tables S4 and
S5 and ﬁgure S3). Although this analysis may lack preci-
sion by the small number of patients included, it could
have clinical implications regarding target groups for
vitamin D3 supplementation.
Nevertheless, our double-blind RCT has several
strengths. For example, we chose a high daily dose of
vitamin D3 based on published calculations on metabol-
ism and effects on immunity.14 19 Other RCTs using lower
doses of vitamin D3, 400–2000 IU/day, have mainly been
negative with regard to the prevention of infections.20 21
However, one study using 1200 IU/day showed a signiﬁ-
cant reduction of inﬂuenza among school children in
Japan.22 Notably, also studies using higher doses of
vitamin D3 have been negative. Martineau et al used
400 000 IU vitamin D3 during 42 days (9523 IU/day) with
the aim of shortening time to sputum conversion in
tuberculosis. No signiﬁcant effect on the primary end-
point could be observed in that study, except in a sub-
group with the tt genotype in the VDR gene.23 A recent
study investigated whether 100 000 IU vitamin D3/month
(3333 IU/day) could reduce the incidence of COPD
exacerbations. There was no signiﬁcant effect on the
primary endpoint, although a post hoc analysis revealed
that patients with a low vitamin D3 level at baseline had a
signiﬁcant effect of vitamin D3 supplementation.
24
Importantly, our study is the ﬁrst to utilise high daily
doses for an extended period of one full year. Thus,
we covered all four seasons, which was important
in Sweden with a known seasonal variation in
25-hydroxyvitamin D3 levels.
25 Two previous RCTs were
performed during the winter season—when vitamin D
levels are low—but only during 422 and 6 months,20
respectively. Previous RCTs have been conducted
during shorter periods; 42 days,23 6 weeks26 and
12 weeks,21 respectively. Interestingly, we observed a
clear time-dependent effect suggesting that a long-term
supplementation approach (>6 months) may be neces-
sary to affect immunity. To expand on the results of a
previous study in healthy individuals where no differ-
ence between the intervention and placebo groups was
observed,21 we chose a study population with frequent
RTIs and at least 42 days with infection during the year
prior to inclusion. Notably, patients in the study repre-
sent a selected group of individuals with frequent RTI,
although the immune disorders that they represent
(sIgAD, IgG-subclass deﬁciency and patients with no
deﬁned immune disorder) are generally mild in charac-
ter and dominated by mucosal RTIs. We also included
a small number of CVID-patients, which can be consid-
ered to be a more severe immune disorder, but all
these patients are treated with IgG replacement therapy
and thus well controlled. Hence, the results from this
study cannot directly be applied to the general healthy
population. Nevertheless, the results provide solid
support for additional interventional studies of vitamin
D3, especially in groups consuming large amounts of
antibiotics.
The mechanism of the observed effects remains
largely unknown. Vitamin D3 modulates the immune
response at many levels, such as induction of AMPs,
skewing of T-cells from Th1/Th17 to Tregs as well as
general anti-inﬂammatory effects.14 Here, we investi-
gated the role of AMPs in nasal ﬂuid. However, we could
not detect any signiﬁcant changes of LL-37 or HNP1-3
during the study period, but noted that placebo-treated
patients tended to have higher levels of AMPs after
1 year of treatment. This was paralleled by a shift of the
microﬂora in the nasal compartment that could explain
the unexpected ﬁnding of higher AMP-levels in the
placebo group. Recently, it was shown that 1,25
(OH)2-vitamin D3 induces both HNP1-3 and LL-37 in
nasal ﬂuid of healthy volunteers,27 supporting that
LL-37 may indeed be induced in vivo. However, our
study design did not allow such conclusions but rather
support that vitamin D3 affect mucosal immunity,
leading to a shift of the microﬂora. Recently, we showed
that the bacterial composition in nasal swabs is an
important determinant of AMP-levels in nasal ﬂuid.28
Given that vitamin D3 induces LL-37 in epithelial cells
and that LL-37 kills bacteria in vitro, we expected a reduc-
tion of the classical bacterial pathogens H inﬂuenza,
M catharralis and S pneumonia in the intervention group.
However, the frequency of these bacteria was not reduced
8 Bergman P, Norlin A-C, Hansen S, et al. BMJ Open 2012;2:e001663. doi:10.1136/bmjopen-2012-001663
Vitamin D3 supplementation and respiratory tract infections
but a reduction of S aureus and fungal species that often
colonise the airways was observed. This could be
explained by speciﬁc effects by vitamin D3 on immunity
against S aureus. In fact, vitamin D3 induces human
β-defensin-2 (HBD-2) with bactericidal activity against
S aureus.29 A recent study showed that low vitamin D3
levels were associated with an increased risk of being colo-
nised by this bacterium.30 Further, vitamin D3 affects
immunity against C albicans, which indicates direct effects
of vitamin D3 on human immunity.
31 Alternatively, it is
possible that vitamin D3 may have prevented symptomatic
viral infections, which prompted patients to leave a bac-
terial sample from the airways. Interestingly, there is both
mechanistic and clinical evidence that vitamin D3 can
prevent viral infections,32–34 although we did not address
this in the current study.
Notably, we observed a prominent increase in the
serum concentration of 25-hydroxyvitamin D3, which
indicated good compliance and tolerability of the study
drug. In fact, there was a trend towards adverse events
being reported more often in the placebo group, sug-
gesting that vitamin D3 possibly could be efﬁcient
against other diseases, but this observation requires
further studies. No clinically relevant changes of blood
chemistry (calcium, phosphate, albumin or creatine)
were observed. Despite few adverse events and high tol-
erability, 16 exclusions occurred during the study year.
The main reason was problems to adhere to the proto-
col and 6/16 patients dropped out of the study after a
few weeks. The rest failed to send in the diaries, did not
leave blood for monitoring of safety parameters or did
not take the study drug. One patient was excluded based
on symptoms that could be attributed to vitamin D3
(facial paraesthesia). However, this patient was later con-
ﬁrmed to have been allocated to placebo.
In summary, we found that supplementation with
vitamin D3 reduced the total infectious score with 47
points per patient (23% reduction in the adjusted ana-
lysis) during the study year. The observed reduction was
lower than the assumed reduction of 70 points per
patient (predeﬁned assumption: 210 points=>140 points;
a reduction of 30%) that formed the basis for the power
calculation. However, despite the predeﬁned level of a
reduction of infectious score by 30% as a clinically mean-
ingful effect, we believe that effects lower than this also
could be relevant for the individual patient. We base this
line of reasoning on the fact that a reduction of 47 points
per patient can be translated into 47 days with cough
(47 points), 23 days with ear and sinus symptoms
(23×2=46 points) or 9 days with cough, sinus and ear
symptoms together with malaise and antibiotics (9×5=45
points). In addition, our data indicate that vitamin D3
supplementation reduces the odds of taking antibiotics
by approximately 60% in patients with frequent respira-
tory tract infections. Thus, supplementation with vitamin
D3 could provide a novel strategy to reduce antibiotic use
among high consumers and indirectly prevent the emer-
ging epidemic of bacterial resistance.
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Abstract 
The importance of vitamin D in immunologic processes has recently emerged, but the role of vitamin 
D in allogeneic hematopoietic stem cell transplantation (SCT) is not determined. Reports indicate that 
SCT recipients, particularly children, often suffer from vitamin D deficiency. In addition, others have 
suggested that adequate levels of vitamin D reduce graft‐versus‐host disease (GvHD). Here we have 
investigated the role of vitamin D in children (n=123) undergoing SCT in the years 2004‐2011. Vitamin 
D  (i.e.,  serum  calcidiol) was analyzed  in prospectively  collected  cryostored  samples. Patients were 
grouped  according  to  pre‐SCT  calcidiol  level:  insufficient  (<50  nM,  n=38)  and  sufficient  (≥50  nM, 
n=85). Older  children,  those  transplanted during  quarter  1‐2  and  children with Middle‐Eastern or 
African origin were more commonly found in the insufficient group. Acute GvHD grade II‐IV occurred 
more  frequently  in  the vitamin D  sufficient group  (47% vs. 30%, p=0.05). No  significant difference 
between  the  two  groups was  seen with  regard  to  chronic GvHD. When  comparing  patients with 
moderate  to  severe  cGvHD  to  those without  cGvHD,  there was a  significant difference  in  calcidiol 
levels  at  6 months  post  SCT  (23nmol/L  vs  37  nmol/L,  p=0.004).  The  neutrophil  granulocytes  rose 
significantly  faster  in  the  vitamin  D  sufficient  group.  No  differences  in  lymphocyte  counts  or 
infectious disease burden during the first year post‐SCT were observed. The overall survival (OS) was 
comparable between the groups. However, when only comparing patients with malignancies, OS was 
significantly better  in  the vitamin D sufficient group  (97% vs. 50%, p=0.001). Additionally,  rejection 
(0% vs. 11%, p=0.06) and relapse (4% vs. 33%, p=0.03) rates were more favorable for these patients. 
To conclude, vitamin D might have a role in pediatric SCT by virtue of its immunomodulatory activity. 
However,  since  observational  studies  may  be  flawed  by  confounding  factors,  randomized  and 
controlled trials on the role of vitamin D in pediatric SCT are highly warranted.  
 
Keywords:  bone marrow transplantation, micronutrient, 25‐OH‐vitamin D 
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Introduction 
Over the years, numerous reports have concluded that vitamin D has biological effects far beyond its 
hormonal  activity  in  calcium  homeostasis,  including  a  role  in  both  innate  and  adaptive  immune 
responses (1, 2). Observational studies have demonstrated an association between low serum levels 
of vitamin D and an increased risk of infections, such as tuberculosis and respiratory tract infections 
(3, 4).  
In  the  context  of  allogeneic  hematopoietic  stem  cell  transplantation  (SCT)  vitamin  D  has  been 
suggested  to  prevent  graft‐versus‐host  disease  (GvHD). Vitamin D  exposure  resulted  in  immature 
dendritic  cell  populations  with  bias  towards  tolerizing  rather  than  stimulatory  T‐lymphocyte 
populations, which could provide a possible mechanism for the beneficial effects against GvHD (5, 6). 
Humans attain vitamin D mainly from exposure to sunlight and to lesser extent from dietary sources. 
Following SCT, children have decreased exposure to direct sunlight and they might also suffer from 
poor nutrition and malabsorption due to SCT‐related side‐effects. An increased catabolism due to the 
use of glucocorticoids and other immunosuppressants could also affect the vitamin D levels in serum 
(7).  Low  vitamin D  levels  in  children undergoing  SCT have  recently been  reported, but  these data 
were not related to the clinical outcome (8). We believe that the role of vitamin D in the context of 
pediatric SCT  remains elusive. Therefore, we designed a  study with  the aim of  relating  the clinical 
outcome in pediatric SCT with baseline vitamin D levels. 
 
Material and methods  
Patients 
Between June 2004 and December 2011 163 pediatric patients underwent SCT at our center at the 
Karolinska University Hospital, Huddinge. Of these 123 were included in this study (exclusion due to 
lack of follow‐up data). The majority of the patients had hematologic malignancies, but patients with 
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non‐malignant  conditions  (i.e.  benign  hematologic,  metabolic,  and  primary  immunodeficiency 
disorders) were also  included  (Table 1). The population was 67% male and  the ethnic composition 
was 75% European, 7% African, 15% Middle Eastern and 3% of other ethnic groups. The study was 
approved by the Regional Ethical Review Board in Stockholm. 
SCT procedure 
The  SCT procedure  and  conditioning  regimens have been published previously  (9),  and  treatment 
data  are presented  in Table 1. Myeloablative  conditioning was  frequently  applied  (n=82, 67%).  In 
most patients cyclosporine A (CsA) and MTX (n=81, 66%) were used as prophylaxis against GvHD. The 
remaining patients received CsA and prednisolone (n=17, 14%), tacrolimus and sirolimus (n=21, 17%) 
or other combinations (n=4, 3.2%). Anti‐thymocyte globulin (ATG) serotherapy was applied when the 
stem  cell  source was  an unrelated donor  and  to  all patients with non‐malignant disorders  (n=96, 
78%).   Cotrimoxazole was used as P.  jiroveci prophylaxis,  in most cases 3 days per week during the 
first 6 months post‐SCT. In patients who developed hypogammaglobulinemia (i.e., plasma IgG <4 g/L) 
post‐SCT, IgG substitution was applied as previously described (10). 
Data collection 
Data on each patient were obtained from medical records and patient databases. The collected data 
includes basic parameters (e.g. sex, age at transplantation, ethnicity etc.), transplant characteristics 
(e.g.  diagnosis,  conditioning,  GvHD  prophylaxis,  donor  source,  and  cell  dose  etc.)  and  outcome 
parameters (e.g. survival rate, rejection, relapse, number of infections and GvHD). Data on vitamin D 
substitution  (daily  doses  and  length  of  treatment),  immunoglobulin  substitution  (number  of 
treatments)  and  total  parenteral  nutrition  (length  of  treatment) were  extracted  from medication 
administration records. To verify the reproducibility of the abstracted data, 10 cases were selected 
randomly and reabstracted. Complete agreement between the two abstractions was confirmed.  
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Outcome data 
Vitamin D insufficiency was defined as a serum level of <50 nmol/L of 25‐OH‐vitamin D (calcidiol) at 
baseline (11).  
The  endpoints  in  this  study  were:  ´presence  of  acute  GvHD´  (aGvHD;  graded  1‐4  following 
international criteria (12)), ´presence of chronic GvHD´ (cGvHD; defined by international criteria (13)), 
´immune recovery´ (cell counts and measurements of immunoglobulins), ´presence of infections´ (as 
explained  below),  ´overall  survival´  (OS),  ´rejection´  (defined  as  progressive  mixed  chimerism 
reaching >95 % recipient‐derived cells in the lineage of interest) and ´relapse´ (defined as increasing 
minimal residual disease reaching diagnostic criteria).  
Infections were  recorded  if  they were  registered  in  the  patient’s medical  record  by  a  physician. 
Bacterial  and  fungal  infections  required positive  cultures  to be  recorded. Viral  infections  required 
positive diagnostics with the exception of those with a typical clinical picture (e.g. “winter vomiting 
disease”,  a  calici  virus  gastroenteritis).  Documented  infections  that  could  not  be  classified  as 
bacterial, viral or fungal were denominated as ´other infections´. Immune recovery was assessed by 
determining full blood counts and immunoglobulin levels.  
Clinical chemistry 
Full blood counts and immunoglobulin levels were analyzed routinely for clinical purposes and values 
were obtained  from  the patient medical  records. Serum samples were collected prospectively pre‐ 
and  post‐SCT  (+3,  6  and  12  months)  and  were  cryostored  for  analysis  of  calcidiol  by  a 
chemiluminescence assay. All laboratory procedures were carried out by accredited methodology at 
the  Department  of  Clinical  Chemistry,  Karolinska  University  Laboratory,  Karolinska  University 
Hospital. 
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Statistics 
Continuous variables and proportions were compared using the Mann‐Whitney test or the Kruskal‐
Wallis test and the Fischer’s exact test or the χ2 test, respectively. GvHD, relapse and rejection were 
estimated  using  an  estimator  of  cumulative  incidence  curves,  taking  competing  events  into 
consideration (14, 15). The Cox regression method was used in the predictive analysis for OS and RFS 
while the method by Fine & Gray was used  for predictive analysis for GvHD and relapse. Statistical 
significance was set at p <0.05. Analysis was performed using  the cmprsk software package, S‐Plus 
6.2 software and Statistica software. 
 
Results 
Baseline vitamin D levels and demographics 
Patients were divided into two cohorts based on calcidiol level at baseline (i.e. pre‐SCT); ´D‐low ´ (<50 
nmol/L) and ´D‐sufficient´ (≥ 50 nmol/L). Clinical outcomes were followed for up to eight years post‐
SCT. The mean calcidiol level at baseline was 33 nmol/L (range 13‐49) in the low level group and 63 
nmol/L  (range  50‐97)  in  the  sufficient  level  group  (P<0.001). Calcidol  levels  remained  significantly 
higher in the sufficient level group during at least 6 months follow‐up post‐SCT. 
Patients in the ´D‐low´ group were older than patients in the ´D‐sufficient´ group (mean 10 vs. 5 years 
with  interlacing ranges, P=0.025). There were more patients with myelodysplastic syndrome  (MDS) 
among patients with sufficient calcidiol levels (P<0.001).  No differences in other characteristics were 
seen  between  the  groups  at  baseline  (Table  1).  The  season  of  transplantation  had  a  significant 
impact on  calcidiol  levels, patients  transplanted  in  the  first 6 months of  the year had  significantly 
lower levels than patients transplanted in the last 6 months (P=0.002, Figure 1). 
The distribution of ethnic origins differed between groups. Patients with African and Middle Eastern 
origin were most likely to display low calcidiol levels (100% and 89%, respectively), whereas patients 
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with European and other origins displayed a more even distribution (63% and 67%, respectively). The 
differences between  groups were  significant  (European  vs. African,  P=0.001;  European  vs. Middle 
Eastern, P=0.001). 
Baseline vitamin D levels, GvHD and immune recovery 
Acute GvHD occurred in 62 patients, corresponding to 50% of the patients, out of which 43 patients 
(35%)  suffered  from  moderate  to  severe  aGvHD  (i.e.  grade  II‐IV).  In  the  ´D‐sufficient´  group  at 
baseline, moderate to severe aGvHD was more frequently occurring, compared to the ´D‐low´ group 
(47% vs. 30%, p=0.05; Figure 2A).  
In  multivariate  analysis  of  factors  affecting  aGvHD,  disease  stage  was  significant  while  level  of 
calcidiol at baseline was borderline significant (Table 2).  
Chronic GvHD occurred in 17 patients (14%), with no significant difference between the ´D‐low´ and 
´D‐sufficient´ group. However, when  comparing patients with moderate  to  severe  cGvHD  to  those 
without cGVHD, there was a significant difference in calcidiol levels at 6 months post SCT (23 nmol/L, 
range 18‐24 vs. 37 nmol/L, range 10‐80, p=0.004).  
Neutrophil granulocytes (measured as absolute neutrophil count) rose significantly faster during the 
first 3 months post‐SCT among patients with sufficient calcidiol levels at baseline. During the next 9 
months no significant difference was observed (Figure 2B).  
When comparing patients with  the highest baseline  levels of calcidiol  (> 75 nmol/L)  to  the others, 
significantly lower baseline IgG levels at SCT were observed (IgG 5.1 g/L, range 1.6‐8.3 vs. IgG 8.3 g/L, 
range 1.4‐19 g/L, p=0.01). This difference remained when the group with calcidiol levels > 75 nmol/L 
was compared to patients with calcidiol levels 50‐74 nmol/L (IgG 5.1 g/L, range 1.6‐8.3 vs. IgG 8.6 g/L, 
range 2.3‐15 g/L, p=0.005) and to patients with calcidiol levels < 50 nmol/L (IgG 5.1 g/L, range 1.6‐8.3 
vs. IgG 7.9 g/L, range 1.4‐19 g/L, p=0.03) (Figure 2C).  The difference in IgG levels did not remain over 
time post‐SCT. IgG substitution was more common in the ´D‐sufficient group´ (76% vs. 56%, p=0.04). 
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Baseline vitamin D and infections 
The number of observed  clinical  infections did not differ  significantly between  the  two groups.  In 
both  groups  most  patients  suffered  from  1‐4  infections  during  the  first  year  post‐SCT.  Data  on 
specific viral  infections (HSV, CMV and VZV) did not show significant differences other than a  lower 
incidence of HSV and VZV at 3 months post transplantation in the ´D‐sufficient´ group (35% vs. 27%, 
P=0.05 and  37% vs 25%, P=0.04; respectively) compared to the ´D‐low´ group. 
Baseline vitamin D and survival 
Overall survival (OS) in all patients did not differ significantly between groups (69% vs. 87% in the ´D‐
low´  and  ´D‐sufficient´  groups,  respectively). Nor  did OS  differ  between  ´D‐low´  and  ´D‐sufficient´ 
patients with  non‐malignant  diseases  (87%  in  both  groups).  In  patients with malignant  diseases, 
sufficient  calcidiol  levels were  associated with  better OS  compared  to  patients with  low  calcidiol 
levels (87% vs. 50%, p=0.01; Figure 3A).  
There was no difference in transplant related mortality (TRM) between the groups. In a multivariate 
analysis factors affecting OS were baseline calcidiol  levels, unrelated donor, and patients with MDS 
(Table 2). Graft rejection did not occur among patients in the sufficient level group but among 11% of 
patients  in  the  low  level  group,  though  this  difference  was  only  borderline  significant  (p=0.06). 
Relapse was more common among patients in the ´D‐low´ group (33% vs. 4%, p=0.03; Figure 3B).  
Analysis  by  a multivariate  regression model  found  that  baseline  calcidiol  levels were  significantly 
associated with relapse (Table 2). Relapse‐free survival (RFS) was significantly higher in patients with 
sufficient levels of calcidiol (87% vs. 41%, p=0.002). Factors affecting RFS in the multivariate analysis 
were calcidiol levels at baseline and the use of an unrelated donor (Table 2). 
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Discussion 
It has been known  for decades  that  the steroid hormone vitamin D affects  immunologic processes 
but  over  the  years  more  precise  mechanisms  of  action  have  been  uncovered  (16).  Gathering 
evidence has shown that sufficient vitamin D levels may be beneficial for patients undergoing SCT (5, 
6, 8). In the present study we have followed 123 pediatric patients for up to eight years post‐SCT and 
recorded clinical outcomes. We have related theses outcomes to baseline vitamin D levels that have 
been obtained by analyzing cryopreserved serum samples. This is one of the first reports describing a 
correlation between vitamin D and clinical outcome parameters in pediatric SCT.  
We  chose  to  define  vitamin D  deficiency  as  baseline  calcidiol  (25(OH)‐vitamin D)  levels  in  serum 
below 50 nmol/L, based on previous reports and guidelines  [11‐14]. To date  there  is no consensus 
regarding  sufficient  levels, but  several  authors  claim  75 nmol/L or higher  to be  sufficient  in  both 
children and adults (17). Most recommendations are based on studies of vitamin D and bone health; 
however  levels  for optimal  influence on  immunologic processes might be even higher  (18).  It has 
been observed that intestinal calcium absorption is maximized above 80 nmol/L, in postmenopausal 
women and that parathyroid hormone (PTH) concentrations in adults continue to decline and reach 
their nadir at 75‐100 nmol/L (19‐21). This shows an inverse relationship between vitamin D and PTH. 
Young children,  institutionalized patients and non‐western  immigrants are usually  regarded as  risk 
groups for vitamin D deficiency (22), but also up to a third of American children and adolescents are 
vitamin D deficient with seasonal variation (18, 23). In adult SCT patients numbers are even higher, 
70‐89% of adult SCT patients are vitamin D deficient prior to transplantation  (24, 25). Duncan et al 
followed  67  pediatric  SCT  patients  and  found  that  37%  were  deficient  at  baseline,  but  in  the 
subgroup of patients ≥11 years 67% were deficient (8). This is in accordance with our findings (69%). 
SCT patients are more prone to develop vitamin D deficiency due to sun avoidance, hospitalization, 
corticosteroid  treatment,  diminished  uptake  from  intestines  affected  by  GvHD  and  bacterial 
overgrowth  (8, 26‐28). The  lowest baseline  levels  in our study were  found  in patients  transplanted 
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during winter until early  summer, which  is before  sun exposure at  the  latitude  in which  the  study 
took place is enough to raise serum levels. In brief, our patients with insufficient baseline levels were 
older, came  from certain ethnic groups  (African and Middle Eastern) and were transplanted during 
time of year when vitamin D levels tend to be lower. The groups did not differ significantly regarding 
SCT‐parameters  (i.e., conditioning, donor,  stem cell  source etc.). Comparable and diverging  results 
were  reported  by  others  (8,  25,  26,  29),  and might  be  explained  by  intrinsic  and  extrinsic  study 
population differences. However, it is clear that certain patients are at risk for developing vitamin D 
deficiency, which easily can be treated.  
Since GvHD  is a major obstacle to successful SCT great efforts are made to understand and prevent 
this condition. T‐lymphocyte responses, which can be modified by vitamin D, are central in the GvHD 
pathogenesis. Pakkala et al  showed  that a  vitamin D analogue decreased  signs of aGvHD  in mice, 
probably  by  down‐regulation  of  both  T‐lymphocyte  activation  and  inflammatory  effector 
mechanisms (30). In vitro studies have shown that active vitamin D dose‐dependently inhibits mixed 
lymphocyte  cultures  (31) and affects dendritic  cell  (DC) maturation  resulting  in a Th2 polarized T‐
lymphocyte  population  (5).  Active  vitamin  D  also  alters  DC  surface  phenotype  and  morphology, 
which may compromise contacts between DC and T‐lymphocytes and  thereby diminish  interaction 
and  T‐lymphocyte  cytokine  secretion  (32).  Together  this  would  lead  to  tolerating  rather  than 
stimulated T‐lymphocyte populations. These findings serve as a rationale for treating or preventing 
GvHD with vitamin D. Rosenblatt et al  reported  two cases of adult patients  suffering  from  steroid 
refractory  GvHD,  where  improvement  occurred  when  vitamin  D  levels  were  corrected  (5). 
Contradictory  to  this,  the  frequency of aGvHD was higher and moderate  to severe cGvHD  lower  in 
patients with sufficient calcidiol levels in our material. These findings emphasize that the two forms 
of GvHD have different pathogenesis, but may also underline the fact that vitamin D has dual roles – 
both  immune  stimulatory  and  inhibitory.  The  linkage  between  vitamin  D  levels  and  cGvHD  are 
supported by observations in adult SCT (6, 33). We found that calcidiol levels were significantly lower 
in  patients with moderate  to  severe  cGvHD  at  6 months  post‐SCT  compared  to  patients without 
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cGvHD  (p=0.004). The difference can partially be explained by  inferior nutritional status and  lower 
sun  exposure  among  the  severely  ill  patients.  Since  low  levels  of  calcidiol  in  this  context  are 
unfavorable, substitution with cholecaliferol may be considered. 
Systemic or locally produced calcitriol (1,25(OH)2‐vitamin D) affects several types of immune cells. In 
addition to showing inhibitory actions on parts of the adaptive immune system, active vitamin D can 
stimulate monocyte proliferation and enhance synthesis of the antibacterial peptide cathelicidin (1, 
2, 34, 35). The effect of vitamin D on immune reconstitution after SCT is not well established. In our 
material neutrophil and  lymphocyte counts were significantly higher  first 3 months post‐SCT  in the 
´D‐sufficient´  group.  This  might  be  interpreted  as  a  vitamin  D‐mediated  stimulatory  effect  on 
immunity  in the early phases of  immune recovery. Notably, this period  is when aGvHD  is observed 
and  our  data  suggests  that  higher  calcidiol  levels  are  associated with  an  increased  frequency  of 
aGvHD. The difference  in neutrophil and  lymphocyte recovery did not remain beyond the 3‐month 
period. Calcitriol has been shown to suppress B‐lymphocyte proliferation, plasma cell differentiation 
and IgG‐secretion (1, 2), which was in accordance with our findings. Patients with the highest levels 
of calcidiol at baseline had the  lowest  IgG  levels during follow‐up and more commonly needed  IgG 
replacement. A faster normalization of immune cell counts might have beneficial effect on infection 
susceptibility but no significant  impact of this parameter was discerned  in our material. One reason 
for  this  could  be  that  our  study  population  had  relatively  low  baseline  calcidiol  levels.  Effects  on 
infection susceptibility might only occur  in  individuals with vitamin D  levels > 75 nmol/L  (6, 34, 36, 
37).  In  addition,  studies  have  suggested  that  very  high  vitamin  D  serum  concentrations  activate 
feedback  systems effectively blocking  the effect of  vitamin D  (38, 39). A  cross‐sectional  trial  from 
Greenland  , recently published, demonstrates that both  low  (< 75 nmol/L) and high  (> 140 nmol/L) 
serum concentrations were associated with an increased risk of tuberculosis (40). 
Overall survival did not differ between the two groups, probably because of the good survival rate in 
patients with non‐malignant disease. However, in patients transplanted due to malignancies OS was 
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significantly higher  in  the  ´D‐sufficient´ group. Notably, another  study on adult patients  could not 
detect significant difference with regard to OS and baseline vitamin D  levels  (33). Also relapse was 
significantly more  common  in  the  ´D‐low´  group  suggesting  that  low  levels  of  vitamin D  is  a  risk 
factor, which should be taken into account in the transplant setting. Since sufficient levels of vitamin 
D appears to be associated with the triad of better OS, less risk of relapse and more events of aGvHD 
it  can  be  postulated  that  vitamin  D  has  immune  stimulatory  effects  mediating  expansion  of 
alloreactive  cells  including  those with  a  capacity  of  killing malignant  cells  (i.e.,  graft‐vs.‐leukemia 
reaction). An alternative explanation  to  the association between vitamin D  levels and OS might be 
that calcidiol  levels constitute a surrogate marker  for patient wellbeing and performance status at 
start of SCT  (41). However,  in multivariate analysis calcidiol  levels remained significantly associated 
to OS, which  supports  a  true  association. Rejection did only occur  among  patients  in  the  ´D‐low´ 
group in our material. This suggests a beneficial role of vitamin D in allograft survival. In analogy with 
the hypothesis of OS and relapse, higher vitamin D  levels might stimulate expansion of alloreactive 
cells  killing  recipient  cells  giving  rise  to  full  donor  chimerism  development.  Clinical  relevant 
immunomodulatory  actions  of  vitamin D  seems  to  request  higher  levels  of  active  vitamin D  (31). 
These findings merit further experimental studies as well as clinical trials in larger patient cohorts. 
This study is based on a large pediatric cohort with a high degree of available data. We conclude that 
baseline  vitamin  D  levels  seem  to  have  a  role  in  the  clinical  course  of  children  undergoing  SCT.  
Vitamin D  deficiency was  associated with  an  increased  risk  of  death,  relapse  and  cGvHD. Higher 
calcidiol  levels were not always beneficial,  since aGvHD occurred more  frequently among patients 
with  sufficient baseline  levels of vitamin D. There were no clear effects on  immune  reconstitution 
and risk of infection. Since this study is a retrospective and observational study, no causality can be 
inferred  by  these  associations.  Thus,  further  studies  are  needed  to  confirm  our  findings  and  to 
establish whether vitamin D could impact immunologic processes in SCT and the subsequent clinical 
outcome. 
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 Table 1  Patient characteristics (n=123)  
  Calcidiol at baseline     
Characteristic  <50 nM (n=85)  ≥50 nM (n=38)  p 
       
Age (years)  10 (0‐19)  5 (0‐15)  0.03 
Sex (male/female)  57 (67%)/28 (33%)  26 (68%)/12 (32%)   
BMI  18.5 (12.0‐45.1)  17.0 (13.1‐26.7)   
       
Ethnic origin 
European 
African 
Middle Eastern 
Other 
 
Diagnosis 
Non malignant 
AML/ALL 
CML 
Lymphoma 
MDS 
Other 
 
Stage (early/late) 
 
Conditioning 
fTBI + Cy 
Bu + Cy 
Flu + Bu 
Flu + Cy 
Flu + fTBI + Cy 
Flu + Treo 
ATG 
 
Donor 
Age (years) 
Female to Male 
MRD 
MUD 
MM 
 
Stem Cell Source 
Bone marrow 
PBSC 
Cord blood 
 
Cell dose 
Nucleated cells, ×108/kg
CD34 cells, ×106/kg 
 
 
 
57 (67%) 
9 (11%) 
16 (19%) 
3 (4%) 
 
 
42 (49%) 
8/22 (9%/26%) 
3 (4%) 
3 (4%) 
7 (8%) 
0 
 
58/27 
 
 
26 (31%) 
30 (35%) 
4 (5%) 
7 (8%) 
4 (5%) 
16 (19%) 
67 (79%) 
 
 
22 (0‐55) 
20 (24%) 
29 (34%) 
38 (45%) 
18 (21%) 
 
 
55 (65%) 
16 (19%) 
14 (16%) 
 
 
4.1 (0.3‐37) 
4.8 (0.1‐44) 
 
 
 
34 (90%) 
0 
3 (8%) 
1 (3%) 
 
 
15 (39%) 
2/6 (5%/16%) 
0 
0 
13 (34%) 
2 (5%) 
 
20/18 
 
 
7 (18%) 
19 (50%) 
1 (3%) 
7 (18%) 
1 (3%) 
3 (8%) 
29 (76%) 
 
 
22 (0‐46) 
8 (21%) 
14 (37%) 
19 (50%) 
5 (13%) 
 
 
29 (76%) 
5 (13%) 
4 (11%) 
 
 
5.2 (0.4‐34) 
5.5 (0.1‐15) 
 
 
 
 
 
 
 
 
 
 
 
 
 
<0.001 
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GvHD prophylaxis 
CsA + MTX 
CsA + prednisolone 
Tacrolimus + sirolimus 
Other 
 
Acute GvHD 
0 
I 
II‐IV 
 
Chronic GvHD (Y/N) 
 
IgG replacement 
 
52 (61%) 
12 (14%) 
18 (21%) 
3 (4%) 
 
 
46 (54%) 
14 (16%) 
25 (29%) 
 
11/73 
 
48 (56%) 
 
 
29 (76%) 
5 (13%) 
3 (8%) 
1 (3%) 
 
 
15 (39%) 
5 (13%) 
18 (47%) 
 
6/32 
 
29 (76%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Table 1. Abbreviations: BMI denotes body mass index; AML, acute myeloid leukemia; ALL, acute lymphatic leukemia; CLL, 
chronic  lymphatic  leukemia;  MDS,  myelodysplastic  syndrome;  fTBI,  fractionated  total  body  irradiation;  Cy, 
cyclophosphamide; Bu, busulphan; Flu,  fludarabine; Treo,  treosulphan; ATG, anti‐thymocyte globuline serotherapy; MRD, 
human leukocyte antigen (HLA) matched related donor; MUD, HLA matched unrelated donor; MM, HLA mismatched donor; 
PBSC,  peripheral  blood  stem  cells;  GvHD,  graft‐versus‐host  disease;  CsA,  cyclosporine  A;  MTX,  methotrexate;  IgG, 
immunoglobulin G.      
 
Figure 1 
 
 
 
Figure  1:  Time  of  transplantation  had  significant  impact  on  levels  of  calcidiol  at  baseline.  The  p–value  denotes  a 
comparision of all four groups with Kruskal‐Wallis test.  
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Table 2  Multivariate  analysis* of  factors  associated  to  acute GvHD, mortality,  relapse  and 
relapse‐free survival (RFS). 
aGvHD grade II‐IV  HR  95% CI  P 
calcidiol >50 nM  1.72  0.96‐3.13  0.065 
High risk disease stage  2.59  1.42‐4.71  0.002 
       
Mortality  HR  95% CI  P 
calcidiol >50 nM  0.15  0.04‐0.57  0.005 
URD  3.77  1.11‐12.8  0.03 
MDS  2.93  1.09‐7.88  0.03 
       
Relapse  HR  95% CI  P 
calcidiol >50 nM  0.08  0.01‐0.63  0.02 
       
Relapse‐Free Survival  HR  95% CI  P 
calcidiol >50 nM  0.14  0.04‐0.50  0.002 
URD  3.58  1.23‐10.4  0.02 
 
Table 2. Abbreviations: *, corrected for differences in characteristics (age, stage and MDS); aGvHD; acute graft‐versus‐host 
disease, RFS;  relapse‐free  survival, HR; hazards  ratio, 95% CI; 95%  confidence  interval, URD; unrelated donor, High  risk; 
beyond CR (complete remisson) 1/CP (chronic phase) 1, MDS; myelodysplastic syndrome. 
 
 
 
 
 
Figure 2A 
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Figure 2B 
 
 
 
Figure 2C 
 
 
Figure  2:  (A) Moderate  to  severe  aGvHD occurred more  commonly  among patients with  sufficient  levels of  calcidiol  at 
baseline. (B) Absolute neutrophil count rose faster during the first 3 months post‐SCT among patients with sufficient levels 
of calcidiol at baseline. (C) Levels of IgG were significantly lower in a group with calcidiol above 74 nM at baseline compared 
to other groups. 
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Figure 3A 
 
 
Figure 3B 
 
 
Figure 3: (A) In patients with malignant diseases sufficient calcidiol  levels at baseline were associated with greater overall 
survival. (B) Relapse was less common among patients with sufficient levels of calcidiol at baseline. 
 

